apixaban profile

ID Source	ID
PubMed CID	10182969
CHEMBL ID	231779
CHEBI ID	72296
SCHEMBL ID	118023
MeSH ID	M0512702

Synonym
HY-50667
eliquis (tn)
apixaban (jan/usan/inn)
D03213
503612-47-3
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide
GG2 ,
bms-562247-01
eliquis
2P16
chembl231779 ,
apixaban ,
bdbm19023
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1h,4h,5h,6h,7h-pyrazolo[3,4-c]pyridine-3-carboxamide
bms-562247
chebi:72296 ,
AKOS005146204
bms 562247-01
bms562247-01
3z9y7uwc1j ,
bms562247
1h-pyrazolo(3,4-c)pyridine-3-carboxamide,4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-
bms 562247
1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1h-pyrazolo(3,4c)pyridine-3-carboxamide
unii-3z9y7uwc1j
apixaban [usan:inn:jan]
hsdb 8223
BCP9000310
apixabanum
FT-0686944
BCPP000396
apixaban,bms-562247-01
NCGC00346555-01
apixaban [vandf]
apixaban [orange book]
apixaban [ema epar]
apixaban [mart.]
apixaban [jan]
1h-pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-( 4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-
1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyi)-4,5,6,7-tetrahydro-1h-pyrazolo(3,4-c)pyridine-3-carboxamide
apixaban [who-dd]
apixaban [usan]
apixaban [inn]
apixaban [mi]
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide?bms-562247; bms-562247-01
CS-0401
S1593
gtpl6390
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide
DB06605
smr004676529
MLS006010026
SCHEMBL118023
PB10976
ME-0152
QNZCBYKSOIHPEH-UHFFFAOYSA-N
1-(4-methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide
J-200194
c25h25n5o4
AC-26301
apixaban(bms-562247-01)
DTXSID80436500 ,
AB01565766_02
apixaban 13cd3
CCG-229675
EX-A048
HMS3655O07
mfcd11977295
NCGC00346555-08
SW220177-1
apixaban (bms 562247-01)
Q414462
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[5,4-c]pyridine-3-carboxamide
503612-47-3, eliquis,
BCP02451
AMY1826
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide
AR-270/43507990
NCGC00346555-05
nsc-784102
nsc784102
NCGC00346555-02
apixaban- bio-x
BM164185
SY097159
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidyl)phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide
eliquis30-day starter pack
1h-pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-
apixaban (mart.)
4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-
1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1h-pyrazolo(3,4-c)pyridine-3-carboxamide
dtxcid60387324
b01af02
Z195110238

Excerpt	Reference	Relevance
"Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late-stage clinical development for the prevention and treatment of thromboembolic diseases."	( Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. Crain, EJ; Knabb, RM; Lam, PY; Luettgen, JM; Pinto, DJ; Wexler, RR; Wong, PC; Xin, B, 2008)	3.23
"Apixaban is a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. "	( Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. He, K; Knabb, RM; Luettgen, JM; Pinto, DJ; Rendina, AR, 2011)	3.25
"Oral apixaban is a valid oral alternative to subcutaneous dalteparin for the treatment of a large spectrum of patients with cancer-associated VTE."	( Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022)	2.62
"Apixaban is an oral factor Xa inhibitor anticoagulant that requires no dose adjustment or monitoring."	( Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Armbruster, B; Aston, VT; Branch, DW; Elliott, CG; Groat, D; Kaplan, D; Lloyd, JF; Rondina, MT; Stevens, SM; Wang, TF; Wilson, EL; Woller, SC, 2022)	2.89
"Apixaban is a direct oral anticoagulant (DOAC). "	( Development of a Bayesian estimation tool to determine the optimal duration of apixaban discontinuation before a high-bleeding risk procedure. Delavenne, X; Gibert, A; Janisset, L; Lanoiselée, J; Ollier, E; Pernod, G, 2022)	2.39
"Apixaban is a possible alternative that is potentially better for compliance and requires no additional testing."	( Apixaban: Alternative Anticoagulation for HeartMate 3 Ventricular Assist Device. Avula, D; Costelle, D; Dunbar-Matos, C; Kahlon, T; Pahwa, S; Slaughter, MS; Trivedi, JR; Whitehouse, KR, 2022)	2.89
"Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT."	( An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022)	1.66
"Apixaban is a factor Xa (FXa) inhibitor and standard-of-care anticoagulant with FXa Ki and plasma protein binding (free fraction) averages 0.08 nM and 0.13 in humans and 0.16 nM and 0.37 in rabbits, respectively. "	( Calibration and validation of the rabbit model of electrolytic-mediated arterial thrombosis against the standard-of-care anticoagulant apixaban. Crain, E; Wong, PC, 2022)	2.37
"Apixaban is a direct-acting oral anticoagulant (DOAC) with a short half-life allowing for brief interruptions of anticoagulation for procedures."	( The utilization and safety of apixaban for therapeutic anticoagulation in heart transplant population requiring routine endomyocardial biopsies. Badiye, A; Baran, DA; Cameron, C; Herre, JM; Ingemi, AI; Lichvar, A; Lindauer, KE; McMahon, MR; Old, W; Sawey, EJ; Yao, A; Yehya, A, 2022)	1.73
"Apixaban is a substrate for p-glycoprotein and is extensively metabolized by cytochrome P450 (CYP) 3A4. "	( A Real-World Matched Cohort Study of the Effect of Concomitant Amiodarone or Diltiazem Administration on Apixaban Peak and Trough Concentrations. Ainsworth, M; Bookstaver, DA; Gleaton, M; Milner, E, 2023)	2.57
"Apixaban is an anticoagulant requiring less testing than warfarin which has been shown to be effective in other indications."	( Apixaban Anticoagulation in Children and Young Adults Supported With the HeartMate 3 Ventricular Assist Device. Blume, ED; Cetatoiu, MA; Daly, KP; Esteso, P; Fynn-Thompson, F; Hawkins, B; Kobayashi, RL; VanderPluym, C; Ventresco, C, 2023)	3.07
"Apixaban is a superior direct oral anticoagulant exihibiting interindividual variability in concentration and response in the real world. "	( Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers. Bao, J; Cui, Y; Jiang, J; Liao, M; Liu, Z; Meng, X; Mu, G; Song, J; Wang, Z; Xiang, Q; Xie, Q; Zhang, F; Zhang, H; Zhao, X; Zhou, S, 2023)	2.57
"Apixaban is a non-vitamin K antagonist oral anticoagulant (NOACs) recently emerged as an effective alternative to conventional vitamin K antagonists (VKAs) in the treatment of several thromboembolic disorders. "	( Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report. Angelini, A; Ballarini, M; Dalmastri, V; Grammatico, F; La Manna, G; Minerva, V; Pizzini, AM; Silingardi, M; Todeschini, P, 2023)	2.57
"Apixaban is a direct-acting oral anticoagulant that selectively inhibits factor Xa. "	( Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report. DelBianco, J; Jenniches, D; Kerns, AF; Philp, AS; Stripp, MP, 2023)	2.57
"Apixaban (Eliquis) is a direct acting oral anticoagulant (DOAC) indicated for treatment of deep vein thrombosis, non-valvular atrial fibrillation, pulmonary embolism and postoperative venous thromboprophylaxis following hip or knee replacement. "	( Apixaban-induced haematoma causing small bowel intussusception. Berry, G; Rodriguez, JM; Santos, AP, 2019)	3.4
"Apixaban acts as an inhibitor of blood clots formation."	( Thrombin Aptamer-Modified Metal-Organic Framework Nanoparticles: Functional Nanostructures for Sensing Thrombin and the Triggered Controlled Release of Anti-Blood Clotting Drugs. Chen, WH; Karmi, O; Nechushtai, R; Willner, B; Willner, I, 2019)	1.24
" Apixaban is a safe alternative to LMWH for the treatment in patients with CAT. "	( Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021)	1.89
"Oral apixaban is an effective alternative to enoxaparin as a thromboprophylactic drug for patients undergoing elective total knee replacement surgery."	( Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. Ali Hasan, M; Azeez Alsaadi, M; Tahseen Mehsen, J, 2021)	1.47
"Apixaban is a safe alternative to conventionally used enoxaparin for chemoprophylaxis in patients undergoing THA or TKA."	( Apixaban or enoxaparin: Which is better for thromboprophylaxis after total hip and total knee arthroplasty in Indian patients? Banerjee, S; Elhence, A; Garg, PK; Kunal, K, 2022)	2.89
"Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation pathway. "	( Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions. Dobrotova, M; Kubisz, P; Mokan, M; Samos, M; Stanciakova, L; Stasko, J, 2017)	3.34
"Apixaban is an oral direct factor Xa inhibitor superior to warfarin at preventing stroke or systemic embolism and may stabilize coronary atherosclerosis."	( Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression. Budoff, MJ; Li, D; Nakanishi, R; Nezarat, N; Osawa, K; Rahmani, S; Sheidaee, N; Win, TT, 2017)	1.43
"Apixaban is a selective factor Xa inhibitor, approved for use in the prevention of stroke in patients with nonvalvular atrial fibrillation and in the prevention and treatment of acute VTE."	( Quick reference guide to apixaban. Handa, A; Hurst, KV; O'Callaghan, JM, 2017)	1.48
"Apixaban is a direct oral anticoagulant (DOAC) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). "	( Assessment of Apixaban Prescribing Patterns for Nonvalvular Atrial Fibrillation in Hospitalized Patients. Davis, S; Gibson, CM; Scalese, MJ; Smith, CB, 2018)	2.28
"Apixaban is a new oral anticoagulant characterized by good bioavailability and renal elimination accounting for only 25%, showing a safety profile and effectiveness in patients with renal impairment."	( Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure. Carbonara, S; Ciccone, MM; Corbo, F; Cortese, F; Franchini, C; Gesualdo, M; Pia Schiavone, BI; Ricci, G; Scicchitano, P, 2017)	2.62
"Apixaban show to be an effective anticoagulant in patients with atrial fibrillation, even superior to warfarin in reducing the risk of stroke and systemic embolism regardless of the presence of renal insufficiency. "	( Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure. Carbonara, S; Ciccone, MM; Corbo, F; Cortese, F; Franchini, C; Gesualdo, M; Pia Schiavone, BI; Ricci, G; Scicchitano, P, 2017)	3.34
"Apixaban is a non-vitamin K oral anticoagulant approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). "	( Initial apixaban dosing in patients with atrial fibrillation. Bollmann, A; Buchholz, A; Dagres, N; Dinov, B; Gorczynska, K; Hilbert, S; Hindricks, G; Husser, D; Ueberham, L, 2018)	2.36
"Apixaban is a factor Xa inhibitor which is a non-vitamin K dependent oral anticoagulant known tocause the lowest rate of intracranial bleeding among the same kind of inibitors. "	( Apixaban-induced subdural bleeding: case presentation and literature review. Alayad, E; Aloraidi, A; Khairy, S, 2018)	3.37
"Apixaban is a direct oral anticoagulant (DOAC) with a specific inhibition of activated factor X (FXa). "	( Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery. Johnen, E; Körber, MK; Krüger, K; Langer, E; Schmidt, K; Schmutzler, M; von Heymann, C; Wernecke, KD, 2019)	2.34
"Apixaban is a direct oral anticoagulant, which inhibits factor Xa. "	( Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia. Cortes, J; Giner-Soriano, M; Gomez-Lumbreras, A; Morros, R; Quijada-Manuitt, MA, 2018)	2.25
"Apixaban is a favorably cost-effective alternative to warfarin in AF patients with normal kidney function and potentially cost-saving in those with renal impairment."	( Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Alshogran, OY; Altawalbeh, SM; Smith, KJ, 2018)	2.23
"Apixaban is an oral direct anti-Xa."	( Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Auger-Quittet, S; Bareau, B; Belhadj-Merzoug, K; Benboubker, L; Bosson, JL; Boyle, E; Cliquennois, M; Decaux, O; Fuzibet, JG; Karlin, L; Leleu, X; Leyronnas, C; Orsini-Piocelle, F; Pegourie, B; Pernod, G; Rey, P; Rodon, P; Royer, B; Slama, B; Tiab, M; Voog, E; Zarnitsky, C, 2019)	2.68
"Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been approved for clinical use in several thromboembolic disorders, including reduction of stroke risk in non-valvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, the treatment of deep vein thrombosis or pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism. "	( Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Boyd, RA; Byon, W; Frost, CE; Garonzik, S, 2019)	3.4
"Apixaban is an oral factor Xa inhibitor approved for stroke prevention in atrial fibrillation and thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery and under development for treatment of venous thromboembolism. "	( Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Barrett, YC; Boyd, RA; Byon, W; Frost, C; Lacreta, F; Mosqueda-Garcia, R; Nepal, S; Schuster, A; Shenker, A; Wang, J; Yu, Z, 2013)	2.06
"Apixaban is an oral, direct, factor-Xa inhibitor approved for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery and for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. "	( Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Barrett, YC; Boyd, RA; Byon, W; Frost, CE; LaCreta, FP; Pursley, J; Upreti, VV; Wang, J, 2013)	2.05
"Apixaban is a safe, effective, and attractive alternative to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. "	( The safety and efficacy of apixaban : where do we stand in 2013? Alexander, JH; de Souza Brito, F; Lopes, RD, 2013)	2.13
"Apixaban is a new oral anticoagulant with a direct, specific and reversible inhibitory action on coagulation factor Xa and with demonstrated safety and efficacy in the prophylaxis and treatment of venous thromboembolism in several clinical studies involving thousands of patients subjected to major orthopedic surgery."	( Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Arellano-Rodrigo, E; Escolar, G; Galán, AM; Pujadas-Mestres, L, 2013)	2.55
"Apixaban is a direct factor Xa inhibitor that has been shown in clinical trial use to safely reduce the composite of VTE and mortality rates in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA); however, the cost-effectiveness of apixaban treatment in Canadian settings has not been studied."	( A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. El-Hadi, W; Kadambi, A; Patterson, J; Raymond, V; Revankar, N, 2013)	1.37
"Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. "	( Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis. Malone, DC; Ross, D; Villa, LA, 2013)	2.1
"Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. "	( Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. Arellano-Rodrigo, E; Diaz-Ricart, M; Escolar, G; Fernandez-Gallego, V; Galan, AM; Lopez-Vilchez, I; Molina, P; Reverter, JC; Roquer, J; Sanz, VV, 2013)	2.21
"Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin."	( Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H; Rublee, DA, 2014)	1.44
"Apixaban is a substrate for various cytochrome P450 isoenzymes and for P-glycoprotein, creating a risk of multiple drug-drug interactions."	( Apixaban and atrial fibrillation: no clear advantage. , 2014)	2.57
"Apixaban was found to be a cost-effective alternative to warfarin and aspirin for stroke prevention in patients with AF in Sweden."	( Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. De Geer, A; Jacobson, L; Kongnakorn, T; Lanitis, T, 2014)	2.16
"Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and treatment of thromboembolic disorders. "	( Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. Baghaei, F; Berndtsson, M; Fagerberg Blixter, I; Faxälv, L; Gustafsson, KM; Hillarp, A; Lindahl, TL; Strandberg, K, 2014)	2.1
"Apixaban is a novel oral anticoagulant associated with significantly lower hazard rates for stroke, major bleedings and treatment discontinuations, compared to VKAs."	( Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. Le, HH; Pompen, M; Postma, MJ; Rozenbaum, MH; Stevanović, J; Tieleman, RG, 2014)	1.43
"Apixaban is a NOAC that selectively inhibits the coagulation factor Xa; it is approved for the prevention of VTE after total hip replacement and total knee replacement surgery."	( Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review. Benedetti, R; Caforio, M; Imberti, D; Maniscalco, P; Porcellini, G, 2015)	2.58
"Apixaban is a newly developed direct oral anticoagulant targeting activated factor X (FXa). "	( How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. Bassi, L; Chantarangkul, V; Legnani, C; Ludovici, S; Padovan, L; Peyvandi, F; Scalambrino, E; Testa, S; Tripodi, A, 2015)	2.14
"Apixaban is a cost-effective alternative to aspirin for patients with AF in Belgium who decline or cannot tolerate VKA treatment."	( Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. Annemans, L; Kongnakorn, T; Lanitis, T; Lieven, A; Marbaix, S; Thijs, V, 2014)	2.16
"Apixaban is an orally active inhibitor of coagulation factor Xa and is eliminated by multiple pathways, including renal and non-renal elimination. "	( Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Boyd, RA; Byon, W; Dias, C; Frost, CE; LaCreta, F; Schuster, AE; Shenker, A; Song, Y; Wang, J; Yu, Z; Zhang, D, 2015)	2.1
"Apixaban is a direct inhibitor of coagulation factor Xa. "	( [Proper use of apixaban: an outline for clinical practice]. Albaladejo, P; Deplanque, D; Fossati, F; Mahagne, MH; Mismetti, P; Mourad, JJ; Nguyen, P; Roy, P; Touze, E, 2014)	2.2
"Apixaban is an oral, direct factor Xa inhibitor indicated for the prevention and treatment of thromboembolic disease. "	( Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval. Boyd, R; Byon, W; Frost, C; LaCreta, F; Moore, K; Nepal, S; Reeves, RA, 2015)	2.07
"Apixaban is a novel oral anticoagulant which is approved for the management of atrial fibrillation and venous thromboembolism prophylaxis. "	( Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Aryal, MR; Ghimire, S; Karmacharya, P; Pandit, A; Pathak, R; Poudel, DR; Shamoun, FE, 2015)	2.13
"Apixaban is a direct oral anticoagulant (DOAC) targeting factor Xa and thus quenching thrombin generation and clot formation. "	( How the direct oral anticoagulant apixaban affects thrombin generation parameters. Padovan, L; Peyvandi, F; Scalambrino, E; Testa, S; Tripodi, A; Veena, C, 2015)	2.14
"Apixaban is an oral factor Xa inhibitor with a rapid onset of action and predictable pharmacokinetics that allows a fixed dose regimen. "	( Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside. Jezovnik, MK; Poredos, P, 2018)	2.18
"Apixaban is a factor Xa inhibitor recently approved for the treatment and prevention of VTE in the United States."	( Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants. Bongu, N; Chinnakotla, B; Kocheril, A; Turagam, MK; Velagapudi, P, 2015)	2.58
"Apixaban is a new oral anticoagulant (NOACs: Novel Oral Anticoagulant), like dabigatran, rivaroxaban, and edoxaban. "	( To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban. Ciccone, MM; Devito, F; Maiello, M; Palmiero, P; Zito, A, 2018)	2.16
"Apixaban is a direct factor Xa inhibitor approved for the treatment and prevention of thromboembolic disease. "	( Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage. Dickneite, G; Doerr, B; Herzog, E; Kaspereit, F; Krege, W; Mueller-Cohrs, J; Niebl, P, 2015)	2.11
"Apixaban is a cost-effective alternative to warfarin and dabigatran and is dominant over rivaroxaban in AF patients from the perspective of the Portuguese national healthcare system. "	( Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal. Borges, M; Caldeira, D; Costa, J; Fiorentino, F; Gouveia, M; Inês, M; Lopes Pereira, C; Pinheiro, L; Vaz-Carneiro, A, 2015)	1.86
"Apixaban is a substrate of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein. "	( Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Boyd, RA; Byon, W; Dias, C; Frost, C; LaCreta, F; Shenker, A; Vakkalagadda, B; Wang, J; Yu, Z; Zhang, D, 2016)	2.14
"Apixaban is a safe and effective anticoagulant for VTE treatment. "	( Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis. Chong, BH; Chong, JJ; Zheng, SS, 2016)	2.12
"Apixaban was found to be a cost-effective strategy over warfarin (incremental cost-effectiveness ratio=$25 816) and dominated other anticoagulants."	( Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Hayes, CJ; Martin, BC; Shah, A; Shewale, A, 2016)	1.16
"Apixaban is a new oral anticoagulant with the potential to overcome these limitations."	( Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016)	2.6
"Apixaban is likely to be a cost-effective alternative to warfarin for stroke prophylaxis in Chinese patients with NVAF in Hong Kong."	( Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. Chan, EW; Cheung, BM; Lau, WC; Li, X; Lip, GY; Tse, VC; Wong, IC, 2016)	2.19
"Apixaban is a novel oral anticoagulation agent that exerts its effect through direct factor Xa inhibition. "	( Anti-Xa activity in apixaban overdose: a case report. Barton, J; Graudins, A; Wong, A, 2016)	2.2
"Apixaban is a direct inhibitor of Factor Xa that was approved in December 2012 by the US Food and Drug Administration (FDA) for the prevention of stroke in patients with non-valvular atrial fibrillation."	( Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban. John, J; Mezue, K; Obiagwu, C; Shani, J; Sharma, A; Yang, F, 2017)	1.42
"Apixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment."	( Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Barasch, NS; Stanton, BE; Tellor, KB, 2017)	2.16
"Apixaban is a promising candidate and may be a useful alternative to warfarin for thromboprophylaxis of mechanical heart valves. "	( Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. Coleman, DM; Diaz, JA; Frost, CE; Grant, BT; Hawley, AE; Jackson, TO; Knabb, RM; Lester, PA; Mathues, AR; Myers, DD; Ramacciotti, E; Song, Y; Wakefield, TW, 2017)	3.34
"Apixaban is an attractive anticoagulant for stroke prevention in patients with AF with or without anemia."	( Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Alexander, JH; Alings, M; De Caterina, R; Granger, CB; Hanna, M; Hylek, EM; Keltai, M; Lopes, RD; Steg, PG; Thomas, L; van Gilst, WH; Wallentin, L; Westenbrink, BD; Wojdyla, DM, 2017)	1.38
"Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. "	( Apixaban, an oral, direct inhibitor of activated Factor Xa. Lip, GY; Shantsila, E, 2008)	3.23
"Apixaban is an oral, direct factor Xa (FXa) inhibitor in late-stage clinical development. "	( Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. Crain, EJ; Watson, CA; Wong, PC; Xin, B, 2009)	2.03
"Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clinical development for the prevention and treatment of thromboembolic diseases. "	( In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Chen, SY; Frost, CA; Frost, CE; Goosen, TC; Grossman, SJ; He, K; Humphreys, WG; Ma, L; Maxwell, BD; Raghavan, N; Wang, L; Yao, M; Zhang, D, 2010)	2.04
"Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clinical development for the prevention and treatment of thromboembolic diseases. "	( Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. Bostwick, JS; Schumacher, WA; Steinbacher, TE; Stewart, AB; Wong, PC; Xin, B, 2010)	2.07
"Apixaban is an orally active, selective, direct-acting, reversible inhibitor of factor Xa that is under evaluation for the management of acute coronary syndromes (ACS). "	( Apixaban in acute coronary syndromes. Eikelboom, JW; Karthikeyan, G, 2011)	3.25
"Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late-stage clinical development. "	( Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Jiang, X; Wong, PC, 2010)	3.25
"Apixaban is an oral, direct factor Xa inhibitor under development for secondary prevention in acute coronary syndrome (ACS). "	( Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Alexander, JH; Barrett, Y; Becker, RC; Harrington, RA; Mohan, P; Newby, LK; Wallentin, LC; Wang, J; Yang, H, 2010)	2.21
"Apixaban is a potent, highly selective, reversible, oral, direct factor Xa (fXa) inhibitor in development for thrombosis prevention and treatment. "	( Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Grace, JE; Grossman, SJ; He, B; He, K; Knabb, RM; Lam, PY; Luettgen, JM; Pinto, DJ; Wexler, RR; Wong, PC; Xin, B; Zhang, D, 2011)	2.06
"Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin."	( Apixaban versus warfarin in patients with atrial fibrillation. Al-Khalidi, HR; Alexander, JH; Ansell, J; Atar, D; Avezum, A; Bahit, MC; Diaz, R; Easton, JD; Ezekowitz, JA; Flaker, G; Garcia, D; Geraldes, M; Gersh, BJ; Golitsyn, S; Goto, S; Granger, CB; Hanna, M; Hermosillo, AG; Hohnloser, SH; Horowitz, J; Hylek, EM; Jansky, P; Lewis, BS; Lopes, RD; Lopez-Sendon, JL; McMurray, JJ; Mohan, P; Pais, P; Parkhomenko, A; Verheugt, FW; Wallentin, L; Zhu, J, 2011)	2.53
"Apixaban is a novel oral factor Xa inhibitor that recently completed evaluation in clinical trials for its use in the prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery. "	( Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Martin, MT; Nutescu, EA, 2011)	2.12
"Apixaban is a promising new agent awaiting regulatory approval for its use in thromboprophylaxis after TKA."	( Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Martin, MT; Nutescu, EA, 2011)	2.12
"Apixaban is a highly selective and potent Factor Xa Inhibitor with Ki=0 8nM to both free as well as prothrombinase bound FXa."	( Apixaban: a new player in the anticoagulant class. Agrawal, R; Dikshit, SN; Jain, P, 2012)	2.54
"Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free factor Xa and prothrombinase activity, and clot-bound factor Xa activity. "	( Apixaban: an oral direct factor-xa inhibitor. Jiménez, D; Ramacciotti, E; Yusen, RD, 2012)	3.26
"Apixaban is a potent, selective direct inhibitor of the coagulation factor Xa, recently approved in Europe for the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery."	( Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Gallerani, M; Imberti, D; Manfredini, R, 2012)	1.4
"Apixaban is an anticoagulant drug that acts by directly inhibiting coagulation factor Xa. "	( Practical use of apixaban in the prevention of venous thromboembolism after total knee or hip replacement. Lassen, MR, 2012)	2.16
"Apixaban (Eliquis™) is an orally active and selective direct inhibitor of factor Xa indicated for twice-daily use in the EU for the prevention of venous thromboembolism (VTE) in adults who have had knee or hip replacement surgery. "	( Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Deeks, ED, 2012)	3.26
"Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. "	( Apixaban: a novel oral inhibitor of factor Xa. Nutescu, E, 2012)	3.26
"Apixaban is a potent reversible inhibitor of the activated human coagulation factor X. "	( [Apixaban]. Konstantinides, S; Münzel, T, 2012)	2.73

Excerpt	Reference	Relevance
"Apixaban has an additional advantage of not requiring bridging with heparin which often necessitates long hospitalizations for patients with ESKD."	( Healthcare utilization differences between an apixaban-based and warfarin-based strategy for acute venous thromboembolism in patients with end-stage kidney disease. Ardeshirrouhanifard, S; Brotman, DJ; Deitelzweig, SB; Ellenbogen, MI; Segal, JB; Streiff, MB, 2023)	1.89
"Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer. "	( Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021)	2.28
"Apixaban has a half-life of about 12 hours, and the normal dosage is 5 mg orally twice daily."	( Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation. Lam, S, )	2.3
"Apixaban has been shown in the AVERROES trial to be superior to aspirin in preventing stroke and systemic embolism without significantly increasing the risk of major bleeding among patients with AF who are unsuitable for VKA therapy."	( Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. Annemans, L; Kongnakorn, T; Lanitis, T; Lieven, A; Marbaix, S; Thijs, V, 2014)	1.44
"Apixaban has been recently approved to use for the treatment of deep vein thrombosis."	( [Apixaban in the treatment of venous thrombosis associated with permanent pacemaker implantation]. Carrizo, S; Figueroa, JA; Vivero, A, 2015)	2.05
"Apixaban has been approved in the EU for the prevention of venous thromboembolism (VTE) after hip or knee replacement."	( Apixaban: first global approval. Perry, C; Watson, J; Whiteside, G, 2011)	2.53
"Apixaban has been studied in Phase II and Phase III trials for a variety of indications."	( Apixaban for the prevention of stroke in atrial fibrillation. Flaker, G; Littrell, R, 2012)	2.54
"Apixaban has been extensively studied worldwide in about 12,000 patients in four clinical studies that have demonstrated the efficacy and safety of apixaban respect to enoxaparin for the prevention of thromboembolism after major orthopedic surgery."	( Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Gallerani, M; Imberti, D; Manfredini, R, 2012)	1.4

Excerpt	Reference	Relevance
"Apixaban did not inhibit digoxin transport in Caco-2 cells."	( Characterization of efflux transporters involved in distribution and disposition of apixaban. Balimane, PV; Frost, CE; Gan, J; Han, YH; He, K; Herbst, JJ; Humphreys, WG; Kolb, J; Shou, W; Wang, L; Zhang, D, 2013)	1.34
"Apixaban had a lower risk of recurrent VTE, MB, and CRNMB compared to warfarin."	( Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status. Cohen, AT; Dhamane, AD; Emir, B; Hlavacek, P; Keshishian, A; Lee, T; Luo, X; Rosenblatt, L; Sah, J; Yuce, H, 2021)	1.64
"Apixaban showed a lower correlation coefficient for all TG parameters compared with rivaroxaban, and thrombin generation was less influenced by apixaban than rivaroxaban at plasma levels >100 ng/ml."	( Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA. Behrendt, LC; Bönigk, H; Franke, D; Metze, M; Petros, S; Pfrepper, C; Siegemund, A; Siegemund, T, 2022)	1.44
"Apixaban did not cause a missed diagnosis of protein S deficiency."	( Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods. Maryamchik, E; Van Cott, EM, 2020)	2.72
"Apixaban had lower MB (Hazard Ratio [HR]:0.76; 95% CI:0.64-0.91) and similar recurrent VTE risks (HR:1.04; 95% CI:0.75-1.43) vs warfarin."	( Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population. Ferri, M; Guo, JD; Hlavacek, P; Keshishian, A; Mardekian, J; McBane, R; Poretta, T; Rosenblatt, L; Russ, C; Yuce, H, 2021)	1.64
"Apixaban showed lower hemorrhagic risk alone (HR 0.24, 95% CI 0.10-0.55) and similar risk when administered with antiplatelets (HR 0.93, 95% CI 0.55-1.56)."	( Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference? Cooper, C; George, J; Ionescu, F; Mansuri, S; Petrescu, I, 2021)	1.75
"Apixaban may have a lower risk of major bleeding and comparable risk of stroke when compared with warfarin in AF patients with ESRD."	( Safety and Efficacy of Apixaban, Rivaroxaban, and Warfarin in End-Stage Renal Disease With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Abdullah, HM; Alam, M; Alraies, MC; Fischman, DL; Jafar, MS; Saeed, R; Ullah, W; van Zyl, M, 2021)	2.37
"Apixaban had a lower rate of CRNMB compared with rivaroxaban in patients with GI cancer (3.83 vs 9.40 per 100 person-years; P=.03)."	( Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021)	1.56
"With apixaban lower costs per patient in TKR (-14 €) were generated, so it was the dominant treatment."	( [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement]. Betegón-Nicolás, L; de Salas-Cansado, M; Gómez-Arrayás, I; Gómez-Cerezo, JF; Rubio-Terrés, C; Suárez-Fernández, C, )	0.87
"Apixaban did not cause false-positive lupus anticoagulant results."	( Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. Baghaei, F; Berndtsson, M; Fagerberg Blixter, I; Faxälv, L; Gustafsson, KM; Hillarp, A; Lindahl, TL; Strandberg, K, 2014)	1.38
"Apixaban yielded a lower NNT/year for preventing death than for primary-outcome prevention."	( Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights. Cheung, BM; Kumana, CR; Lauder, IJ; Siu, DC; Tse, HF, 2016)	1.16
"Apixaban would generate more costs per patient for the NHS (€1,742 per patient) but savings would result from the social perspective (€2,887 saved per patient)."	( [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain]. Barón-Esquivias, G; Betegón-Nicolás, L; Canal-Fontcuberta, C; de Salas-Cansado, M; Escolar-Albaladejo, G; Rubio-Rodríguez, D; Rubio-Terrés, C; Zamorano, JL, )	1.14
"Apixaban, a probable cause for the hepatocellular injury, was discontinued and replaced with intravenous unfractionated heparin to bridge anticoagulation with warfarin."	( Apixaban-induced liver injury. Alsaad, AA; Clarke, SA; Mack, A; Phillips, MB, 2016)	2.6
"Apixaban had a lower risk of association with GI bleeding in the very elderly than dabigatran (HR, 0.45; 95% CI, 0.29-0.71) or rivaroxaban (HR, 0.39; 95% CI, 0.25-0.61)."	( Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Abraham, NS; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X, 2017)	1.18
"Apixaban also had lower major or clinically relevant bleeding (by 34%) compared with rivaroxaban."	( Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2012)	1.1
"All apixaban groups had lower primary efficacy event rates than either comparator."	( The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. Ansell, J; Davidson, BL; Deitchman, D; Gallus, A; Lassen, MR; Pineo, G, 2007)	1.12

Excerpt	Reference	Relevance
"In apixaban-treated patients, the D-dimer level in the left atrium was lower than in edoxaban-treated patients on the day of ablation, suggesting that the anticoagulant effect of apixaban on the left atrium is better than that of edoxaban in patients with AF."	( Difference in left atrial D-dimer level in patients with atrial fibrillation treated with direct oral anticoagulant. Fukuoka, H; Hoshida, S; Inoue, S; Inui, H; Minamisaka, T; Mine, K; Shinoda, Y; Tachibana, K; Ueno, K; Watanabe, T, 2021)	1.24
"New apixaban treatment was followed for the first 6 months."	( Direct costs in patients with nonvalvular atrial fibrillation newly indicated to apixaban: a retrospective prospective single arm cohort study. Doležal, T; Doležalová, H; Herold, M; Lžičařová, L; Měrou, TAPS; Pilnáčková, B; Štrosová, D; Tužil, J; Typovská, V, 2022)	1.43
"Apixaban treatment was discontinued, and mechanical ventilation was initiated."	( Apixaban-Associated Diffuse Alveolar Hemorrhage in an Elderly Man with Multiple Complications. Fukunaga, K; Hayashida, K; Ishii, M; Kajino, A; Kamata, H; Kishino, Y; Nishie, M; Otake, S; Ozawa, T; Saito, A; Terai, H, 2022)	2.89
"Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin."	( Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. Arachchillage, DRJ; Farag, M; Gorog, DA; Gue, Y; Lip, GYH; Spinthakis, N; Srinivasan, M; Wellsted, D, 2019)	2.68
"Apixaban treatment initiation had minimal influence on the level of immunosuppression."	( Apixaban Level and Its Influence on Immunosuppression and Graft Outcome in Kidney Transplant Recipients With Atrial Fibrillation. Avni, S; Fuchs, S; Green, H; Nissan, R; Rahamimov, R; Rozen-Zvi, B; Spectre, G, 2021)	2.79
"Apixaban treatment discontinuation occurred in a total of 122 patients during follow-up (12.5/100 patient-years in Kaplan-Meier analysis)."	( Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. Beyer-Westendorf, J; Helmert, S; Marten, S; Mizera, H; Reitter, A; Sahin, K; Tittl, L, 2017)	1.47
"apixaban n = 4802 per treatment group)."	( Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system. Ahmad, A; Evans, A; Oh, K; Petrini, M; Rush, T; Schwartzman, E; Tang, W; Thompson, D; Villines, TC, 2019)	1.47
"Apixaban treatment was associated with the most favourable safety profile of the NOACs, showing a statistically significantly reduced risk of 'major or clinically relevant non-major (CRNM) bleed' compared with rivaroxaban (0.47 [0.36, 0.61]), dabigatran (0.69 [0.51, 0.94]), and edoxaban (0.54 [0.41, 0.69])."	( Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Batson, S; Bird, A; Cohen, AT; Hamilton, M; Liu, X; Mitchell, SA; Phatak, H; Tushabe, D, 2015)	1.4
"Apixaban treatment was associated with a nonsignificant trend toward reduction in the composite of clinical ischemic stroke and covert embolic-pattern infarction and did not increase the number of microbleeds in patients with atrial fibrillation compared with aspirin."	( Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Avezum, A; Connolly, S; Dias, R; Diener, HC; Eikelboom, JW; Flaker, G; Gladstone, DJ; Hart, RG; Lewis, G; O'Donnell, MJ; Sharma, M; Smith, EE; Yusuf, S; Zhu, J, 2016)	2.28
"Apixaban treatment was cost-effective compared to 6-month treatment with LMWH/VKA at an incremental cost-effectiveness ratio (ICER) of £6692 per QALY."	( Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. Browne, C; Cohen, AT; Hamilton, M; Lanitis, T; Leipold, R; Quon, P; Rublee, D, 2017)	1.49
"The apixaban treatment resulted in favorable and effective control of the patient's VTE on day33."	( Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy. Hamahata, K; Nohgawa, M; Oka, S; Shiragami, H; Takeuchi, S, 2017)	1.19
"apixaban). In the treatment model, these inhibitors equally prevented growth of a preformed thrombus."	( Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. Crain, EJ; Watson, CA; Wong, PC; Xin, B, 2009)	1.31
"Treatment with apixaban resulted in total cost savings of €883 and higher life years (LYs) and quality-adjusted LYs (QALYs) per patient than VKA (net difference, LYs: 0.13; QALYs: 0.11). "	( Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. Dhanda, D; Di Fusco, M; Kang, A; Kongnakorn, T; Polanco, C; Rivolo, S; Savone, M; Skandamis, A; Soto, J, 2021)	1.26
"Treatment with apixaban was introduced, initially in a dose of 2.5 mg twice daily, as creatinine concentration was 2.0 mg/dl, and after 2 days - when creatinine concentration dropped, the dose was augmented to 5 mg twice a day."	( Fast apixaban-related resolution of left ventricular thrombi in a patient with dilated cardiomyopathy. Elikowski, W; Fertała, N; Kruzel, K; Małek-Elikowska, M; Zawodna, M, 2018)	1.33
"Treatment with apixaban compared with warfarin for stroke prevention in patients with AF was associated with less reduction in thrombin generation and fibrin turnover. "	( Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Alexander, JH; Alings, M; Andersson, U; Christersson, C; De Caterina, R; Gersh, BJ; Granger, CB; Halvorsen, S; Hanna, M; Huber, K; Hylek, EM; Lopes, RD; Oh, BH; Siegbahn, A; Wallentin, L, 2019)	1.27
"Treatment with apixaban compared to VKAs resulted in an ICER of €10,576 per quality adjusted life year (QALY). "	( Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. Le, HH; Pompen, M; Postma, MJ; Rozenbaum, MH; Stevanović, J; Tieleman, RG, 2014)	1.07
"Treatment with apixaban versus placebo for 12 months significantly reduced symptomatic recurrent venous thromboembolism (VTE) or all-cause death without increasing the rate of major bleeding in the AMPLIFY-EXT trial. "	( Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial. Cohen, AT; Johnson, M; Liu, X; Mardekian, J; Phatak, H; Porcari, A; Thompson, J, 2016)	1.08
"Treatment with apixaban (RR 0.23, 95% CrI 0.10, 0.55) or dabigatran (RR 0.55, 95% Crl 0.43, 0.71) was associated with a statistically significantly reduced risk of 'major or clinically relevant non-major bleed' compared with warfarin INR 2.0-3.0."	( Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Batson, S; Bird, A; Cohen, AT; Hamilton, M; Horblyuk, R; Li, S; Mitchell, SA, 2016)	1.03

Excerpt	Reference	Relevance
" Most adverse events were mild or moderate."	( Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-. Kanmuri, K; Ogawa, S; Shinohara, Y, 2011)	0.61
"Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation."	( Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S, 2012)	0.62
" Subjects underwent safety assessments and were monitored for adverse events (AEs)."	( Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Barrett, YC; Boyd, RA; Byon, W; Frost, C; Lacreta, F; Mosqueda-Garcia, R; Nepal, S; Schuster, A; Shenker, A; Wang, J; Yu, Z, 2013)	0.62
"Multiple oral doses of apixaban were safe and well tolerated over a 10-fold dose range, with pharmacokinetics with low variability and concentration-related increases in clotting time measures."	( Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Barrett, YC; Boyd, RA; Byon, W; Frost, C; Lacreta, F; Mosqueda-Garcia, R; Nepal, S; Schuster, A; Shenker, A; Wang, J; Yu, Z, 2013)	0.93
" Adverse events, vital signs and laboratory assessments were monitored."	( Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Barrett, YC; Boyd, RA; Byon, W; Frost, CE; LaCreta, FP; Pursley, J; Upreti, VV; Wang, J, 2013)	0.6
" Only after the preceding dose was confirmed to be safe and well-tolerated subjects were enrolled into the next-higher-dose panel."	( Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Frost, C; Fukase, H; Hiraoka, M; LaCreta, F; Pursley, J; Wang, J; Yamahira, N; Yu, Z, 2014)	0.63
"Apixaban was safe and well-tolerated in these healthy Japanese male subjects across the doses evaluated."	( Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Frost, C; Fukase, H; Hiraoka, M; LaCreta, F; Pursley, J; Wang, J; Yamahira, N; Yu, Z, 2014)	2.07
"Apixaban was safe and well-tolerated in healthy Japanese subjects."	( Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Frost, C; Fukase, H; Hiraoka, M; LaCreta, F; Pursley, J; Wang, J; Yamahira, N; Yu, Z, 2014)	2.07
" Left atrial ablation procedures under continuous oral anticoagulation with apixaban are feasible and as safe as under continuous oral anticoagulation with phenprocoumon."	( Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Ammar, S; Bourier, F; Buiatti, A; Deisenhofer, I; Dillier, R; Grebmer, C; Hessling, G; Kaess, BM; Kolb, C; Lennerz, C; Reents, T; Semmler, V, 2015)	0.85
" Of importance, adverse event rates did not differ between the two groups after adjusting by a propensity score analysis."	( Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015)	0.73
"The use of apixaban during the periprocedural period of AF ablation seemed as efficacious and safe as warfarin."	( Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015)	1.12
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation."	( Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015)	0.42
" Comparing the pharmacovigilance reports for the individual NOACs, more hepatic adverse events were reported for rivaroxaban than for dabigatran or apixaban."	( Hepatotoxicity of New Oral Anticoagulants (NOACs). Krähenbühl, S; Liakoni, E; Rätz Bravo, AE, 2015)	0.62
" Bleeding is an adverse event in patients taking anticoagulants."	( To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban. Ciccone, MM; Devito, F; Maiello, M; Palmiero, P; Zito, A, 2018)	0.72
"Apixaban was as effective and safe as VKAs in the periprocedural period of CA."	( Meta-Analysis of Efficacy and Safety of Apixaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation. Liu, Q; Lu, D; Shan, QJ; Wang, K; Zhang, QI, 2016)	2.14
" Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as efficacious, safe and convenient stroke prevention agents."	( Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H, 2016)	0.64
"Apixaban, one of the non-vitamin K antagonist oral anticoagulants, was reported to be effective and safe in stroke prevention in patients with atrial fibrillation (AF) based on the global randomized clinical trial, but data are limited on the efficacy and safety of apixaban in Japanese elderly patients."	( Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. Akao, M; Okumura, K; Yamashita, T, 2016)	2.09
"Anticoagulation with NOAC with a short period of periprocedural interruption without bridging with LMWH seems safe and well-tolerated."	( Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation. Hansen, PS; Sanchez, R; Walfridsson, H, 2016)	0.43
" This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the setting of PVI using CB."	( The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients. Dahmen, A; Gorr, E; Hoppe, C; Horlitz, M; Keskin, K; Koektuerk, B; Schoett, M; Turan, CH; Turan, RG; Yang, A; Yorgun, H, 2016)	0.43
"The incidence of adverse events in PVI using the second-generation CB with the periprocedural administration of NAOCs was not significantly different compared to phenprocoumon."	( The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients. Dahmen, A; Gorr, E; Hoppe, C; Horlitz, M; Keskin, K; Koektuerk, B; Schoett, M; Turan, CH; Turan, RG; Yang, A; Yorgun, H, 2016)	0.43
" All NOACs seem to be safe and effective alternatives to warfarin in a routine care setting."	( Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F, 2016)	0.43
" In conclusion, DOACs are effective and safe for the extended treatment of VTE, and may reduce the risk of all-cause mortality."	( Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F, 2016)	0.43
"Driven by the need of pharmacovigilance centres and companies to routinely collect and review all available data about adverse drug reactions (ADRs) and adverse events of interest, we introduce and validate a computational framework exploiting dominant as well as emerging publicly available data sources for drug safety surveillance."	( Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies. Jaulent, MC; Koutkias, VG; Lillo-Le Louët, A, 2017)	0.46
" We acquired data from the FDA Adverse Event Reporting System (FAERS), PubMed and Twitter."	( Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies. Jaulent, MC; Koutkias, VG; Lillo-Le Louët, A, 2017)	0.46
" In order to contribute to the debate on their safety profile, we conducted a comparative analysis of the reports of suspected adverse drug reactions (ADRs) associated with DOACs in VigiBase."	( Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Biagi, C; Conti, V; Donati, M; Melis, M; Monaco, L; Motola, D; Vaccheri, A; Venegoni, M, 2017)	0.46
"Cerebrovascular adverse events collected by the Pharmaceutical and Medical Devices Agency (PMDA) during 2014 were analyzed to describe and compare efficacy and safety among patients prescribed DTI and FXa."	( Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data. Terayama, Y, 2017)	0.46
" In addition, NOACs have been demonstrated to be safe and associated with a significant reduction in major and intracranial bleeding events."	( [New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world]. Di Pasquale, G; Riva, L, 2017)	0.46
"End points and adverse events (AEs) are collected separately in clinical trials, yet regulatory requirements for serious AE reporting vary across regions, so classifying end points according to seriousness criteria can be useful in global trials."	( Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. Alexander, JH; Alexander, KP; Giraldez, RRCV; Guimarães, PO; Haque, G; James, SK; Lopes, RD; Stevens, SR; Wruck, L; Zimerman, A, 2017)	0.46
" In conclusion, the use of apixaban is as safe and effective as warfarin for uninterrupted OA therapy during catheter-based ablation of AF."	( Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation. Doppalapudi, H; Gunter, A; Kumar, V; Maddox, WR; McElderry, T; Meggo, D; Pentecost, E; Pillai, A; Plumb, V; Schafer, P; Shah, RR; Yamada, T, 2017)	1.03
" The secondary efficacy outcome was major adverse cardiovascular events (MACE; composite of myocardial infarction, stroke, and all-cause mortality)."	( Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome. Arshad, A; Kaluski, E; Khan, SU; Nasir, F; Riaz, IB; Talluri, S, 2018)	0.71
" Patients commenced on NOACs should be assessed and followed up in a multidisciplinary AF clinic to ensure safe and effective prescribing and stroke prevention."	( Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke pre Burke, C; Collins, R; Coughlan, T; Egom, EE; McAuliffe, C; McHugh, J; Moore, D; Morrissey, E; O'Brien, J; Pharithi, RB; Ranganathan, D; Ryan, D; Vaughan, M, 2019)	0.51
"The safety of the NOACs compared with warfarin was generally favourable across different patient subgroups, including those perceived to be at "high risk" for adverse outcomes."	( The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. Lip, GYH, 2019)	0.51
" Our data might give some assurance to clinicians that apixaban can be an effective and safe therapeutic option for treatment of patients with venous thromboembolism."	( Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Brown, J; Dawwas, GK; Dietrich, E; Park, H, 2019)	1.06
"Our findings provide evidence that apixaban is efficacious and safe across the spectrum of weight, including in low- (≤60 kg) and high-weight patients (>120 kg)."	( Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Al-Khatib, SM; Alexander, JH; Atar, D; Bahit, MC; Ezekowitz, JA; Fudim, M; Granger, CB; Hanna, M; Hijazi, Z; Hohnloser, SH; Lopes, RD; Lopez-Sendon, JL; Wallentin, L; Wojdyla, DM, 2019)	1.1
"Direct oral anticoagulants (DOACs) are at least as efficacious and safe as warfarin among non-valvular atrial fibrillation (NVAF) patients; limited evidence is available regarding NVAF patients with heart failure (HF)."	( Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. Amin, A; Dhamane, A; Di Fusco, M; Friend, K; Garcia Reeves, AB; Keshishian, A; Li, X; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H, 2019)	0.51
"We analyzed adverse event cases submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from January 2013 to December 2018."	( Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS). Choshen Cohen, L; Goldstein, R; Muszkat, M; Perlman, A; Singer, DE; Wanounou, M, 2019)	0.51
"During this period, 9693 adverse event cases reported concomitant use of FXa-DOACs and AEDs."	( Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS). Choshen Cohen, L; Goldstein, R; Muszkat, M; Perlman, A; Singer, DE; Wanounou, M, 2019)	0.51
" The risks of ischemic stroke, intracranial hemorrhage (ICH), major bleeding, mortality, and composite adverse events were compared between NOACs and warfarin in all patients ≥ 65 years of age and, specifically, with different age strata (ie, 65-74, 75-89, ≥ 90 years)."	( Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Chao, TF; Chen, SA; Chen, TJ; Chiang, CE; Liao, JN; Lip, GYH, 2020)	0.56
"Compared with warfarin, NOACs were associated with a significantly lower risk of adverse events, with heterogeneity in treatment effects among different age strata."	( Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Chao, TF; Chen, SA; Chen, TJ; Chiang, CE; Liao, JN; Lip, GYH, 2020)	0.56
" Secondary outcomes included incidence of venous thromboembolic events, adverse events, medication adherence, participant quality of life, and medication satisfaction."	( Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. Babayan, LM; Behbakht, K; Breed, CA; Brennecke, A; Cheng, G; Corr, BR; Flink, D; Guntupalli, SR; Lefkowits, C; Matsuo, K; Ramzan, AA; Sheeder, J; Tayebnejad, A; Wheeler, LJ, 2020)	0.87
"68), adverse events, medication adherence, or quality of life between the groups."	( Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. Babayan, LM; Behbakht, K; Breed, CA; Brennecke, A; Cheng, G; Corr, BR; Flink, D; Guntupalli, SR; Lefkowits, C; Matsuo, K; Ramzan, AA; Sheeder, J; Tayebnejad, A; Wheeler, LJ, 2020)	0.87
" Early administration of apixaban (< 48 h), after onset of acute LVO in patients with NVAF, was generally safe compared with those who received it Late (≥ 48 h)."	( Safety of Early Administration of Apixaban on Clinical Outcomes in Patients with Acute Large Vessel Occlusion. Enomoto, Y; Ezura, M; Fukawa, N; Hatano, T; Imamura, H; Kamiya, Y; Kimura, N; Matsumoto, Y; Morimoto, M; Morimoto, T; Nonaka, T; Ohta, H; Ota, T; Sakai, N; Shibata, M; Shimamura, N; Shimizu, F; Takeuchi, M; Tanaka, K; Uchida, K; Yamagami, H; Yoshimura, S, 2021)	1.2
"Our real-life data study suggests that secondary stroke prevention with DOACs is as effective and safe as primary prevention, both in standard and reduced doses, in a typical group of patients who are older than patients included in RCTs."	( Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention. Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP, 2020)	0.56
"Primary thromboprophylaxis with apixaban therapy seems to be safe and effective in patients with gastrointestinal cancers."	( Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. Caiano, L; Carrier, M; Ladha, D; Mallick, R; Wang, TF; Wells, PS, 2021)	1.22
" These data suggest that apixaban may be safe to use for lung transplant patients, and larger studies are warranted to assess long-term outcomes as well as safety and efficacy of alternative DOACs."	( A retrospective analysis of the safety and efficacy of apixaban use after lung transplant. Ausloos, KA; Grazia, TJ; Lam, ILL; Naik, CA; Patel, RS; Reininger, KA; Rosenblatt, RL; Sam, T, 2021)	1.17
" Setting FDA Adverse Event Reporting System (FAERS) database."	( Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database. Cui, X; Guo, M; Thai, S; Wang, T; Wei, J; Xu, W; Zhao, Y; Zhou, J, 2021)	0.92
" There were no unacceptable toxicities to report and no treatment-related adverse events."	( Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma. Chan, K; Goodwin, A; Holmes, CE; Prasad, P; Ross, H; Thomas, AA; Wright, H, 2022)	1.12
" We used weighted Cox proportional hazards models to estimate separately the hazard ratios (HRs) with 95% confidence intervals (CIs) of ischemic stroke, major bleeding, and major adverse limb events associated with the use of apixaban compared with rivaroxaban."	( Effectiveness and Safety of Apixaban versus Rivaroxaban in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus. Azoulay, L; Chowdhury, KR; Michaud, J; Renoux, C; Yin, H; Yu, OHY, 2022)	1.2
"In conclusion, 30 days of postoperative apixaban appears to be safe and effective with minimal side effects while preventing thromboembolic events."	( The Safety and Efficacy of Apixaban (Eliquis) in 5017 Post-bariatric Patients with 95.3% Follow-up: a Multicenter Study. Belnap, L; Cottam, D; Medlin, W; Potts, J; Richards, C; Roslin, M; Surve, A; Uchal, M, 2022)	1.29
"Heparin-induced thrombocytopenia (HIT) is a serious adverse drug reaction due to its related risk of life- and limb-threatening thrombosis."	( An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022)	0.94
"Apixaban is safe to use for anticoagulation of heart transplant recipients undergoing routine biopsies."	( The utilization and safety of apixaban for therapeutic anticoagulation in heart transplant population requiring routine endomyocardial biopsies. Badiye, A; Baran, DA; Cameron, C; Herre, JM; Ingemi, AI; Lichvar, A; Lindauer, KE; McMahon, MR; Old, W; Sawey, EJ; Yao, A; Yehya, A, 2022)	2.45
"We investigated whether apixaban is safe for the prevention of further adverse events in non-valvular atrial fibrillation (NVAF) patients with intra-/extracranial artery stenosis (Stenosis group) compared with acute large vessel occlusion without intra-/extracranial artery stenosis (No stenosis group)."	( Safety of Apixaban Monotherapy for Non-Valvular Atrial Fibrillation-Related Acute Stroke with Intra-/Extracranial Artery Stenosis. Enomoto, Y; Ezura, M; Fukawa, N; Hatano, T; Koyanagi, M; Matsumoto, Y; Morimoto, M; Morimoto, T; Nonaka, T; Ogura, T; Ohta, H; Ota, T; Sakai, N; Shibata, M; Shimizu, F; Takeuchi, M; Uchida, K; Yamagami, H; Yoshimura, S, 2023)	1.62
"Apixaban monotherapy appears safe for the prevention of further adverse events in the Stenosis group patients similar to the No stenosis group patients."	( Safety of Apixaban Monotherapy for Non-Valvular Atrial Fibrillation-Related Acute Stroke with Intra-/Extracranial Artery Stenosis. Enomoto, Y; Ezura, M; Fukawa, N; Hatano, T; Koyanagi, M; Matsumoto, Y; Morimoto, M; Morimoto, T; Nonaka, T; Ogura, T; Ohta, H; Ota, T; Sakai, N; Shibata, M; Shimizu, F; Takeuchi, M; Uchida, K; Yamagami, H; Yoshimura, S, 2023)	2.76
" Poisson regression and Cox proportional hazard models were used to estimate adjusted adverse event rates."	( Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation. Ali, MA; Barnes, GD; DeCamillo, D; Haymart, B; Kaatz, S; Kong, X, 2023)	1.15

Excerpt	Reference	Relevance
" While the anticoagulant effect of the new thrombin and FXa inhibitors is similar, differences in the pharmacokinetic and pharmacodynamic parameters may influence their use in clinical practice."	( Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Eriksson, BI; Quinlan, DJ; Weitz, JI, 2009)	0.35
" Studies of apixaban in rabbits showed a good correlation between apixaban concentrations and inhibition of FXa activity, prolongation of prothrombin time and modified prothrombin time, with no lag time between these ex vivo pharmacodynamic markers and plasma drug levels."	( Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. Crain, EJ; He, B; He, K; Luettgen, JM; Raghavan, N; Wang, L; Wong, PC; Xin, B; Zhang, D, 2010)	0.97
" The preclinical pharmacokinetic (PK) attributes of apixaban feature small volume of distribution (Vd), low systemic clearance (CL), and good oral bioavailability."	( Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Grace, JE; Grossman, SJ; He, B; He, K; Knabb, RM; Lam, PY; Luettgen, JM; Pinto, DJ; Wexler, RR; Wong, PC; Xin, B; Zhang, D, 2011)	0.87
"Compared with the reference body weight group, low body weight had approximately 27% [90% confidence interval (CI): 8-51%] and 20% (90% CI: 11-42%) higher apixaban maximum observed plasma concentration (Cmax) and area under the concentration-time curve extrapolated to infinity (AUC(0,∞)), respectively, and high body weight had approximately 31% (90% CI: 18-41%) and 23% (90% CI: 9-35%) lower apixaban Cmax and AUC(0,∞) , respectively."	( Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Barrett, YC; Boyd, RA; Byon, W; Frost, CE; LaCreta, FP; Pursley, J; Upreti, VV; Wang, J, 2013)	0.8
" The present method was successfully applied to a pharmacokinetic study following oral administration of apixaban."	( Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. Basset, T; Delavenne, X; Mismetti, P, 2013)	0.91
" Though the anticoagulation efficacy of these NOACs has been characterized, differences in their pharmacokinetic and pharmacodynamic profiles have become a significant consideration in terms of drug selection and dosing."	( Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Gong, IY; Kim, RB, 2013)	0.6
"To review pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs) involving new oral anticoagulants for atrial fibrillation."	( Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Gulseth, M; Hellwig, T, 2013)	0.39
"Articles reviewed focused on drugs affecting the permeability glycoprotein (P-gp) efflux transporter protein and/or cytochrome P (CYP) 450 3A4 enzymes, and pharmacodynamic DDIs when drugs are administered concomitantly."	( Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Gulseth, M; Hellwig, T, 2013)	0.39
" Pharmacokinetic parameters, including peak plasma concentration (Cmax), time to Cmax (Tmax), area under the concentration-time curve from time 0 to infinity (AUCINF), and terminal half-life (T½), were derived from apixaban plasma concentration-time data."	( Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Boyd, RA; Frost, C; Mondal, S; Tirucherai, G; Wang, J; Wang, X; Zhang, D, 2014)	0.87
" Apixaban Cmax and Tmax were similar across treatments."	( Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Boyd, RA; Frost, C; Mondal, S; Tirucherai, G; Wang, J; Wang, X; Zhang, D, 2014)	1.6
"To assess pharmacokinetic and pharmacodynamic interactions between naproxen (a non-steroidal anti-inflammatory drug) and apixaban (an oral, selective, direct factor-Xa inhibitor)."	( Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Barrett, YC; Boyd, RA; Byon, W; Frost, C; Gandhi, MD; LaCreta, F; Pursley, J; Shenker, A; Wang, J; Zhang, D, 2014)	0.83
" The pharmacokinetics of apixaban and effect on pharmacodynamic variables (clotting assays and anti-Xa activity) were assessed on day 1 and day 7 of treatment."	( Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Frost, C; Fukase, H; Hiraoka, M; LaCreta, F; Pursley, J; Wang, J; Yamahira, N; Yu, Z, 2014)	0.93
" The pharmacokinetic profile of apixaban following multiple twice-daily doses was linear, and exposure parameters such as C(max), observed at ~ 3 hours post-dose, and area under the plasma concentration-time curve increased in a dose-proportional manner."	( Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Frost, C; Fukase, H; Hiraoka, M; LaCreta, F; Pursley, J; Wang, J; Yamahira, N; Yu, Z, 2014)	0.91
" Blood and urine samples were collected for pharmacokinetic and pharmacodynamic (blood only) analyses."	( Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Barrett, YC; Frost, CE; Harris, SI; LaCreta, F; Schuster, A; Shenker, A; Song, Y; Wang, J, 2015)	0.64
" All three pharmacodynamic measures exhibited a positive linear correlation with the plasma apixaban concentration."	( Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Barrett, YC; Frost, CE; Harris, SI; LaCreta, F; Schuster, A; Shenker, A; Song, Y; Wang, J, 2015)	0.86
"To determine pharmacokinetic and pharmacodynamic properties of the novel factor Xa inhibitor apixaban in clinically normal cats."	( Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats. Bright, JM; Martinez, CM; Myers, JA; Olver, CS; Wittenburg, LA, 2015)	0.87
" Pharmacodynamic effects of apixaban were determined with a commercial assay for factor × activity, which measures endogenous factor Xa activity chromogenically."	( Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats. Bright, JM; Martinez, CM; Myers, JA; Olver, CS; Wittenburg, LA, 2015)	0.95
" Pharmacokinetic analysis revealed moderate clearance, short half-life, and high bioavailability for apixaban."	( Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats. Bright, JM; Martinez, CM; Myers, JA; Olver, CS; Wittenburg, LA, 2015)	0.87
" Blood samples were collected for determination of apixaban pharmacokinetic parameters, measures of clotting (prothrombin time, international normalized ratio, activated partial thromboplastin time), and anti-factor Xa (FXa) activity."	( Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. Boyd, RA; Chang, M; Frost, C; Marbury, TC; Pursley, J; Song, Y; Tirucherai, G; Wang, J; Wang, X; Zhang, D, 2016)	0.94
" Secondary objectives included assessment of safety and tolerability as well as international normalized ratio (INR) and anti-factor Xa activity as pharmacodynamic endpoints."	( Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. Boyd, RA; Byon, W; Chang, M; Frost, CE; LaCreta, F; Pursley, J; Shenker, A; Wang, J; Yu, Z, 2016)	0.66
"These studies evaluate the relative bioavailability of crushed apixaban tablets and the effect of food on apixaban pharmacokinetic properties."	( Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Chang, M; Frost, C; Frost, RJ; Kelly, A; LaCreta, F; Song, Y; Suzuki, A, 2016)	0.9
" Cmax and AUC decreased by 21."	( Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Chang, M; Frost, C; Frost, RJ; Kelly, A; LaCreta, F; Song, Y; Suzuki, A, 2016)	0.66
" Current apixaban dosing recommendations for this patient population are based largely on a single-dose pharmacokinetic study of eight patients."	( Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis. Kufel, WD; Lehmann, DF; Miller, CD; Zayac, AS, 2016)	1.1
"The objective was to characterise apixaban pharmacodynamic (PD) activity in umbilical cord (UC), paediatric, and adult plasma."	( Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma. Adamczyk, R; Barrett, YC; Frost, C; Ramacciotti, E; Wang, J; Wang, Z; Yetman, RJ, 2017)	2.18
" The pharmacokinetics in patients treated with standard and reduced doses of the four anticoagulants using liquid chromatography-tandem mass spectrometry was compared with the concentration ranges estimated using physiologically based pharmacokinetic modeling."	( Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital. Endo, S; Kishi, H; Kogiku, M; Noda, M; Notsu, Y; Ota, M; Shimizu, M; Takekawa, M; Yamazaki, H; Yamazaki-Nishioka, M, 2019)	0.79
" Apixaban is rapidly absorbed, with maximum concentration occurring 3-4 h after oral administration, and has a half-life of approximately 12 h."	( Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Boyd, RA; Byon, W; Frost, CE; Garonzik, S, 2019)	2.87
" Physiologically-based pharmacokinetic models for apixaban and rivaroxaban were developed to estimate the net effect of CYP3A induction, P-gp inhibition, and P-gp induction by rifampicin."	( Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A. Bonate, PL; Choules, MP; Komatsu, K; Otsuka, Y, 2020)	0.81
"To develop a physiologically based pharmacokinetic (PBPK) model for apixaban, an oral anticoagulant with a narrow therapeutic index, and to predict PK profiles and potential drug-drug interactions (DDIs) in patients with renal impairment and paediatrics."	( Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations. Chen, L; Ge, W; Tang, H; Xu, R; Yang, J, 2021)	1.1
"Mild or moderate hepatic impairment had no clinically relevant impact on apixaban pharmacokinetic or pharmacodynamic measures, suggesting that dose adjustment may not be required."	( Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. Frost, CE; Garonzik, SM; Ly, V, 2021)	2.3
" The method was successfully applied to the pharmacokinetic study of CX3002 (30 mg) in healthy Chinese subjects."	( A validated UPLC-MS/MS method for the determination of CX3002 in human plasma and its application to a pharmacokinetic study. Chen, J; Hu, X; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Shen, Y; Xu, Y; Yang, D, 2021)	0.62
"To investigate single-dose pharmacokinetic (PK) and pharmacodynamic (PD) parameters of apixaban when administered to patients undergoing vertical sleeve gastrectomy (VSG) or Roux-en-Y gastric bypass (RYGB) and to determine whether the PK and PD parameters are affected by type of bariatric surgery and weight loss in the immediate and postoperative period up to 12 months."	( The APB study: apixaban pharmacokinetics in bariatric patients before to 1 year after vertical sleeve gastrectomy or Roux-en-Y gastric bypass. Canner, JP; Harris, C; Jurao, RA; Kickler, TS; Petty, BG; Prokopowicz, GP; Steele, KE; Streiff, MB, 2022)	1.3
" A single dose of apixaban 10 mg was administered orally to kidney and lung transplant recipients maintained on either tacrolimus or cyclosporine, and pharmacokinetic parameters were compared to a reference cohort of 12 healthy subjects who used the same apixaban dose and pharmacokinetic blood sampling."	( Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients. Alcorn, J; Bashir, B; Douketis, JD; Fenton, ME; Kraft, WK; Mansell, H; Semchuk, W; Shoker, A; Tam, JS; Yao, S, 2022)	1.38
" Further studies using physiologically based pharmacokinetic modelling are required to investigate the drug-drug interactions between these drugs."	( Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Chan, ECY; Soh, XQ; Tan, DS, 2023)	0.91
" The developed dronedarone physiologically based pharmacokinetic (PBPK) model was verified using reported drug-drug interactions (DDIs) between dronedarone and CYP3A4 and P-gp substrates."	( Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. He, QF; Jiao, Z; Wen, HN; Xiang, XQ; Yu, JG, 2022)	0.93
" After oral administration APB and MET to rats, the comparison of pharmacokinetic parameters of APB in the single and co-administrated groups showed significant difference in AUC(0-t) from 730."	( LC-MS/MS Method Assay for Simultaneous Determination of the Apixaban and Metformin in Rat Plasma: Assessment of Pharmacokinetic Drug-Drug Interaction Study. Dong, W; Feng, T; Shang, K; Shen, X; Wang, F; Wang, L, 2023)	1.15

Excerpt	Reference	Relevance
" We evaluated apixaban, a direct and highly selective factor Xa inhibitor, in combination with clinically relevant doses of aspirin and/or clopidogrel for prevention of arterial thrombosis in rabbits."	( Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Crain, EJ; Watson, CA; Wong, PC, 2008)	0.96
" The metabolic drug-drug interaction potential of apixaban was evaluated in vitro."	( In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Chen, SY; Frost, CA; Frost, CE; Goosen, TC; Grossman, SJ; He, K; Humphreys, WG; Ma, L; Maxwell, BD; Raghavan, N; Wang, L; Yao, M; Zhang, D, 2010)	0.85
"To review pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs) involving new oral anticoagulants for atrial fibrillation."	( Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Gulseth, M; Hellwig, T, 2013)	0.39
" Phase I DDI studies have reported pharmacokinetic DDIs mediated by P-gp alone (dabigatran etexilate) or in combination with CYP3A4 enzymes (rivaroxaban and apixaban)."	( Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Gulseth, M; Hellwig, T, 2013)	0.59
" No clinically relevant age- or sex-dependent difference in the apixaban pharmacokinetics and pharmacodynamics which would lead to the modification of the dose exists, apixaban may even be administered with or without food."	( Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions. Dobrotova, M; Kubisz, P; Mokan, M; Samos, M; Stanciakova, L; Stasko, J, 2017)	2.14
" This work aimed to assess potential P-gp-mediated drug-drug interactions between PDE5is and DOACs using in vitro methods."	( In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. Bertoletti, L; Delavenne, X; Delézay, O; Hodin, S; Jacqueroux, E; Margelidon-Cozzolino, V, 2018)	0.68
"There have been concerns about bleeding risks for patients with atrial fibrillation treated with dronedarone in combination with new oral anticoagulants (NOACs)."	( Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Friberg, L, 2018)	0.88
" All patients with atrial fibrillation who used dronedarone in combination with apixaban or warfarin during 2013-2016 were identified."	( Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Friberg, L, 2018)	1.11
"Major bleedings were rare among patients with atrial fibrillation treated with dronedarone in combination with apixaban or warfarin."	( Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Friberg, L, 2018)	1.09
" Apixaban 10 mg was administered orally alone, in combination with 100 mg cyclosporine or 5 mg tacrolimus."	( Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers. Bashir, B; Chervoneva, I; Kraft, WK; Stickle, DF, 2018)	1.68
" NOAC have also been studied in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease, and reduced doses will presumably emerge as routine treatment also in these conditions."	( [NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease]. Gottsäter, A, 2018)	0.48
" To evaluate drug-drug interactions, the impact of ketoconazole, a known strong inhibitor of cytochrome P450 3A4 and P-glycoprotein, was studied."	( Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. Burhenne, J; Foerster, KI; Haefeli, WE; Lehmann, ML; Mikus, G; Schaumaeker, M, 2019)	0.51
" This is the first study that has been conducted to evaluate drug-drug interactions with a drug class, and the low administered doses also allow evaluation in vulnerable target populations."	( Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. Burhenne, J; Foerster, KI; Haefeli, WE; Lehmann, ML; Mikus, G; Schaumaeker, M, 2019)	0.51
"As an alternative to vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) are increasingly prescribed in combination with riociguat in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH)."	( In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants. Bertoletti, L; Delavenne, X; Hodin, S; Jacqueroux, E; Margelidon-Cozzolino, V; Mercier, C, 2020)	0.56
"Apixaban, a direct oral anticoagulant, has emerged over the past few years because it is considered to have a low risk of drug-drug interactions compared to vitamin K antagonists."	( Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Fernandez, S; Lenoir, C; Rollason, V; Samer, C, 2020)	2.31
" The models were verified with observed clinical drug-drug interactions with CYP3A and P-gp inhibitors."	( Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A. Bonate, PL; Choules, MP; Komatsu, K; Otsuka, Y, 2020)	0.56
"To develop a physiologically based pharmacokinetic (PBPK) model for apixaban, an oral anticoagulant with a narrow therapeutic index, and to predict PK profiles and potential drug-drug interactions (DDIs) in patients with renal impairment and paediatrics."	( Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations. Chen, L; Ge, W; Tang, H; Xu, R; Yang, J, 2021)	1.1
"In this article, we present a case of apixaban elimination prolonged by 450% in a patient with coronavirus disease 2019 because of multiple conditions, including drug-drug interaction, severe inflammation, and acute kidney injury."	( Severe Inflammation, Acute Kidney Injury, and Drug-Drug Interaction: Triple Penalty for Prolonged Elimination of Apixaban in Patients With Coronavirus Disease 2019: A Grand Round. Botelho-Nevers, E; Delavenne, X; Demartin, AL; Launay, M; Mismetti, P; Ragey, SP, 2021)	1.1
" Therefore, a drug-drug cocrystal of two antithrombotic agents with poor solubility was developed, which exhibited greatly improved solubility, bioavailability and superior stability, indicating a novel method to overcome the shortages of drug combination."	( Cocrystal of Apixaban-Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs. Du, G; Jiao, L; Kong, D; Lu, Y; Song, J; Wang, H; Yang, D; Yang, H; Yang, S; Zhang, L; Zhao, X, 2021)	0.99
" The aim of this study was to assess the potential P-gp-mediated drug-drug interactions between 11 tyrosine kinase inhibitors (TKIs) with apixaban and rivaroxaban."	( Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein. Bertoletti, L; Bin, V; Delavenne, X; Hodin, S; Lafaie, L; Saïb, S, 2022)	0.92
" The developed dronedarone physiologically based pharmacokinetic (PBPK) model was verified using reported drug-drug interactions (DDIs) between dronedarone and CYP3A4 and P-gp substrates."	( Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. He, QF; Jiao, Z; Wen, HN; Xiang, XQ; Yu, JG, 2022)	0.93
" The results indicated that drug-drug interactions (DDI) occurred might be owing to APB affect one or all of OCTs, MATE1, MATE2-K."	( LC-MS/MS Method Assay for Simultaneous Determination of the Apixaban and Metformin in Rat Plasma: Assessment of Pharmacokinetic Drug-Drug Interaction Study. Dong, W; Feng, T; Shang, K; Shen, X; Wang, F; Wang, L, 2023)	1.15
" In this study, first, a molecularly imprinted polymer combined with magnetic metal organic framework nanocomposite was prepared and then characterized using different techniques."	( Selective extraction of apixaban from plasma by dispersive solid-phase microextraction using magnetic metal organic framework combined with molecularly imprinted polymer nanocomposite. Afshar Mogaddam, MR; Farajzadeh, MA; Fathi, AA; Mohebbi, A; Sorouraddin, SM, 2023)	1.22

Excerpt	Reference	Relevance
"Introduction of the phenyl piperidinone and phenyl pyridinone P4 moieties in the anthranilamide scaffold led to potent, selective, and orally bioavailable inhibitors of factor Xa."	( Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties. Chang, CH; Cheney, DL; Corte, JR; Fang, T; Gauuan, JF; Hadden, M; Han, W; He, K; Hu, Z; Jiang, XJ; Knabb, RM; Lam, PY; Li, YL; Luettgen, JM; Morin, PE; Orton, D; Pinto, DJ; Rendina, AR; Wexler, RR; Wong, PC, 2008)	0.35
" Thus, apixaban is an orally bioavailable inhibitor of factor Xa with elimination pathways that include metabolism and renal excretion."	( Apixaban metabolism and pharmacokinetics after oral administration to humans. Bonacorsi, S; Chen, S; Frost, CE; He, K; Humphreys, WG; Pinto, D; Raghavan, N; Wong, PC; Yu, Z; Zhang, D; Zhang, H, 2009)	2.25
" It is a potent, selective, reversible, and orally bioavailable FXa inhibitor that demonstrates antithrombotic efficacy, with a favorable pharmacokinetic profile."	( Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Ansell, J; Carreiro, J, 2008)	1.79
" A set of compounds obtained from optimization of the R group and the C-3 substituent were orally bioavailable in dogs."	( Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. He, K; King, SR; Knabb, RM; Lam, PY; Luettgen, JM; Qiao, JX; Rendina, AR; Wexler, RR; Wong, PC; Xin, B, 2009)	0.35
" A class of highly potent, selective, efficacious and orally bioavailable direct factor Xa inhibitors was discovered."	( Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Arfsten, AE; Bao, L; Bauer, SM; Clizbe, LA; Edwards, ST; Fan, J; Goldman, EA; Hollenbach, SJ; Huang, W; Hutchaleelaha, A; Jia, ZJ; Kanter, J; Lambing, JL; Li, W; Pandey, A; Park, G; Probst, GD; Scarborough, RM; Sinha, U; Song, Y; Su, T; Wang, L; Wong, PW; Woolfrey, J; Wu, Y; Zhang, P; Zhu, BY, 2009)	0.35
" Rabbits are commonly used in development of thrombosis disease models; however, unlike in other species, apixaban demonstrated poor oral bioavailability (F = 3%) and a high clearance rate (2."	( Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. Crain, EJ; He, B; He, K; Luettgen, JM; Raghavan, N; Wang, L; Wong, PC; Xin, B; Zhang, D, 2010)	0.8
" Apixaban is well absorbed in rat, dog, and chimpanzee, with absolute oral bioavailability of approximately 50% or greater."	( Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Grace, JE; Grossman, SJ; He, B; He, K; Knabb, RM; Lam, PY; Luettgen, JM; Pinto, DJ; Wexler, RR; Wong, PC; Xin, B; Zhang, D, 2011)	1.53
"Concomitant medication with proton pump inhibitors, amiodarone, clarithromycin, and verapamil increased bioavailability whereas rifampicin decreased the bioavailability of dabigatran."	( Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Finsterer, J; Stöllberger, C, 2015)	0.64
" Selected compounds demonstrated oral bioavailability in rat IV/PO pharmacokinetic (PK) studies."	( Development of a novel class of potent and selective FIXa inhibitors. Andre, P; Araki, K; Bateman, TJ; Campeau, LC; Chen, YH; Desai, K; Ellsworth, K; Geissler, WM; Guo, L; Hruza, A; Jian, T; Meng, D; Nishimura, T; Nolting, AF; Orr, R; Parker, DL; Qian, X; Reichert, P; Sakurada, I; Sherer, EC; Shu, M; Smith, CJ; Sonatore, LM; Tschirret-Guth, R; Wood, HB; Zhang, T, 2015)	0.42
" It is important to understand whether new formulations and/or methods of administration impact apixaban bioavailability and pharmacokinetic properties."	( Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. Badawy, S; Frost, C; LaCreta, F; Perlstein, I; Song, Y; Wang, J; Wang, X, 2015)	0.93
" Pharmacokinetic analysis revealed moderate clearance, short half-life, and high bioavailability for apixaban."	( Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats. Bright, JM; Martinez, CM; Myers, JA; Olver, CS; Wittenburg, LA, 2015)	0.87
" Apixaban absolute oral bioavailability was 49 % when administered alone and 39 % following induction by rifampin."	( Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Boyd, RA; Byon, W; Dias, C; Frost, C; LaCreta, F; Shenker, A; Vakkalagadda, B; Wang, J; Yu, Z; Zhang, D, 2016)	1.6
"Co-administration of apixaban with rifampin reduced apixaban exposure via both decreased bioavailability and increased systemic clearance."	( Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Boyd, RA; Byon, W; Dias, C; Frost, C; LaCreta, F; Shenker, A; Vakkalagadda, B; Wang, J; Yu, Z; Zhang, D, 2016)	1.01
"These studies evaluate the relative bioavailability of crushed apixaban tablets and the effect of food on apixaban pharmacokinetic properties."	( Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Chang, M; Frost, C; Frost, RJ; Kelly, A; LaCreta, F; Song, Y; Suzuki, A, 2016)	0.9
"An open-label, randomized, crossover study in 33 healthy adults compared the bioavailability of 2 × 5-mg apixaban tablets administered whole (reference), crushed and suspended in 30 mL of water, and crushed and mixed with 30 g of applesauce."	( Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Chang, M; Frost, C; Frost, RJ; Kelly, A; LaCreta, F; Song, Y; Suzuki, A, 2016)	0.88
" This new oral anticoagulant represents an immediate-release form of peroral drug with quick dissolution, linear pharmacokinetics, good bioavailability and rapid onset and offset of action."	( Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions. Dobrotova, M; Kubisz, P; Mokan, M; Samos, M; Stanciakova, L; Stasko, J, 2017)	1.9
" Apixaban is a new oral anticoagulant characterized by good bioavailability and renal elimination accounting for only 25%, showing a safety profile and effectiveness in patients with renal impairment."	( Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure. Carbonara, S; Ciccone, MM; Corbo, F; Cortese, F; Franchini, C; Gesualdo, M; Pia Schiavone, BI; Ricci, G; Scicchitano, P, 2017)	2.81
"Anticoagulation in patients with impaired kidney function can be challenging since drugs' pharmacokinetics and bioavailability are altered in this setting."	( Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Baldovino, S; Fenoglio, R; Radin, M; Roccatello, D; Schreiber, K; Sciascia, S, 2017)	0.46
" However, due to altered pharmacokinetics and bioavailability of these drugs in CKD, a significant risk of bleeding exists."	( [The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease]. Mohebbi, N, 2018)	0.48
" The absolute oral bioavailability of apixaban is ~ 50%."	( Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Boyd, RA; Byon, W; Frost, CE; Garonzik, S, 2019)	2.23
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" In this work, novel cocrystals, consisting of two antithrombotic drugs with poor solubility and low bioavailability in vivo, namely, apixaban (Apx) and quercetin (Que), were developed to discover a potential method to improve the poor solubility and internal absorption of the drug combination."	( Cocrystal of Apixaban-Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs. Du, G; Jiao, L; Kong, D; Lu, Y; Song, J; Wang, H; Yang, D; Yang, H; Yang, S; Zhang, L; Zhao, X, 2021)	1.19
"Direct-acting oral anticoagulants (DOACs) vary in bioavailability and sites of absorption in the gastrointestinal tract (GIT)."	( Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery. Alawaji, Z; Alkhani, M; Alyahya, Z; Hakeam, HA; Ofori, S, 2021)	0.62
"Solid lipid nanoparticles (SLnPs) are usually utilized as lipid-based formulations for enhancing oral bioavailability of BCS class IV drugs."	( Application of Design of Experiment in the Optimization of Apixaban-Loaded Solid Lipid Nanoparticles: In Vitro and In Vivo Evaluation. Arafa, MF; El-Gizawy, SA; Osman, MA; Ramadan, SE, 2023)	1.15

Excerpt	Relevance	Reference
"To evaluate the safety and efficacy of apixaban, a potent, direct, oral inhibitor of FXa, in patients following total knee replacement (TKR), and to investigate dose-response relationships."	( The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. Ansell, J; Davidson, BL; Deitchman, D; Gallus, A; Lassen, MR; Pineo, G, 2007)	0.91
" Clopidogrel at 3 mg kg(-1) was dosed orally once daily for three days, with the last dose given 2 h before injury."	( Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Crain, EJ; Watson, CA; Wong, PC, 2008)	0.6
" Bile samples were also collected for 3 to 8 h after dosing from group 2 subjects."	( Apixaban metabolism and pharmacokinetics after oral administration to humans. Bonacorsi, S; Chen, S; Frost, CE; He, K; Humphreys, WG; Pinto, D; Raghavan, N; Wong, PC; Yu, Z; Zhang, D; Zhang, H, 2009)	1.8
" These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials [corrected]."	( New anticoagulants for atrial fibrillation. Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M, 2009)	0.35
"A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial."	( Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Feng, Y; Leil, TA; Mohan, P; Paccaly, A; Pfister, M; Zhang, L, 2010)	0.9
" Depending on its dosage its effectiveness in comparison with vitamin K antagonists is equal or even better without disadvantages in safety."	( [New oral anticoagulants: better than vitamin K antagonists?]. Alban, S; Völler, H; Westermann, D, 2010)	0.36
" Efficacy and safety of oral anticoagulation is limited by a narrow therapeutical range as well as by inter- and intraindividual variability of INR-values due to genetic disposition, differences in alimentation, dosage errors, rare control of INR-levels and drug-interactions."	( [Novel anticoagulants for stroke prevention in atrial fibrillation]. Baumhäkel, M; Böhm, M; Schirmer, SH, 2010)	0.36
" These compounds present a convenient route of administration with predictable pharmacokinetics and pharmacodynamics that allow fixed dosing regimens without requiring coagulation monitoring."	( Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. Ageno, W; Romualdi, E, 2011)	0.37
" Clinicians are increasingly being challenged with making uncertain anticoagulant dosing decisions, as the optimal dosing strategy for most anticoagulants in the obese patient population remains unknown."	( Anticoagulating obese patients in the modern era. Arya, R; Patel, JP; Roberts, LN, 2011)	0.37
" In addition, we must be aware to have a deliberate evaluation for each result, even pharmacological profiles of each Xa inhibitors with a 12 hour half-life period shows similarity, the difference in twice-daily dosing with once a day, or the difference in severity of patients' atrial fibrillation risk factor each trial contains might affect the results of phase III trials."	( [Current status and future of anti-Xa inhibitors]. Nagao, T, 2011)	0.37
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."	( Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Halperin, JL; Varughese, CJ, 2012)	0.38
"5 mg twice daily initiated after surgery was generally more effective in preventing VTE in patients undergoing knee or hip replacement surgery than subcutaneous enoxaparin sodium initiated before surgery at the EU recommended dosage of 40 mg once daily, with apixaban conferring this benefit without significantly increasing the risk of bleeding."	( Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Deeks, ED, 2012)	2
" These agents promise to be more convenient to administer with fixed dosing but still have equivalent efficacy and improved bleeding risk compared to warfarin."	( Newer oral anticoagulant agents: a new era in medicine. Goel, R; Srivathsan, K, 2012)	0.38
" It has a plasma elimination half-life of 12 hours and has been administered in a twice-daily dosing regimen in clinical trials without the need for anticoagulation monitoring or dosage adjustment."	( Apixaban: a novel oral inhibitor of factor Xa. Nutescu, E, 2012)	1.82
" They have a slow onset and offset of action, narrow therapeutic window, marked dose-response variability, and multiple food and drug interactions, and require frequent coagulation monitoring and dose adjustments."	( Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. Mangiafico, M; Mangiafico, RA, 2012)	0.38
" Patients who met at least one caution or contraindication criteria were deemed "non-candidates"; potential dosage reductions of the new oral anticoagulants were not considered."	( Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital. Carter, KL; Kraus, PS; Ross, PA; Shermock, KM; Streiff, MB; Thomas, ML; Wellman, JC, 2012)	0.62
" These newer agents possess a highly predictable pharmacokinetic-pharmacodynamic relationship, allowing for fixed dosing and no necessity for routine laboratory monitoring; additionally these agents have minimal drug interactions."	( New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence. Kopecky, S, 2012)	0.38
" Linearity of dose-response and responsiveness to increasing dose in addition to standardization are other important issues to consider."	( Laboratory tests and the new oral anticoagulants. Tripodi, A, 2012)	0.38
" The first, monitoring, implies laboratory testing to assess the drug's effect and to adjust the dosage to maintain anticoagulation within the therapeutic interval."	( The laboratory and the new oral anticoagulants. Tripodi, A, 2013)	0.39
" The choice of tests is based on such characteristics as availability, linearity of the dose-response curve, standardization, and responsiveness to increasing drug dosage."	( The laboratory and the new oral anticoagulants. Tripodi, A, 2013)	0.39
" The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and P-gp inhibitor)."	( Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Frost, CE; Goosen, TC; He, K; Humphreys, WG; Rodrigues, AD; Wang, L; Wang, X; Zhang, D, 2013)	0.89
" Apixaban has a half-life of about 12 hours, and the normal dosage is 5 mg orally twice daily."	( Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation. Lam, S, )	2.48
" Rivaroxaban, apixaban, and dabigatran have different pharmacological characteristics, and guidance is needed on optimum doses and dosing intervals and the effects of renal or hepatic impairment, age, food, and other drugs."	( Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Graff, J; Harder, S, 2013)	0.75
" Consequently, if renal function is impaired, there is a risk of drug accumulation that is highest for dabigatran followed by rivaroxaban and then apixaban and thus dosing recommendations are different."	( Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R, 2013)	0.8
" In this review, we outline key pharmacokinetic and pharmacodynamic features of each compound and provide guidance on selection and dosing of the 3 NOACs relative to warfarin when considering OAC therapy for AF patients."	( Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Gong, IY; Kim, RB, 2013)	0.6
" However the choice of dosing regimens in different clinical conditions has been different for the various NOACs, and has been established on the basis of widely different considerations, including the clinical setting (venous versus arterial thrombosis), the indications (prophylaxis versus treatment), the likelihood of concomitant antiplatelet drugs, and marketing opportunities; these latter were based on the knowledge that patients' compliance is generally better with once daily than with twice daily dosing."	( The new oral anticoagulants in atrial fibrillation: once daily or twice daily? De Caterina, R; Renda, G, )	0.13
" These new anticoagulants do not require strict and frequent laboratory monitoring, dosing adjustments, or dietary restrictions, and they incur fewer drug-drug interactions than warfarin."	( Novel oral anticoagulants: a review of new agents. Wanat, MA, 2013)	0.39
"Pharmacogenetics-guided warfarin dosing is an alternative to standard clinical algorithms and new oral anticoagulants for patients with nonvalvular atrial fibrillation."	( Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Hughes, DA; Lane, S; Pink, J; Pirmohamed, M, 2014)	0.4
" Advantages and disadvantages to using these newer agents are presented, as are dosing adjustments for renal and hepatic impairment."	( Outpatient management of oral anticoagulation in atrial fibrillation. Manning, JA, 2013)	0.39
" In contrast to warfarin, most NOACs need dosage adjustments in renal impairment and are contraindicated in severe liver impairment, and there are no specific antidotes for treating NOAC-related over-anticoagulation."	( New oral anticoagulants in practice: pharmacological and practical considerations. Bajorek, B; Wang, Y, 2014)	0.4
" They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring."	( Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014)	0.4
" On day 7, peak plasma concentrations were reached ~ 3 hours postdose, and increases in peak plasma concentration (C(max)), trough plasma concentration, and area under the plasma concentration-time curve across one dosing interval (12 hours) were tested dose-proportional across the dose range."	( Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Frost, C; Fukase, H; Hiraoka, M; LaCreta, F; Pursley, J; Wang, J; Yamahira, N; Yu, Z, 2014)	0.63
" In the studied dosing regimens, these drugs failed to show a net clinical benefit in addition to dual antiplatelet therapy."	( Direct oral anticoagulants in acute coronary syndrome. Ahrens, I; Bode, C, 2014)	0.4
" Chromogenic anti-FXa assays showed linear dose-response curves with apixaban."	( Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. Baghaei, F; Berndtsson, M; Fagerberg Blixter, I; Faxälv, L; Gustafsson, KM; Hillarp, A; Lindahl, TL; Strandberg, K, 2014)	0.89
"Ease of dosing and simplicity of monitoring make new oral anticoagulants an attractive therapy in a growing range of clinical conditions."	( Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. Baumann Kreuziger, LM; Dries, DJ; Keenan, JC; Morton, CT, 2014)	0.4
" The development of apixaban reflects a strategy to optimize the clinical pharmacology profile, dosing posology, trial designs, and statistical analyses across multiple indications, and to seek alignment with global health authorities."	( Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Frost, C; Gupta, E; Hanna, MS; Knabb, R; Lawrence, JH; Mohan, P, 2014)	1.08
" Practical advantages of NOACs over warfarin include fixed once- or twice-daily oral dosing without the need for coagulation monitoring, and few known or defined drug or food interactions."	( Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Bell, AD; Douketis, J; Eikelboom, J; Liew, A, 2014)	0.4
" This study examines the relative cost-effectiveness of dabigatran (BID dosing of 150 mg or 110 mg based on patient age), rivaroxaban, and apixaban from a UK payer perspective."	( Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y, 2014)	0.6
"New oral anticoagulants require dosing adjustment according to renal function."	( Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Andreu-Cayuelas, JM; Gallego, P; Lip, GY; Manzano-Fernández, S; Marín, F; Orenes-Piñero, E; Roldán, V; Valdés, M; Vicente, V, 2015)	0.42
"Among the overall population, relative to Cockcroft-Gault, discordance in dabigatran dosage was 11."	( Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Andreu-Cayuelas, JM; Gallego, P; Lip, GY; Manzano-Fernández, S; Marín, F; Orenes-Piñero, E; Roldán, V; Valdés, M; Vicente, V, 2015)	0.42
" The RapidTEG activated clotting time test allowed the creation of a dose-response curve for all 3 NOACs."	( Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL, 2015)	0.42
"To review current literature for target-specific oral anticoagulants (TSOACs) and provide critical analysis for dosing recommendations in special population groups."	( Dosing of Target-Specific Oral Anticoagulants in Special Populations. Ge, D; Morrill, AM; Willett, KC, 2015)	0.42
" It is valuable to understand the rationale for labeled dosing recommendations in nonvalvular atrial fibrillation and venous thromboembolism treatment and prevention, particularly in patients that fall into special population groups."	( Dosing of Target-Specific Oral Anticoagulants in Special Populations. Ge, D; Morrill, AM; Willett, KC, 2015)	0.42
" In this regard, novel oral anticoagulants (NOACs) have shown promise in the shift toward the "ideal" anticoagulant therapy, in that fixed dosing is the norm, drug interactions are few, food interactions are absent, onset is fairly immediate and offset predictable, and, in the majority of patients, therapeutic monitoring is not required."	( Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician. Mookadam, F; Mookadam, M; Shamoun, FE, )	0.13
" Further studies will be needed to determine pharmacokinetics and pharmacodynamics after multidose administration, effects of cardiac disease on pharmacokinetics and pharmacodynamics, dosing recommendations, and efficacy of apixaban for use in the treatment and prevention of thromboembolic disease in cats."	( Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats. Bright, JM; Martinez, CM; Myers, JA; Olver, CS; Wittenburg, LA, 2015)	0.84
" The effect of interrupted apixaban on intraprocedural heparin dosing requirements and levels of achieved anticoagulation with heparin has not been well studied."	( Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study. Bin Abdulhak, AA; Giocondo, M; Gupta, S; Kennedy, KF; Ramza, B; Wimmer, AP, 2015)	0.99
"The direct oral anticoagulants (DOAC) dabigatran, rivaroxaban, and apixaban are increasingly prescribed in atrial fibrillation (AF) patients, although dosage in elderly patients, safety in chronic kidney disease, food- and drug-interactions, laboratory tests for monitoring, and antidote are not clarified."	( A Probable Life-Saving Switch from Apixaban to Phenprocoumon. Finsterer, J; Stöllberger, C, 2015)	0.93
" The aim of the present study was to evaluate the hypothetical need for dosage adjustment (based on fluctuations in kidney function) of dabigatran, rivaroxaban and apixaban during the first 6 months after hospital discharge in patients with concomitant atrial fibrillation and heart failure."	( Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M, 2016)	0.63
" The hypothetical recommended dosage of dabigatran, rivaroxaban and apixaban according to renal function was determined at discharge."	( Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M, 2016)	0.67
"Among the overall study population, 44% of patients would have needed dabigatran dosage adjustment during follow-up, 35% would have needed rivaroxaban adjustment, and 29% would have needed apixaban dosage adjustment."	( Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M, 2016)	0.62
"The need for dosage adjustment of nonvitamin K oral anticoagulants during follow-up is frequent in patients with atrial fibrillation after acute decompensated heart failure, especially among older patients and those with renal impairment."	( Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M, 2016)	0.43
" The developed methods were successfully applied for the determination of apixaban in bulk powder and its tablet dosage form."	( Stability-indicating spectrophotometric methods for determination of the anticoagulant drug apixaban in the presence of its hydrolytic degradation product. Abdelkawy, M; El-Ragehy, NA; Hassan, NY; Tantawy, MA, 2016)	0.89
" We also aimed to propose expected steady state peak and trough antifactor Xa activities for these agents based upon dosing regimens approved for nonvalvular atrial fibrillation."	( Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Beyer, J; Fisher, S; Kiser, TH; Ko, A; Lind, SE; Trujillo, T, 2016)	0.43
" Further research is needed to better understand appropriate dosing of patients with novel anticoagulants."	( Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Coleman, CI; Crivera, C; Fields, LE; Nguyen, E; Patel, MR; Peacock, WF; White, CM, 2016)	0.85
" The hospital protocol for heparin infusions was reinstituted on hospital day 7, with dosage adjustments based on antifactor Xa levels."	( Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury. VanOverschelde, B; Voss, G; Wendte, J, 2016)	0.8
" His heparin dosage was successfully adjusted based on antifactor Xa levels and aPPTs."	( Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury. VanOverschelde, B; Voss, G; Wendte, J, 2016)	0.8
"All the newer oral anticoagulants compared were more effective than adjusted dosed warfarin."	( Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Hayes, CJ; Martin, BC; Shah, A; Shewale, A, 2016)	0.43
" However the peri-procedural dosing protocols used in various studies especially in terms of whether NOAC use is interrupted or uninterrupted during AF ablation, have significant inter-operator and inter-institution variability."	( Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation. Fox, DJ; Sankaranarayanan, R, )	0.13
"It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state."	( Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers. Bachman, B; Chervoneva, I; Kraft, WK; Nagalla, S; Oppong, Y; Thomson, L, 2016)	0.97
" Nonetheless, the absence of the ability for clinicians to assess compliance or washout with a simple laboratory test (or to adjust dosing with a similar assessment) and the absence of an antidote to rapidly stop major hemorrhage or to enhance safety in the setting of emergent or urgent surgery/procedures have been limitations to greater non-vitamin K antagonist oral anticoagulant usage and better thromboembolic prevention."	( NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI, 2016)	0.43
" Differences in the ACT before ablation and adequate initial heparin dosing in patients receiving non-vitamin K antagonist oral anticoagulants (NOACs) were examined."	( Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Higashiya, S; Hina, K; Kamikawa, S; Kawamura, H; Komtasubara, I; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H, 2016)	0.43
"A triple or dual therapy induced a comparable decrease in shed blood β-TG at 3 hours after therapy dosing but was more pronounced at steady-state conditions with the more intense treatment combination."	( The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study. Bucher, S; Kapiotis, S; Kyrle, PA; Litschauer, B; Riesenhuber, M; Weisshaar, S; Wolzt, M, 2016)	0.68
" In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists."	( Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Antman, EM; Giugliano, RP; Ruff, CT, 2016)	0.43
" It is part of a family of novel oral anticoagulants (NOACs) which has advantage over warfarin of less dosing variability, rapid onset of action and no INR monitoring required."	( Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban. John, J; Mezue, K; Obiagwu, C; Shani, J; Sharma, A; Yang, F, 2017)	0.7
" With similar efficacy, better safety, and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer."	( Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Jaffer, IH; Weitz, JI, 2016)	0.43
" Current apixaban dosing recommendations for this patient population are based largely on a single-dose pharmacokinetic study of eight patients."	( Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis. Kufel, WD; Lehmann, DF; Miller, CD; Zayac, AS, 2016)	1.1
" We collected data on type and dosage of anticoagulation; suspected or confirmed bleeding events, hospital admissions, and mortality; and pattern and management of vaginal bleeding events."	( Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. Beyer-Westendorf, J; Hauswald-Dörschel, S; Marten, S; Michalski, F; Tittl, L, 2016)	0.43
"Compared to enoxaparin (most commonly dosed 40 mg once daily), the relative risk (RR) of VTE was lowest for edoxaban 30 mg once daily (0."	( Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT, 2017)	0.46
"Direct oral anticoagulants currently have no indication for monitoring even though there are data that imply that individual dosing can improve and add safety to the therapy."	( Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum. Boehr, S; Haen, E, 2017)	0.68
"Surgical procedures under NOACS can be scheduled at the beginning of next dosing interval or omitted in low/minimal bleeding risk patients, so that only 2-3 NOAC doses are not administered."	( [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?] Buerke, M; Hoffmeister, HM, 2017)	0.46
" To ensure responsible use of these agents, every hospital needs a bleeding management algorithm that identifies patients eligible for reversal and outlines appropriate dosing regimens."	( Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. Weitz, JI, 2017)	0.46
" The fact that the NOACs don't require routine monitoring to assure that patients remain within the therapeutic range and have relatively simple dosing requirements and a safer risk profile makes them attractive substitutes to warfarin in HF patients with atrial fibrillation and other conditions (e."	( Anticoagulation Therapy and NOACs in Heart Failure. EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I, 2017)	0.46
" Much shorter half-life of NOACs raises the question of optimal dosing regimen."	( [The Problem of Adherence to Anticoagulant Therapy and Ways to Its Solution]. Kobalava, ZD; Troitskaya, EA; Villewalde, SV, 2016)	0.43
" The objective is to present a case report that illustrates there may be important dosing issues when considering the use of these agents in patients with the antiphospholipid syndrome."	( Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome. Hassell, K; Schofield, JR, 2018)	0.48
"Despite a similar half-life, pharmacokinetics and pharmacodynamics, the manufacturer-recommended maintenance dosing of apixaban is twice daily and rivaroxaban once daily."	( Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome. Hassell, K; Schofield, JR, 2018)	0.69
"We compared NOACs (as a group) to warfarin in non-valvular atrial fibrillation, studying all 12,694 patients starting NOAC treatment within the Swedish clinical register and dosing system Auricula, from July 1, 2011 to December 31, 2014, and matching them to 36,317 patients starting warfarin using propensity scoring."	( Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ, 2017)	0.46
" Identification of additional clinical and molecular determinants that more fully predict patients at risk for excessively high or low DOAC concentrations may enable a more precise DOAC dosing regimen for the individual patient."	( Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. Alfonsi, JE; Dresser, GK; Gryn, SE; Gulilat, M; Henderson, SL; Kim, RB; Leong-Sit, P; Lizotte, DJ; Rose, RV; Schwarz, UI; Skanes, AC; Tang, A; Teft, WA; Tirona, RG, 2017)	0.72
"To determine if adherence to Food and Drug Administration (FDA)-approved dosing for apixaban is maintained in hospitalized patients with NVAF."	( Assessment of Apixaban Prescribing Patterns for Nonvalvular Atrial Fibrillation in Hospitalized Patients. Davis, S; Gibson, CM; Scalese, MJ; Smith, CB, 2018)	1.07
" Apixaban was dosed according to FDA labeling by providers in 83."	( Assessment of Apixaban Prescribing Patterns for Nonvalvular Atrial Fibrillation in Hospitalized Patients. Davis, S; Gibson, CM; Scalese, MJ; Smith, CB, 2018)	1.75
" Off-label indications and dosage too low were the most common not per protocol reasons for apixaban and rivaroxaban prescriptions."	( Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols. Carley, B; Draper, E; Griesbach, S; Krueger, K; Larson, T; Parkhurst, B, 2017)	0.68
"Once-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may increase patient adherence to treatment but may also be associated with a higher risk of bleeding."	( Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study. Akyüz, A; Başaran, Ö; Berilgen, R; Çelik, O; Çetin, N; Coşar, S; Dereli, Y; Doğan, T; Doğan, V; Emren, SV; Enhoş, A; Ergene, O; Gürsul, E; İnci, S; Karaca, I; Karaca, Ö; Köseoğlu, C; Levent, F; Onrat, E; Otlu, YÖ; Özdemir, İH; Özmen, Ç; Sümerkan, M; Zoghi, M, 2018)	0.48
"The direct oral anticoagulants (DOACs), also referred to as novel (or non-vitamin K antagonist) oral anticoagulants (NOACs), represent a major development in anticoagulation therapy due to their rapid onset of action, predictable dose-response with fixed doses and limited interactions with food and drugs."	( An update on the bleeding risks associated with DOACs. , 2017)	0.46
" As an alternative to inconvenient and expensive injections of fondaparinux, personalized dosing of a direct oral anticoagulant was sought using clinical pharmacology techniques."	( Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome. Kim, RB; Pollak, PT; Sun, GR, 2018)	0.75
" Drug dosage changes and serum creatinine determinations were recorded during 1-year follow-up."	( Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. Albendin Iglesias, H; Andreu Cayuelas, JM; Bailen Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Januzzi, JL; Manzano-Fernández, S, 2018)	0.48
" Compliance with kidney function monitoring recommendations was associated with adequate NOAC dosage at 1-year follow-up."	( Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. Albendin Iglesias, H; Andreu Cayuelas, JM; Bailen Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Januzzi, JL; Manzano-Fernández, S, 2018)	0.48
"The aim of this study was to analyze adherence to current labeling instructions concerning initial apixaban dosing in clinical practice and identify factors associated with inappropriate dose reduction."	( Initial apixaban dosing in patients with atrial fibrillation. Bollmann, A; Buchholz, A; Dagres, N; Dinov, B; Gorczynska, K; Hilbert, S; Hindricks, G; Husser, D; Ueberham, L, 2018)	1.13
"In clinical practice, apixaban dosing is frequently inconsistent with labeling."	( Initial apixaban dosing in patients with atrial fibrillation. Bollmann, A; Buchholz, A; Dagres, N; Dinov, B; Gorczynska, K; Hilbert, S; Hindricks, G; Husser, D; Ueberham, L, 2018)	1.23
"There is limited evidence on patients' adherence and the impact of the prescribed dosing regimen in non-vitamin-K oral anticoagulants (NOACs)."	( Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. de Boer, PT; Hoffmann, M; Jacobs, MS; Levin, LÅ; Postma, MJ; Schouten, JF, 2018)	0.48
" Patients using a consistent dosage for at least 180 consecutive days were included."	( Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. de Boer, PT; Hoffmann, M; Jacobs, MS; Levin, LÅ; Postma, MJ; Schouten, JF, 2018)	0.48
"Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a fixed dosing regimen."	( Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L, 2018)	0.48
" Future directions include identification of clinically relevant SNPs, and change in optimum dosage for patients who are carriers of significant variants."	( Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. Ašić, A; Marjanović, D; Mirat, J; Primorac, D, 2018)	0.48
"To investigate the risk of bleeding events and stroke/systemic embolism (SE) among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial dosage of apixaban and patient age."	( Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. Katada, J; Kohsaka, S; Saito, K; Terayama, Y, 2018)	0.97
"The safety, efficacy, and optimal dosing regimen for apixaban at the time of AF ablation are uncertain."	( A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial. Allison, JS; Cannon, CP; Ellenbogen, KA; Hsieh, WH; Natale, A; Reynolds, MR; Richards, M; Sutherland, J; Weisberg, IL, 2018)	1.01
" However, apixaban has specific dosing recommendations in CKD leading to use in clinical practice."	( Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease. Casey, AL; Dupre, KA; Schafer, JH; Staubes, BA, 2018)	1.19
" Data are limited regarding both total dose and repeated dosing with this population."	( Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient. Cottingham, LG; Hughes, RE; King, GS; Ratliff, PD, 2018)	0.48
" Ten of 39 patients (26%) were not receiving a DOAC dosage consistent with the package insert."	( Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population. Hedvat, J; Howlett, C; McCloskey, J; Patel, R, 2018)	0.48
" Additionally, in this case the interaction was managed with concentration-guided dosing of apixaban, suggesting this approach may represent a feasible strategy for managing patients requiring treatment with direct-acting oral anticoagulants and enzyme-inducing antiepileptic drugs."	( Managing Direct Oral Anticoagulants in Patients With Antiepileptic Medication. Dagan, G; Hochberg-Klein, S; Kalish, Y; Muszkat, M; Perlman, A, 2018)	0.7
" We describe a patient diagnosed with anti-phospholipase A2 receptor antibody positive membranous nephropathy and recurrent VTE while on therapeutic dosing of apixaban."	( Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. Crona, DJ; Derebail, VK; Mooberry, MJ; Nachman, PH; Reynolds, ML, 2019)	0.71
"8%)] and peak [n = 16 (20%)] levels, especially octogenarians with the 5-mg bid dosage [n = 6 (30%) for trough and n = 8 (40%) for peak]."	( Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation. Cooper, L; Fuchs, S; Green, H; Grossman, A; Hershkovitz, A; Nakav, S; Nissan, R; Shimony, S; Shochat, T; Spectre, G, 2019)	1.96
"High and above-range peak apixaban steady-state levels are highly prevalent in octogenarians receiving the appropriate dosage of 5 mg bid for NVAF stroke prevention."	( Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation. Cooper, L; Fuchs, S; Green, H; Grossman, A; Hershkovitz, A; Nakav, S; Nissan, R; Shimony, S; Shochat, T; Spectre, G, 2019)	2.26
" The goal of our study was to evaluate the outcomes of our reduced dosing strategy with FEIBA in patients experiencing a DOAC-related bleeding event."	( Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Dager, WE; Nishijima, DK; Roberts, AJ, 2019)	0.51
"Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly used in routine clinical practice because of their fixed dosing and favourable pharmacological profiles."	( Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Brown, J; Dawwas, GK; Dietrich, E; Park, H, 2019)	2.25
" The observed effect could be a secondary consequence of dosage control or alternatively a result of different anticoagulant effects among the different medications."	( Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants. Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M, 2018)	0.48
"In the past decade, direct-acting oral anticoagulants (DOAC) have been introduced to medical practice for several indications, with a wide range of dosing regimens."	( Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Aldouby-Bier, G; Fisher Negev, T; Hirsh-Raccah, B; Hochberg-Klein, S; Horwitz, E; Kalish, Y; Muszkat, M; Perlman, A, 2019)	0.51
" dosing interval) or patient experiences while on treatment."	( Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? Brown, JD; Pham, PN, 2019)	0.51
"Apixaban users had the highest overall adherence despite twice-daily dosing versus once-daily dosing for rivaroxaban."	( Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? Brown, JD; Pham, PN, 2019)	1.96
" Furthermore, we evaluated the appropriateness of labeled and off-label dosing implemented for 348 patients using the obtainable PC threshold."	( Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation　- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. Kino, M; Morii, I; Suwa, M, 2019)	0.87
" Benefits of direct oral anticoagulants include a rapid onset of therapeutic effect, fixed dose-response relationships without the need for routine monitoring, a short half-life, and infrequent need for periprocedural bridging with a parenteral agent."	( Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management. Pickett, JD, 2019)	0.51
"In plasma systems, the assay demonstrates dose-response between 0 and 5 nmol/L rivaroxaban and between 0 and 10 nmol/L apixaban."	( An assay to measure levels of factor Xa inhibitors in blood and plasma. Di Giuseppantonio, LR; Douketis, JD; Gross, PL; Kim, PY; Wu, C, 2019)	0.72
" Andexanet alfa is administered via two different dosing regimens, standard and high dose, based on the specific FXa inhibitor, dose, and time since the patient's last dose of FXa inhibitor."	( Andexanet Alfa (Andexxa) Formulary Review. Beik, N; Connell, NT; Connors, JM; Giugliano, RP; Piazza, G; Reddy, P; Sylvester, KW, 2019)	0.51
" Our goal was to determine the consequences of lower than recommended dosing on plasma apixaban concentrations during the clinical care of older adults with NVAF."	( Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. Alfonsi, JE; Dresser, GK; Gryn, SE; Gulilat, M; Kim, RB; Linton, B; Schwartz, JB; Schwarz, UI; Sukumar, S, 2019)	2.18
" Overall, 48 patients received recommended dosing of 5 mg twice/day, and 42 received lower than recommended dosing."	( Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. Alfonsi, JE; Dresser, GK; Gryn, SE; Gulilat, M; Kim, RB; Linton, B; Schwartz, JB; Schwarz, UI; Sukumar, S, 2019)	1.96
" The findings raise questions about the optimal dosing of apixaban in older adults with NVAF encountered outside of clinical trials and suggest a role for the monitoring of apixaban concentrations during care of patients that differ from those in randomized trials or when considering dosing outside of published guidelines."	( Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. Alfonsi, JE; Dresser, GK; Gryn, SE; Gulilat, M; Kim, RB; Linton, B; Schwartz, JB; Schwarz, UI; Sukumar, S, 2019)	2.2
" To identify the prevalence, outcomes, and patient characteristics associated with off-label DOAC dosing during VTE treatment."	( Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism. Gustafson, WL; Jones, AE; Saunders, JA; Vazquez, SR; Witt, DM, 2019)	0.51
" However, the complexity of DOAC dose regimens can still lead to dosing errors and potential bleeding-related or thromboembolic adverse events, especially in the elderly."	( Burden of Inappropriate Prescription of Direct Oral Anticoagulants at Hospital Admission and Discharge in the Elderly: A Prospective Observational Multicenter Study. Anfosso, M; Bruneau, A; Fernandez, C; Hindlet, P; Schwab, C, 2019)	0.51
" The survey included questions regarding centers' demographics and posed a series of hypothetical clinical scenarios to gather centers' VTE treatment practices including choice of anticoagulant, dosing practices, duration decisions, and monitoring efforts."	( Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosis. Jones, AE; Ratté, MT; Witt, DM; Young, DC, 2020)	0.56
" The excess events with JNJ-9375 compared with apixaban were consistent across all JNJ-9375 dosing cohorts and there was no evidence of improved efficacy with higher JNJ-9375 doses."	( Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. DiBattiste, PM; Francis, C; Fuji, T; Lassen, MR; Lee, M; Peters, G; Raskob, G; Roberts, RS; Segers, A; Strony, J; Swaim, RM; Tesfaye, F; Weitz, JI, 2019)	1
"A quality by design (QbD) based high-resolution HPLC method is described for determination of impurities in apixaban (APX) in the tablet dosage form."	( Stability-indicating RP-HPLC method development and validation for determination of nine impurities in apixaban tablet dosage forms. Robustness study by quality by design approach. Dongala, T; Jonnalagadda, SB; Katari, NK; Subramanian, VB, 2020)	0.99
" Most patients who were taking NOACs had excellent adherence regardless of the dosing frequency."	( NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters? Bae, HJ; Cho, YK; Choi, SW; Han, S; Hur, SH; Hwang, J; Jun, SW; Kim, H; Kim, IC; Lee, CH; Lee, SH; Nam, CW; Park, HS; Yoon, HJ, 2020)	0.56
" The purpose of this study was to assess the impact of the route of administration and dosage regimen on the compliance to the prescription."	( Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study. Bautista, M; Bonilla, G; Castro, J; Llinás, A; Moreno, JP, 2020)	0.56
" In addition, apixaban and rivaroxaban offer more than one dosing option, allowing tailoring of treatment to the patient's specific risk factor profile."	( Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Schindewolf, M; Weitz, JI, 2020)	0.92
" Using the Korean National Health Insurance Service database, we evaluated 16,568 patients with a new prescription of NOAC who are indicated for standard NOAC dosing and compared 4,536 patients with warfarin with respect to thromboembolic events (ischemic stroke or systemic embolization), all-cause mortality and major bleeding."	( Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing. Cho, MS; Kim, H; Kim, YJ; Lee, J; Nam, GB; Park, DW; Park, JJ; Yun, JE, 2020)	0.56
" We observed substantial overlap in the range of exposure to apixaban 5 mg twice daily for patients with or without advanced chronic kidney disease, supporting conventional dosing in patients with CrCl 25 to 30 mL/min."	( Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Alexander, JH; Byon, W; Chertow, GM; Garonzik, S; Granger, CB; Hijazi, Z; Hohnloser, SH; Lopes, RD; Pokorney, SD; Stanifer, JW; Wallentin, L; Wojdyla, DM, 2020)	2.24
"9%) patients receiving rivaroxaban were not initiated on the FDA-recommended 15 mg twice daily dosing for the first 21 days."	( Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series. Barnes, GD; DeCamillo, D; Ellsworth, S; Kaatz, S, 2020)	1.01
" However, warfarin requires regular monitoring and dosage adjustments and fails for many patients, causing thromboembolic and bleeding events."	( Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices. Delgado, RM; Fedson, S; Frazier, OH; George, JK; Lamba, HK; Moctezuma-Ramirez, A; Nair, AP; Parikh, UM; Parikh, VY, 2020)	0.56
"To review the literature on treatment of venous thromboembolism (VTE) and prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low- and high-body-weight patients and to make recommendations regarding agent selection and dosing in these patient populations."	( Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. Branam, DL; Covert, K, 2020)	0.56
"The selection and optimal dosing of DOACs in low- and high-body-weight patients has not yet been fully elucidated by clinical trials; however, evidence suggests that issues of both safety and efficacy in patients at the extremes of body weight may warrant careful consideration when selecting a DOAC for such patients."	( Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. Branam, DL; Covert, K, 2020)	0.56
" Prospective studies are needed to identify a superior reversal agent when comparing andexanet alfa to hospital standard of care (4F-PCC or aPCC) and to further explore the optimal dosing strategy for patients with ICH associated with apixaban or rivaroxaban use."	( Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products. Atallah, S; Baje, M; Cang, W; Castillo, R; Chan, A; Derry, K; Groysman, L; Huang, W; Martin, R; Minokadeh, A; Nova, A; Schomer, K; Stern-Nezer, S; Zimmermann, LL, 2021)	1.05
" Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence."	( [Antithrombotic Treatment of Pulmonary Embolism]. Ebner, M; Lankeit, M, 2020)	0.78
" Factors significantly associated with increased odds of bleeding were an age > 80 years, inappropriately high dosing regimens, and modest anti-Xa levels (100-300 ng/mL) for rivaroxaban specifically."	( Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Dinh, A; Donahue, KR; Jakowenko, N; Nguyen, S; Ruegger, M; Salazar, E, 2020)	2
"Older age and inappropriately high dosing regimens were associated with major bleeding in patients taking apixaban and rivaroxaban."	( Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Dinh, A; Donahue, KR; Jakowenko, N; Nguyen, S; Ruegger, M; Salazar, E, 2020)	2.21
" A growing body of evidence shows that once-daily dosing improves adherence and persistence to therapy, without having an impact on bleeding risk."	( Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. Haas, S; Patti, G, 2020)	0.56
" Our study aimed to describe characteristics and dosing regimens in patients on apixaban or rivaroxaban who experienced a new or recurrent thrombosis."	( Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban. Donahue, KR; Dreucean, D; Nguyen, SN; Ruegger, MC; Salazar, E, 2021)	1.07
" Only 37% of patients on warfarin had optimal dosing control, and they did not differ significantly in TTB, TTT, and OS from patients on DOACs."	( Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry. Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B, 2020)	0.56
" Patients receiving warfarin rarely obtain optimal dosing control, and experience significantly shorter survival compared with patients receiving DOACs."	( Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry. Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B, 2020)	0.56
"All KT patients should have been treated with the standard 5-mg bid apixaban dosage according to the clinical parameters; however, 7 were inappropriately treated with a reduced dosage (2."	( Apixaban Level and Its Influence on Immunosuppression and Graft Outcome in Kidney Transplant Recipients With Atrial Fibrillation. Avni, S; Fuchs, S; Green, H; Nissan, R; Rahamimov, R; Rozen-Zvi, B; Spectre, G, 2021)	2.3
"Similar to nontransplant patients, KT patients administered the standard 5-mg bid dosage had apixaban levels that were well within the recommended manufacturers' expected ranges."	( Apixaban Level and Its Influence on Immunosuppression and Graft Outcome in Kidney Transplant Recipients With Atrial Fibrillation. Avni, S; Fuchs, S; Green, H; Nissan, R; Rahamimov, R; Rozen-Zvi, B; Spectre, G, 2021)	2.28
" Therefore, uncertainty remains concerning benefits, dosing and timing of intake in haemodialysis population."	( Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. Bouillon, T; Coemans, M; Jacquemin, M; Kuypers, D; Meijers, B; Van den Bosch, I; Vanassche, T; Verhamme, P, 2021)	2.06
"5 mg, although significance could only be reached for dosing pre-dialysis (2."	( Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. Bouillon, T; Coemans, M; Jacquemin, M; Kuypers, D; Meijers, B; Van den Bosch, I; Vanassche, T; Verhamme, P, 2021)	2.06
" Further research is needed to determine the impact of ALM on bleeding complications and the potential role of ALM-guided dosing for sarcopenic patients."	( Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation. Afilalo, J; Afilalo, M; Bendayan, M; Blostein, M; Chen-Tournoux, A; Eintracht, S; MacNamara, E; Mardigyan, V; Rudski, L; Williamson, D, 2021)	0.62
" Label adherence to apixaban dosing should be emphasized to achieve the best clinical outcomes for Asian patients with AF."	( Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. Choi, EK; Han, KD; Jung, JH; Lee, SR; Lip, GYH; Oh, S; Park, SH, 2021)	1.26
"Observational studies assessing direct oral anticoagulant (DOACs) dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high-dose DOACs compared to those in randomized controlled trials (RCTs)."	( Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. Brophy, JM; Côté, R; de Denus, S; Dorais, M; Dragomir, A; Dubé, MP; Lenglet, A; Perreault, S; Schnitzer, ME; Tardif, JC; White-Guay, B, 2021)	0.86
" An apixaban dose score (ADS) was defined to account for apixaban dosage and the number of apixaban dose-reduction criteria."	( Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. Choshen Cohen, L; Goldstein, R; Hakimian, D; Hirsh-Raccah, B; Kalish, Y; Matok, I; Muszkat, M; Perlman, A; Singer, DE, 2021)	1.18
"1%), appropriate dosing (83."	( Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe. Al-Dakkak, I; Kahlon, R; Mayall, S; Shen, SW, 2021)	0.9
"The clinical use of factor VIII inhibitor bypassing activity (FEIBA) for factor Xa (FXa) inhibitor reversal is derived from small studies with notable variation in patient eligibility for use, dosage regimens, concurrent supportive care, and outcome measures."	( Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage. Coffeen, SN; Hunt, AR; Ice, C; Parker, J; Shiltz, DL, 2021)	0.86
" These differences between DOACs with almost equal half-life are probably partly due to the differences in dosing interval: twice a day (BID) versus once a day (QD)."	( [Is one DOAC better than another?] Pos, L, 2021)	0.62
" DOAC dosing congruent with the package insert(s) was associated with a lower risk of thrombosis."	( Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. Brown, RS; Hedvat, J; Jennings, DL; Lange, NW; Robbins, H; Salerno, DM; Scheffert, J; Thornberg, ME, 2021)	0.91
" However, the efficacy and safety of different dosage in patients with renal dysfunction is still a clinical challenge."	( Comparison of Low and Full Dose Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Renal Dysfunction (from a National Registry). Barsheshet, A; Elis, A; Giladi, E; Goldenberg, I; Gurevitz, C; Klempfner, R; Kornowski, R, 2021)	0.9
"Ciraparantag provides a dose-related reversal of anticoagulation induced by steady-state dosing of apixaban or rivaroxaban."	( Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S, 2022)	1.19
" To what extent the observed increases in DOAC exposure in the older patients is the cause of their increased risk of bleeding, which could potentially be ameliorated by dosing titration, requires further investigation."	( Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients. Avery, P; Biss, T; Kamali, F; Kampouraki, E; Wynne, H, 2021)	0.62
" Trough and peak AXA values, PT, and APTT were measured at 10 mg BID dosage and then at 5 mg BID dosage."	( Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily. Fukushima, K; Hori, Y; Nishimura, K; Ono, R; Takahashi, H; Yamashita, D; Yamazaki, T, 2022)	0.95
" The secondary outcome evaluated patients who reported time of last known DOAC dose within a preferred time frame of <12 h for once daily dosing DOAC therapy or < 6 h for twice daily dosing DOAC therapy."	( Evaluation of direct oral anticoagulant use on thromboelastography in an emergency department population. Jenrette, J; Ray, L; Schwarz, K; Trujillo, T, 2022)	0.72
" Detailed pharmacokinetic studies are needed to determine the ideal apixaban dosage for future experiments and to enable extrapolation to the clinical situation."	( Apixaban in a porcine model of mechanical valve thrombosis in pulmonary position-a pilot study. Jacquemin, M; Langenaeken, T; Meuris, B; Nachtergaele, B; Rega, F; Truyers, I; Van Hauwermeiren, H; Van Hoof, L; Verhamme, P, 2022)	2.4
"The FXIa inhibitor asundexian at doses of 20 mg and 50 mg once daily resulted in lower rates of bleeding compared with standard dosing of apixaban, with near-complete in-vivo FXIa inhibition, in patients with atrial fibrillation."	( Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Caso, V; Connolly, SJ; Durdil, V; Fox, KAA; Gorog, DA; Jones, WS; Mundl, H; Neumann, C; Oldgren, J; Patel, MR; Piccini, JP; Viethen, T, 2022)	1.16
" Secondary outcomes included new VTE while on apixaban, appropriateness of anticoagulation regimen with regards to FDA labeled dosing and frequency, anticoagulation regimen adjustments, and factor Xa inhibitor-specific anti-Xa levels if available."	( Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy. Chen, J; Dunne, I; Nguyen, S; Ruegger, M; Salazar, E; Samuel, L, 2022)	1.27
" Peak and trough drug plasma concentrations were collected based on the dosing interval and pharmacokinetics of the drugs and quantified using high performance liquid chromatography."	( Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Chan, ECY; Soh, XQ; Tan, DS, 2023)	0.91
"To investigate effects of appropriately and inappropriately dosed apixaban/rivaroxaban versus warfarin on effectiveness and safety outcomes in patients with non-valvular atrial fibrillation (NVAF)."	( Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary care. Brobert, G; Fatoba, S; García Rodríguez, LA; González-Pérez, A; Roberts, L; Saez, ME; Vora, P, 2022)	1.18
" Using logistic regression, adjusted ORs with 95% CIs were calculated for the outcomes comparing apixaban/rivaroxaban use (appropriate or inappropriate dosing based on the product label criteria) and warfarin."	( Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary care. Brobert, G; Fatoba, S; García Rodríguez, LA; González-Pérez, A; Roberts, L; Saez, ME; Vora, P, 2022)	1.16
" They should, therefore, be interpreted with caution, and prescribers should adhere to the dosing instructions in the respective Summary of Product Characteristics."	( Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary care. Brobert, G; Fatoba, S; García Rodríguez, LA; González-Pérez, A; Roberts, L; Saez, ME; Vora, P, 2022)	0.95
" Reduced apixaban and rivaroxaban dosing regimens are recommended when dronedarone is co-administered to patients with AF."	( Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. He, QF; Jiao, Z; Wen, HN; Xiang, XQ; Yu, JG, 2022)	1.34
"There are no clear dosing recommendations when using apixaban for venous thromboembolism (VTE) treatment in patients with severe or end-stage renal disease; clinical trials excluded patients with a creatinine clearance (CrCl) <25 mL/min or on dialysis."	( Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). Abdo, C; Bang, SH; Barriga, A; Cadiz, CL; Huynh, B; Knueppel, P; McCart, T; Pon, T; Shin, J; Stevens, C; Troyer, C; Wilson, M; Yang, NT; Zhou, C, 2022)	1.23
" Exclusions were an inappropriate dosage of apixaban or concomitant dronedarone, verapamil, ranolazine, naproxen, or both amiodarone and diltiazem."	( A Real-World Matched Cohort Study of the Effect of Concomitant Amiodarone or Diltiazem Administration on Apixaban Peak and Trough Concentrations. Ainsworth, M; Bookstaver, DA; Gleaton, M; Milner, E, 2023)	1.39
" In this limited series, apixaban paired with a level-based dosing regimen and low-dose aspirin provided safe and effective antithrombosis with only one hemocompatibility-related event related to medication non-adherence."	( Apixaban Anticoagulation in Children and Young Adults Supported With the HeartMate 3 Ventricular Assist Device. Blume, ED; Cetatoiu, MA; Daly, KP; Esteso, P; Fynn-Thompson, F; Hawkins, B; Kobayashi, RL; VanderPluym, C; Ventresco, C, 2023)	2.66
" The median initial peak apixaban level was 165 ng/mL (23-474; n = 125) in the prophylaxis subgroup and 153 ng/mL (30-450; n = 33) in the treatment subgroup; dosage was adjusted in response to levels in 25% of the patients."	( Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. Ankola, A; Cetatoiu, MA; Esch, JJ; Esteso, P; Gauvreau, K; Hawkins, B; Hellinger, A; Kobayashi, RL; VanderPluym, C; Ventresco, C; Williams, R, 2023)	1.55
"Apixaban use was feasible with a low rate of adverse events across a diverse pediatric cardiac population using commercially available tablets dosed to weight and adjusted based on peak apixaban levels."	( Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. Ankola, A; Cetatoiu, MA; Esch, JJ; Esteso, P; Gauvreau, K; Hawkins, B; Hellinger, A; Kobayashi, RL; VanderPluym, C; Ventresco, C; Williams, R, 2023)	2.69
"Recommendations for apixaban dosing on the basis of kidney function are inconsistent between the US Food and Drug Administration and European Medicines Agency for patients with atrial fibrillation."	( Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease. Chang, AR; Grams, ME; Inker, LA; McAdams-DeMarco, M; Shin, JI; Xu, Y, 2023)	1.58
"5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration."	( Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease. Chang, AR; Grams, ME; Inker, LA; McAdams-DeMarco, M; Shin, JI; Xu, Y, 2023)	1.59
"Possible challenges in dosing non-vitamin K antagonist oral anticoagulants in nonvalvular atrial fibrillation (NVAF) and limited evidence in Saudi Arabia make it difficult to assess their appropriateness."	( Appropriateness of rivaroxaban and apixaban dosing in hospitalized patients with a newly diagnosed nonvalvular atrial fibrillation at a single tertiary hospital. Alshibani, M, 2023)	1.19
" Target apixaban concentrations are reached under standard dosage regimens, but overexposure can rapidly occur in the presence of cumulative factors warranting the development of a predictive tool for tailoring apixaban exposure and its clinical utility in at-risk patients."	( Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study. Csajka, C; Daali, Y; Favre, S; Fontana, P; Gaspar, F; Gosselin, P; Guidi, M; Lenoir, C; Reny, JL; Rollason, V; Samer, CF; Terrier, J, 2023)	1.63
" Both dosing regimens of apixaban, standard or reduced, were accepted."	( Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies. Bezirgianidou, Z; Karatisidis, L; Misidou, C; Mprotsis, T; Pentidou, A; Spanoudakis, E; Zagoridis, K, 2023)	2.66

Role	Description
anticoagulant	An agent that prevents blood clotting.
EC 3.4.21.6 (coagulation factor Xa) inhibitor	An EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of coagulation factor Xa (EC 3.4.21.6).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyrazolopyridine
piperidones
lactam	Cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Effect of intestinal microbiome on anticoagulant response of vitamin K antagonists	4	13

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.0209	0.0013	10.1577	42.8575	AID1259253
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Coagulation factor X (EC 3.4.21.6) (Stuart factor) (Stuart-Prower factor)	Homo sapiens (human)	Ki	0.0001	0.0001	0.0001	0.0001	AID977610
Coagulation factor X	Oryctolagus cuniculus (rabbit)	Ki	0.0002	0.0001	0.0002	0.0002	AID302366
Prothrombin	Homo sapiens (human)	Ki	2.3250	0.0000	0.7846	9.0000	AID1797810; AID302354; AID458312
Coagulation factor X	Homo sapiens (human)	IC50 (µMol)	0.2200	0.0003	0.5937	10.0000	AID1323702; AID1470975
Coagulation factor X	Homo sapiens (human)	Ki	0.1939	0.0000	0.4708	9.0000	AID1180259; AID1797810; AID1802999; AID1803000; AID299798; AID302353; AID331785; AID351693; AID396701; AID458311; AID527394
Trypsin-1	Homo sapiens (human)	Ki	4.2000	0.0000	1.7676	8.9000	AID458313
Trypsin-2	Homo sapiens (human)	Ki	4.2000	0.0043	0.9487	3.2900	AID458313
Trypsin-3	Homo sapiens (human)	Ki	4.2000	0.0043	0.9487	3.2900	AID458313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of protein phosphorylation	Prothrombin	Homo sapiens (human)
proteolysis	Prothrombin	Homo sapiens (human)
acute-phase response	Prothrombin	Homo sapiens (human)
cell surface receptor signaling pathway	Prothrombin	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Prothrombin	Homo sapiens (human)
blood coagulation	Prothrombin	Homo sapiens (human)
positive regulation of cell population proliferation	Prothrombin	Homo sapiens (human)
regulation of cell shape	Prothrombin	Homo sapiens (human)
response to wounding	Prothrombin	Homo sapiens (human)
negative regulation of platelet activation	Prothrombin	Homo sapiens (human)
platelet activation	Prothrombin	Homo sapiens (human)
regulation of blood coagulation	Prothrombin	Homo sapiens (human)
positive regulation of blood coagulation	Prothrombin	Homo sapiens (human)
positive regulation of cell growth	Prothrombin	Homo sapiens (human)
positive regulation of insulin secretion	Prothrombin	Homo sapiens (human)
positive regulation of collagen biosynthetic process	Prothrombin	Homo sapiens (human)
fibrinolysis	Prothrombin	Homo sapiens (human)
negative regulation of proteolysis	Prothrombin	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Prothrombin	Homo sapiens (human)
negative regulation of astrocyte differentiation	Prothrombin	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Prothrombin	Homo sapiens (human)
regulation of cytosolic calcium ion concentration	Prothrombin	Homo sapiens (human)
cytolysis by host of symbiont cells	Prothrombin	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Prothrombin	Homo sapiens (human)
negative regulation of fibrinolysis	Prothrombin	Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptide	Prothrombin	Homo sapiens (human)
neutrophil-mediated killing of gram-negative bacterium	Prothrombin	Homo sapiens (human)
positive regulation of lipid kinase activity	Prothrombin	Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory response	Prothrombin	Homo sapiens (human)
positive regulation of protein localization to nucleus	Prothrombin	Homo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway	Prothrombin	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Prothrombin	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Prothrombin	Homo sapiens (human)
proteolysis	Coagulation factor X	Homo sapiens (human)
blood coagulation	Coagulation factor X	Homo sapiens (human)
positive regulation of cell migration	Coagulation factor X	Homo sapiens (human)
positive regulation of TOR signaling	Coagulation factor X	Homo sapiens (human)
digestion	Trypsin-1	Homo sapiens (human)
extracellular matrix disassembly	Trypsin-1	Homo sapiens (human)
proteolysis	Trypsin-1	Homo sapiens (human)
proteolysis	Trypsin-2	Homo sapiens (human)
digestion	Trypsin-2	Homo sapiens (human)
antimicrobial humoral response	Trypsin-2	Homo sapiens (human)
extracellular matrix disassembly	Trypsin-2	Homo sapiens (human)
positive regulation of cell growth	Trypsin-2	Homo sapiens (human)
collagen catabolic process	Trypsin-2	Homo sapiens (human)
positive regulation of cell adhesion	Trypsin-2	Homo sapiens (human)
proteolysis	Trypsin-3	Homo sapiens (human)
digestion	Trypsin-3	Homo sapiens (human)
antimicrobial humoral response	Trypsin-3	Homo sapiens (human)
zymogen activation	Trypsin-3	Homo sapiens (human)
endothelial cell migration	Trypsin-3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
lipopolysaccharide binding	Prothrombin	Homo sapiens (human)
serine-type endopeptidase activity	Prothrombin	Homo sapiens (human)
signaling receptor binding	Prothrombin	Homo sapiens (human)
calcium ion binding	Prothrombin	Homo sapiens (human)
protein binding	Prothrombin	Homo sapiens (human)
growth factor activity	Prothrombin	Homo sapiens (human)
heparin binding	Prothrombin	Homo sapiens (human)
thrombospondin receptor activity	Prothrombin	Homo sapiens (human)
serine-type endopeptidase activity	Coagulation factor X	Homo sapiens (human)
calcium ion binding	Coagulation factor X	Homo sapiens (human)
protein binding	Coagulation factor X	Homo sapiens (human)
phospholipid binding	Coagulation factor X	Homo sapiens (human)
serine-type endopeptidase activity	Trypsin-1	Homo sapiens (human)
metal ion binding	Trypsin-1	Homo sapiens (human)
metalloendopeptidase activity	Trypsin-2	Homo sapiens (human)
serine-type endopeptidase activity	Trypsin-2	Homo sapiens (human)
calcium ion binding	Trypsin-2	Homo sapiens (human)
protein binding	Trypsin-2	Homo sapiens (human)
serine-type peptidase activity	Trypsin-2	Homo sapiens (human)
serine-type endopeptidase activity	Trypsin-3	Homo sapiens (human)
calcium ion binding	Trypsin-3	Homo sapiens (human)
protein binding	Trypsin-3	Homo sapiens (human)
serine-type peptidase activity	Trypsin-3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
external side of plasma membrane	Prothrombin	Homo sapiens (human)
collagen-containing extracellular matrix	Prothrombin	Homo sapiens (human)
extracellular region	Prothrombin	Homo sapiens (human)
extracellular space	Prothrombin	Homo sapiens (human)
endoplasmic reticulum lumen	Prothrombin	Homo sapiens (human)
Golgi lumen	Prothrombin	Homo sapiens (human)
plasma membrane	Prothrombin	Homo sapiens (human)
extracellular exosome	Prothrombin	Homo sapiens (human)
blood microparticle	Prothrombin	Homo sapiens (human)
collagen-containing extracellular matrix	Prothrombin	Homo sapiens (human)
extracellular space	Prothrombin	Homo sapiens (human)
extracellular region	Coagulation factor X	Homo sapiens (human)
endoplasmic reticulum lumen	Coagulation factor X	Homo sapiens (human)
Golgi lumen	Coagulation factor X	Homo sapiens (human)
plasma membrane	Coagulation factor X	Homo sapiens (human)
external side of plasma membrane	Coagulation factor X	Homo sapiens (human)
extracellular space	Coagulation factor X	Homo sapiens (human)
extracellular region	Trypsin-1	Homo sapiens (human)
collagen-containing extracellular matrix	Trypsin-1	Homo sapiens (human)
blood microparticle	Trypsin-1	Homo sapiens (human)
extracellular space	Trypsin-1	Homo sapiens (human)
extracellular region	Trypsin-2	Homo sapiens (human)
extracellular space	Trypsin-2	Homo sapiens (human)
extracellular matrix	Trypsin-2	Homo sapiens (human)
azurophil granule lumen	Trypsin-2	Homo sapiens (human)
extracellular space	Trypsin-2	Homo sapiens (human)
extracellular region	Trypsin-3	Homo sapiens (human)
extracellular space	Trypsin-3	Homo sapiens (human)
tertiary granule lumen	Trypsin-3	Homo sapiens (human)
extracellular space	Trypsin-3	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1345896	Human coagulation factor X (S1: Chymotrypsin)	2008	Journal of thrombosis and haemostasis : JTH, May, Volume: 6, Issue:5	Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
AID527437	Drug excretion in rat urine	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID527411	Antithrombotic activity in iv dosed rabbit assessed as restoration of integrated blood flow	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID396709	Anticoagulant activity in rabbit plasma assessed as drug level required to double prothrombin time	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID1470974	Inhibition of human F10a assessed as decrease in p-nitroaniline cleavage from pefachrome F10a at 0.5 uM preincubated for 10 mins followed by substrate addition measured after 20 mins relative to control	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
AID1180262	Volume of distribution at steady state in dog at 0.5 mg/kg, iv and 0.2 mg/kg, po administered as cassette dosing	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
AID1214673	Apparent permeability from mucosal to serosal in rat colon at 200 uM by LC/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID527421	Drug excretion in human feces	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1180259	Inhibition of purified human factor Xa	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
AID396708	Oral bioavailability in dog at 0.2 mg/kg	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID302366	Binding affinity to rabbit F10a	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID302353	Binding affinity to human F10a	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID1323706	Anticoagulant activity in rabbit plasma assessed as increase in activated partial thromboplastin time	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
AID527392	Volume of distribution at steady state in rat	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1214672	Apparent permeability from mucosal to serosal in rat ileum at 200 uM by LC/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1252515	Anticoagulant activity in iv dosed rat AV shunt model assessed as decrease in clot weight administered every 0.5 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252515	Anticoagulant activity in iv dosed rat AV shunt model assessed as decrease in clot weight administered every 0.5 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID458312	Inhibition of human factor 2a	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Phenyltriazolinones as potent factor Xa inhibitors.
AID299799	Anticoagulant activity in human plasma assessed as concentration required to double prothrombin time	2007	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16	SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
AID1470970	Anticoagulant activity in rabbit plasma assessed as concentration required to double activated partial thromboplastin time	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
AID1252167	Anticoagulant activity in 10 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252167	Anticoagulant activity in 10 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID527409	Clearance in dog	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID302358	Volume of distribution at steady state in dog at 0.4 mg/kg, iv and 0.2 mg/kg, po	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID331785	Inhibition of human factor 10a	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
AID302364	Aqueos solubility in saline	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID527420	Drug excretion in human urine	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1323703	Anticoagulant activity in healthy human plasma assessed as increase in prothrombin time	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
AID1871813	Anticoagulant activity in rabbit plasma assessed as prothrombin time	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
AID396705	Volume of distribution at steady state in dog at 0.5 mg/kg, iv and 0.2 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID527399	Anticoagulant activity in human platelet assessed as concentration required to double prothrombin time	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1252164	Anticoagulant activity in 0.3 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252164	Anticoagulant activity in 0.3 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID527440	Drug excretion in mouse feces	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID527441	Drug excretion in mouse urine	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID299798	Inhibition of human factor 10a	2007	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16	SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
AID527434	Protein binding in dog	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID331786	Anticoagulant activity in human plasma assessed as concentration required to double prothrombin time	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
AID527442	Drug excretion in rabbit feces	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID527393	Clearance in rat	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1214671	Apparent permeability from mucosal to serosal in rat jejunum at 200 uM by LC/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID527438	Drug excretion in dog feces	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID302361	Apparent permeability across Caco-2 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID1214609	Oral bioavailability in rat	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1180263	Half life in dog at 0.2 mg/kg, po administered as cassette dosing	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
AID331791	Bioavailability in dog at 0.02 to 0.5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
AID1252159	Anticoagulant activity in 0.1 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252159	Anticoagulant activity in 0.1 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID527398	Anticoagulant activity in human platelet assessed as concentration required to double activated partial prothrombin time	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1470975	Inhibition of human F10a assessed as decrease in p-nitroaniline cleavage from pefachrome F10a preincubated for 10 mins followed by substrate addition measured after 20 mins	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
AID302357	Clearance in dog at 0.4 mg/kg, iv and 0.2 mg/kg, po	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID1252163	Anticoagulant activity in 10 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252163	Anticoagulant activity in 10 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID1470976	Inhibition of thrombus formation in Sprague-Dawley rat at 10 mg/kg, po after 2 hrs relative to control	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
AID527407	Oral bioavailability in dog	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1323707	Antithrombotic activity in rat venous thrombus model assessed as inhibition of thrombus formation relative to control	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
AID527444	Volume of distribution in chimpanzee	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID527430	Antithrombotic activity in rabbit venous thrombosis model	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID458313	Inhibition of human trypsin	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Phenyltriazolinones as potent factor Xa inhibitors.
AID1323702	Inhibition of human coagulation factor 10a assessed as reduction in p-nitroaniline cleavage from pefachrome substrate preincubated for 10 mins followed by substrate addition measured after 20 mins	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
AID1214674	Apparent permeability from serosal to mucosal in rat jejunum at 200 uM by LC/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID527433	Protein binding in rat	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID527435	Protein binding in chimpanzee	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1252160	Anticoagulant activity in 0.3 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252160	Anticoagulant activity in 0.3 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID1323704	Anticoagulant activity in rabbit plasma assessed as increase in prothrombin time	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
AID1214586	Inhibition of P-gp in human Caco2 cells assessed as effect on rhodamine123 efflux	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID396706	Clearance in dog at 0.5 mg/kg, iv and 0.2 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID1180260	Apparent permeability from apical to basolateral side of the human Caco2 cells	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
AID1180264	Oral bioavailability in dog at 0.2 mg/kg administered as cassette dosing	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
AID1252512	Anticoagulant activity in human corn trypsin inhibitor citrated platelet poor plasma assessed as reduction of tissue factor-induced thrombin generation at 1 to 20 pM after 5 mins	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252512	Anticoagulant activity in human corn trypsin inhibitor citrated platelet poor plasma assessed as reduction of tissue factor-induced thrombin generation at 1 to 20 pM after 5 mins	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID396700	Anticoagulant activity in human plasma assessed as drug level required to double prothrombin time	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID1214613	Ratio of Cmax in milk to plasma in lactating rat	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1252168	Anticoagulant activity in 20 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252168	Anticoagulant activity in 20 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID1214585	Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux at 12.5 uM	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1214612	Ratio of drug level in brain to blood in po dosed rat	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID351693	Inhibition of Factor 10a	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1252165	Anticoagulant activity in 1 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252165	Anticoagulant activity in 1 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID396710	Antithrombotic activity against iv dosed rabbit arterio-venous shunt model assessed as inhibition of thrombus formation	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID1214611	Oral bioavailability in human	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID396699	Apparent permeability from apical to basolateral side of human Caco-2 cells	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID458311	Inhibition of human factor 10a	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Phenyltriazolinones as potent factor Xa inhibitors.
AID1252166	Anticoagulant activity in 3 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252166	Anticoagulant activity in 3 pM tissue factor stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID527410	Volume of distribution at steady state in dog	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID527394	Inhibition of factor 10a	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID351695	Anticoagulant activity in human plasma assessed as concentration required to double the thrombin generation time	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1470969	Anticoagulant activity in rabbit plasma assessed as concentration required to double prothrombin time	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
AID331807	Inhibition of thrombus formation in rabbit arteriovenous-shunt thrombosis model	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
AID527443	Drug excretion in rabbit urine	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1470971	Anticoagulant activity in human plasma assessed as concentration required to double prothrombin time	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
AID527428	Antithrombotic activity in rabbit arteriovenous-shunt thrombosis model measured per hr	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1252161	Anticoagulant activity in 1 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252161	Anticoagulant activity in 1 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID396707	Half life in dog at 0.2 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID527432	Oral bioavailability in chimpanzee	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID302354	Inhibition of human thrombin	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID458314	Anticoagulant activity in rabbit plasma assessed as concentration required to double prothrombin time by aggregometer	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Phenyltriazolinones as potent factor Xa inhibitors.
AID1323705	Anticoagulant activity in healthy human plasma assessed as increase in activated partial thromboplastin time	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
AID302362	Inhibition of thrombus formation in rabbit arteriovenous shunt thrombosis model	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID331788	Clearance in dog at 0.02 to 0.5 mg/kg, iv and po	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
AID331790	Volume of distribution at steady state in dog at 0.02 to 0.5 mg/kg, iv and po	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
AID302359	Half life in dog at 0.2 mg/kg, po	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID396701	Binding affinity to human coagulation factor 10a	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID1214583	Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux at 50 uM	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1470972	Anticoagulant activity in human plasma assessed as concentration required to double activated partial thromboplastin time	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
AID331789	Half life in dog at 0.02 to 0.5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
AID1180275	Anticoagulant activity in human plasma assessed as concentration required to double prothrombin time	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
AID1214670	Apparent permeability from mucosal to serosal in rat duodenum at 200 uM by LC/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID396712	Protein binding in rabbit plasma	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
AID1214610	Oral bioavailability in dog	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID302360	Oral bioavailability in dog at 0.2 mg/kg, po	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID527445	Clearance in chimpanzee	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1222793	Dissociation constant, pKa of the compound	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Which metabolites circulate?
AID302356	Anticoagulant potency in human plasma assessed as concentration required to double prothrombin time	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID302365	Protein binding in human serum by equilibrium dialysis	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID1470973	Inhibition of human F10a assessed as decrease in p-nitroaniline cleavage from pefachrome F10a at 5 uM preincubated for 10 mins followed by substrate addition measured after 20 mins relative to control	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
AID1214608	Permeability by PAMPA method	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1214614	Ratio of AUC in milk to plasma in lactating rat	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID527419	Half life in po dosed human	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID1214584	Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux at 25 uM	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1252162	Anticoagulant activity in 3 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Development of a novel class of potent and selective FIXa inhibitors.
AID1252162	Anticoagulant activity in 3 pM recombinant coagulation factor 11a stimulated human CTI-citrated plasma assessed as inhibition of thrombin generation incubated for 5 mins by calibrated automated thrombogram analysis	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Development of a novel tricyclic class of potent and selective FIXa inhibitors.
AID1180261	Clearance in dog at 0.5 mg/kg, iv and 0.2 mg/kg, po administered as cassette dosing	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
AID527439	Drug excretion in dog urine	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID527436	Drug excretion in rat feces	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Factor Xa inhibitors: next-generation antithrombotic agents.
AID302368	Anticoagulant potency in human plasma assessed as concentration required to double activated partial thromboplastin time	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1802999	FXa Inhibition Assay from Article 10.3109/14756366.2010.535793: \\Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.\\	2011	Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 26, Issue:4	Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
AID1797810	Enzyme Assay and Determination of the Inhibition Constants. from Article 10.1021/jm070245n: \\Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Hi	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID1803000	FXa Inhibition Assay (in prothrombinase) from Article 10.3109/14756366.2010.535793: \\Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.\\	2011	Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 26, Issue:4	Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
AID1811	Experimentally measured binding affinity data derived from PDB	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	33 (1.42)	29.6817
2010's	1629 (70.25)	24.3611
2020's	657 (28.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	255 (10.60%)	5.53%
Reviews	636 (26.44%)	6.00%
Case Studies	247 (10.27%)	4.05%
Observational	133 (5.53%)	0.25%
Other	1,134 (47.15%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (265)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of Ticagrelor and Apixaban With or Without Acetylsalicylic Acid on Markers of Coagulation Activation at the Site of Thrombus Formation in Vivo in Healthy Male Subjects and in an ex Vivo Perfusion Chamber Model at High and Low Shear Rate [NCT02080858]	Phase 1	40 participants (Actual)	Interventional	2014-05-31	Completed
Single-center, Open, Randomized, Single-dose, Two-cycle, Two-sequence, Crossover Bioequivalence Study to Evaluate the Effects of the Test and the Fed States [NCT05841446]	Phase 1	54 participants (Actual)	Interventional	2021-03-02	Completed
A Randomized, Double-blind, Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study [NCT00320255]	Phase 2	130 participants (Actual)	Interventional	2006-06-30	Completed
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation: a Prospective, Controlled, Randomized Pilot Study [NCT02889562]	Phase 2/Phase 3	56 participants (Actual)	Interventional	2016-09-30	Completed
A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Kn [NCT03251482]	Phase 2	308 participants (Actual)	Interventional	2017-11-13	Completed
Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome [NCT04666454]	Phase 2	1,000 participants (Anticipated)	Interventional	2020-12-14	Recruiting
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism [NCT03988842]	Phase 4	4 participants (Actual)	Interventional	2019-07-25	Terminated(stopped due to COVID-19 pandemic)
"ORBIT Versus HAS-BLED Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants." [NCT05975320]		100 participants (Anticipated)	Observational	2023-08-31	Not yet recruiting
Treatment Patterns and Clinical Outcomes Among Venous Thromboembolism Patients Treated With Anticoagulants After the Entry of Non-vitamin K Antagonist Oral Anticoagulants in Korea [NCT05022563]		55,759 participants (Actual)	Observational	2021-08-31	Completed
Identification of Clinical and Pharmacogenetic Factors Predictive of Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation. [NCT04297150]		700 participants (Anticipated)	Observational	2020-06-18	Active, not recruiting
Pattern of Use of Direct Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients in UK General Practices [NCT03119116]		31,336 participants (Actual)	Observational	2017-05-15	Completed
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial [NCT02942407]	Phase 4	154 participants (Actual)	Interventional	2016-12-31	Completed
Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study [NCT03181386]	Phase 3	60 participants (Actual)	Interventional	2017-05-03	Completed
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation [NCT05757869]	Phase 3	15,500 participants (Anticipated)	Interventional	2023-04-11	Recruiting
Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus [NCT02982590]	Phase 3	27 participants (Actual)	Interventional	2016-11-30	Completed
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects [NCT03310021]	Phase 2	108 participants (Actual)	Interventional	2017-08-28	Completed
A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist or LMWH in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembol [NCT02981472]	Phase 2	192 participants (Actual)	Interventional	2017-01-19	Completed
A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism [NCT00633893]	Phase 3	2,711 participants (Actual)	Interventional	2008-05-31	Completed
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET) [NCT03196349]	Phase 4	44 participants (Actual)	Interventional	2018-08-01	Terminated(stopped due to Lack of enrollment)
Intracerebral Hemorrhage Due to Oral Anticoagulants in the Secondary Prevention of Ischemic Stroke: Prediction of the Risk by the Detection of Leukoaraiosis and Microbleeding With Magnetic Resonance [NCT02238470]		1,000 participants (Actual)	Observational [Patient Registry]	2012-04-30	Completed
Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants Concentration Among Patients With Acute Stroke (The Direct Oral AntiCoagulant Registry in Taiwan-Emergent Department, DOACT-ED) [NCT06144866]		1,000 participants (Anticipated)	Observational [Patient Registry]	2020-05-01	Recruiting
Safety and Effectiveness of Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation: a Multi-database Cohort Study With Meta-analysis (DOACs vs DOACs) [NCT03568916]		227,579 participants (Actual)	Observational	2016-11-30	Completed
Prospective Study With Biological Assessment: Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban [NCT03136510]		60 participants (Anticipated)	Interventional	2016-09-30	Recruiting
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial [NCT03961334]	Phase 3	620 participants (Anticipated)	Interventional	2019-12-05	Recruiting
Effectiveness and Safety of Oral Anticoagulants Among Obese Patients With Non-Valvular Atrial Fibrillation in the Veterans Affairs Population With Medicare [NCT04681482]		107,383 participants (Actual)	Observational	2020-11-02	Completed
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism. [NCT03129555]	Phase 4	5,000 participants (Anticipated)	Interventional	2023-04-01	Recruiting
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF). [NCT03129490]	Phase 4	11,000 participants (Anticipated)	Interventional	2023-04-01	Recruiting
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study) [NCT04432220]	Phase 4	840 participants (Anticipated)	Interventional	2020-07-28	Recruiting
Association Between Socioeconomic Factors and Use of Direct Oral Anticoagulants Versus Standard of Care (Warfarin) in Patients With Non-valvular Atrial Fibrillation in Sweden [NCT03684395]		68,056 participants (Actual)	Observational	2016-06-15	Completed
Development of Precision Medicine Platform for Pharmacogenomics of Novel Oral Anticoagulants (NOACs) [NCT04056143]		500 participants (Anticipated)	Observational	2019-01-02	Recruiting
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy: a Prospective Randomized Clinical Trial [NCT03463317]	Phase 4	1,512 participants (Anticipated)	Interventional	2018-02-28	Recruiting
SIFNOS STUDY: RETROSPECTIVE STUDY IN PATIENTS WITH ATRIAL FIBRILLATION (AF) EXPOSED AND UNEXPOSED TO AN ORAL ANTICOAGULANT THERAPY BETWEEN 2014-2020 IN FRANCE [NCT05838664]		1 participants (Anticipated)	Observational	2023-07-07	Active, not recruiting
Anticoagulant Treatment Patterns and Outcomes Among Non-valvular Atrial Fibrillation Patients With High Risk of Gastrointestinal Bleeding in France: a Retrospective Cohort Analysis Using SNDS Database [NCT05038228]		1 participants (Actual)	Observational	2022-08-01	Active, not recruiting
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study [NCT02066454]	Phase 3	105 participants (Anticipated)	Interventional	2014-04-30	Recruiting
An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation [NCT02227550]	Phase 4	676 participants (Actual)	Interventional	2014-12-31	Completed
Early Post-marketing Study of Eliquis (Apixaban) [NCT02153424]		0 participants (Actual)	Observational	2014-04-30	Withdrawn(stopped due to Business objectives have changed.)
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF) [NCT04437654]	Phase 4	1,800 participants (Anticipated)	Interventional	2020-07-28	Recruiting
Safety and Efficacy of Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk (HBR) Patients With History of Paroxysmal Atrial Fibrillation [NCT04151680]		100 participants (Anticipated)	Observational [Patient Registry]	2019-12-01	Recruiting
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon [NCT03563937]		64,920 participants (Actual)	Observational	2018-06-15	Completed
Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial [NCT02048865]	Phase 2	575 participants (Actual)	Interventional	2014-03-24	Completed
Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis [NCT04874428]	Phase 1	24 participants (Anticipated)	Interventional	2021-05-19	Recruiting
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study [NCT03045406]	Phase 3	1,168 participants (Actual)	Interventional	2017-04-13	Active, not recruiting
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis [NCT02945280]	Phase 4	52 participants (Actual)	Interventional	2017-02-22	Terminated(stopped due to COVID-19 resource allocation)
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome [NCT02295475]	Phase 4	48 participants (Actual)	Interventional	2014-12-10	Completed
[NCT02309970]		90 participants (Anticipated)	Observational	2014-12-31	Not yet recruiting
A Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy [NCT01758432]	Phase 2	54 participants (Actual)	Interventional	2012-12-31	Completed
Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Apixaban Reversal by Ciraparantag as Measured by WBCT [NCT03288454]	Phase 2	60 participants (Actual)	Interventional	2017-08-30	Completed
Effect of Apixaban on the Pharmacokinetics of Digoxin in Healthy Subjects [NCT02262520]	Phase 1	24 participants (Actual)	Interventional	2006-01-31	Completed
Novel Oral Anticoagulants in Oral and Maxillofacial Surgery: Impact on Bleeding Tendency, Surgical Difficulty and Post-operative Complications [NCT04662515]		300 participants (Anticipated)	Observational	2016-06-01	Recruiting
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects [NCT03083704]	Phase 1	153 participants (Actual)	Interventional	2017-02-26	Completed
Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women [NCT02829957]	Phase 2/Phase 3	19 participants (Actual)	Interventional	2016-09-30	Completed
Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial [NCT02818868]		700 participants (Actual)	Observational	2016-07-31	Completed
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE [NCT05171049]	Phase 3	1,655 participants (Anticipated)	Interventional	2022-05-05	Recruiting
A Post-marketing Retrospective Non-interventional Study Using Nationwide Registries and Electronic Medical Records to Investigate the Real-life Effectiveness and Major Bleeding Complications of Oral Anticoagulants in Norwegian Non-valvular Atrial Fibrilla [NCT03715725]		70,000 participants (Actual)	Observational	2018-10-31	Terminated(stopped due to After feasibility assessment and due to delays in data receipt study was terminated)
Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban [NCT05632445]	Phase 4	160 participants (Actual)	Interventional	2019-05-01	Completed
A Multicenter, Randomized, Open-label, Active-controlled, Dose-range Finding Study to Assess the Pharmacodynamic Parameters, Safety and Tolerability of MAA868 and Its Effect on Thrombogenesis Biomarkers Compared to Apixaban in Patients With Atrial Fibrill [NCT03398434]	Phase 2	0 participants (Actual)	Interventional	2018-10-16	Withdrawn(stopped due to Trial cancelled before First Patient First Visit (no patient enrolled))
Apixaban in Patients With Left Ventricular Thrombus Post Myocardial Infarction; A Randomized Clinical Trial [NCT05208398]	Phase 3	50 participants (Actual)	Interventional	2018-02-18	Completed
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Le [NCT02369653]	Phase 3	512 participants (Actual)	Interventional	2015-10-22	Completed
Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter [NCT01195727]	Phase 1	13 participants (Actual)	Interventional	2011-07-26	Terminated
A Phase IV, Randomized, Double Blind Study Evaluating the Safety and Efficacy of Apixaban in Subjects With Calf Vein Thrombosis [NCT03590743]	Phase 4	5 participants (Actual)	Interventional	2019-02-19	Terminated(stopped due to Lack of participant enrollment)
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) [NCT02744092]		811 participants (Actual)	Interventional	2016-12-13	Completed
A Descriptive Non-interventional Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice for Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation [NCT05262322]		234 participants (Actual)	Observational	2019-02-15	Completed
A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome [NCT04278729]	Phase 1	22 participants (Actual)	Interventional	2021-04-14	Completed
Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) [NCT02666157]	Phase 4	3,672 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- a Clinical Trial [NCT05973188]	Phase 4	141 participants (Anticipated)	Interventional	2023-05-01	Recruiting
A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism [NCT00643201]	Phase 3	5,614 participants (Actual)	Interventional	2008-07-31	Completed
Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome [NCT00831441]	Phase 3	7,484 participants (Actual)	Interventional	2009-03-31	Terminated
AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study. [NCT02611635]		382 participants (Actual)	Observational	2016-02-02	Completed
REal-World Treatment Outcomes of Oral-Anticoagulants Among Patients With Atrial Fibrillation - Patient Survey - RETAF-PS [NCT05471830]		600 participants (Actual)	Observational	2022-11-30	Completed
Study on the Pharmacokinetics and Point of Care Testing After a Single Dose of 150 mg Dabigatran, 20 mg Rivaroxaban, 5 mg Apixaban, and 60 mg Edoxaban in Healthy Male Subjects [NCT05491460]	Phase 1	24 participants (Anticipated)	Interventional	2022-07-01	Active, not recruiting
OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs [NCT04262492]		500 participants (Anticipated)	Observational [Patient Registry]	2020-10-21	Recruiting
A Phase 2 Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active-Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery [NCT00097357]	Phase 2/Phase 3	1,238 participants (Actual)	Interventional	2004-10-31	Completed
A Multi-center Observative Study of Apixaban After Left Atrial Appendage Occlusion in Patients With Non-valvular Atrial Fibrillation [NCT04550637]		200 participants (Anticipated)	Observational [Patient Registry]	2022-07-04	Recruiting
An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int [NCT02415400]	Phase 4	4,614 participants (Actual)	Interventional	2015-06-04	Completed
Eliquis Acute Stroke Safety Evaluation [NCT04435418]		100 participants (Actual)	Observational [Patient Registry]	2017-03-01	Completed
Apixaban Versus Low-Molecular Weight Heparin For Thromboprophylaxis In Patients With Acute Spinal Cord Injury: A Pilot Study [NCT03200613]	Phase 2	8 participants (Actual)	Interventional	2017-09-01	Terminated(stopped due to study not feasible due to too slow recruitment)
Real-World Comparisons of Bleeding Among Novel Oral Anticoagulant (NOAC)-Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage, Who Newly Initiated Novel Oral Anticoagulation Therapies or Were Treated With Warfarin [NCT03189069]		36,000 participants (Actual)	Observational	2016-10-06	Completed
HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID): a National Platform Trial [NCT04801940]	Phase 3	2,631 participants (Anticipated)	Interventional	2021-05-19	Recruiting
Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects [NCT04809818]	Phase 1	64 participants (Anticipated)	Interventional	2021-03-21	Recruiting
Pharmacokinetics and Safety Profile of Apixaban in Patients With Peritoneal Dialysis [NCT05532878]		50 participants (Anticipated)	Observational	2020-12-01	Recruiting
A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study) [NCT00452530]	Phase 3	3,221 participants (Actual)	Interventional	2007-06-30	Completed
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial [NCT05735639]	Phase 4	6,660 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation [NCT00412984]	Phase 3	20,976 participants (Actual)	Interventional	2006-12-31	Completed
Randomized Trial of Apixaban vs Dose Adjusted Warfarin in Reducing Rate of Cognitive Function Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Non-valvular Atrial Fibrillation Patients With CHA2DS2-VaSc Score = 2 [NCT03839355]	Phase 3	34 participants (Actual)	Interventional	2018-12-19	Terminated(stopped due to Study terminated due to slower than anticipated enrollment.)
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S [NCT02769078]		14,201 participants (Actual)	Observational	2014-11-30	Completed
Post-Discharge Treatment Patterns and Outcomes in Patients With Venous Thromboembolism [NCT05795062]		47,029 participants (Actual)	Observational	2023-03-10	Completed
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb [NCT04229264]	Phase 3	200 participants (Anticipated)	Interventional	2020-01-09	Recruiting
Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis [NCT02672709]	Phase 4	7 participants (Actual)	Interventional	2016-04-30	Completed
Optimal Dosing of Apixaban in Patients at Risk of Elevated Drug Levels: A Study Evaluating a Strategy of Apixaban Drug Level Measurement and Dose Reduction in Patients With Atrial Fibrillation Who Are at Risk of Elevated Drug Levels [NCT02809469]	Phase 2	120 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Pharmacokinetics of Apixaban in Subjects With End-stage Renal Disease Treated With Peritoneal Dialysis: the ApiDP Study [NCT04006093]	Phase 1	24 participants (Actual)	Interventional	2019-12-08	Completed
Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial [NCT04696120]	Phase 2	200 participants (Anticipated)	Interventional	2021-03-02	Not yet recruiting
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial [NCT03568890]	Phase 4	510 participants (Anticipated)	Interventional	2018-09-01	Recruiting
Clinical Application Model of Direct Oral Anticoagulants (MACACOD). Comprehensive Management of ACOD From a Specialized Center in Antithrombotic Therapy and Its Area of Influence [NCT04042155]		1,600 participants (Anticipated)	Observational [Patient Registry]	2019-07-29	Recruiting
A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome. [NCT00313300]	Phase 2	1,741 participants (Actual)	Interventional	2006-05-31	Completed
A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization. [NCT00457002]	Phase 3	6,758 participants (Actual)	Interventional	2007-06-30	Completed
Venous Thromboembolism Prophylaxis With Apixaban in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma Receiving Induction Therapy With an Immunomodulatory-based Regimen [NCT04106700]	Phase 2	60 participants (Actual)	Interventional	2019-04-12	Terminated(stopped due to Low recruitment)
A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban [NCT04142658]	Phase 3	863 participants (Actual)	Interventional	2020-05-01	Terminated(stopped due to Safety)
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative Atrial Fibrillation After Noncardiac Surgery - The ASPIRE-AF Trial [NCT03968393]	Phase 4	2,800 participants (Anticipated)	Interventional	2019-06-14	Recruiting
AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study [NCT02607371]		198 participants (Actual)	Observational	2015-08-27	Completed
Burden of Ischemic Stroke and Adherence to Oral Anticoagulants in Atrial Fibrillation in the UK Primary Care [NCT04099238]		3,739 participants (Actual)	Observational	2019-10-01	Completed
Pharmacokinetics of Apixaban in Nephrotic Syndrome [NCT02599532]	Phase 1	21 participants (Actual)	Interventional	2017-04-30	Completed
Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study [NCT02581176]	Phase 4	300 participants (Actual)	Interventional	2016-04-30	Completed
Apixaban Versus Antiplatelet Drugs or no Antithrombotic Drugs After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation: A Randomised Phase II Clinical Trial [NCT02565693]	Phase 2	101 participants (Actual)	Interventional	2014-09-30	Completed
Venous Thromboembolism Prevention in Outpatients With Glioma [NCT05683808]	Phase 2	40 participants (Anticipated)	Interventional	2023-01-16	Not yet recruiting
Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischemic and Hemorrhagic Events After Trans-Aortic Valve Implantation for Aortic Stenosis [NCT02664649]	Phase 3	1,510 participants (Anticipated)	Interventional	2016-08-26	Completed
A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Antic [NCT00423319]	Phase 3	5,407 participants (Actual)	Interventional	2007-03-31	Completed
Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction (TARGET-Type 2): A Pilot Randomised Controlled Trial [NCT05419583]		60 participants (Anticipated)	Interventional	2022-11-14	Recruiting
A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery [NCT00371683]	Phase 3	3,608 participants (Actual)	Interventional	2006-11-30	Completed
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery [NCT03907046]	Phase 3	700 participants (Anticipated)	Interventional	2020-01-28	Recruiting
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical [NCT05088928]	Phase 2	40 participants (Anticipated)	Interventional	2022-03-01	Not yet recruiting
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study [NCT02640222]		321,501 participants (Actual)	Observational	2014-01-01	Completed
Towards Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Abdominal or Pelvic Major Cancer Surgery [NCT04479579]	Phase 4	53 participants (Actual)	Interventional	2021-02-22	Completed
Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy [NCT04645550]	Phase 4	120 participants (Actual)	Interventional	2020-11-22	Completed
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation. A Multicenter Randomized Clinical Trial. (Occlusion-AF) [NCT03642509]		750 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Safety and Effectiveness of Apixaban in Very Elderly Patients With NVAF Compared to Warfarin Using Administrative Claims Data [NCT05438888]		77,814 participants (Actual)	Observational	2022-07-01	Completed
Bariatric Surgery and Pharmacokinetics of Apixaban: BAR-MEDS Apixaban [NCT03448783]		12 participants (Anticipated)	Observational	2018-01-02	Recruiting
The Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism [NCT03292666]		39,603 participants (Actual)	Observational	2010-01-01	Completed
A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin), Multicenter Study, To Evaluate The Safety And Efficacy In 2 Doses Of Apixaban In Comparison To Warfarin, Administered For 12 Weeks In Subjects With NVAF [NCT00787150]	Phase 2	222 participants (Actual)	Interventional	2008-06-30	Completed
Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation [NCT02935855]	Phase 4	300 participants (Actual)	Interventional	2015-09-30	Completed
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Non Valvular Atrial Fibrillation in Patients Aged 80 Years and Over, Living at Home or in Nursing Home. A Prospective Cohort Study [NCT02286414]		159 participants (Actual)	Observational	2015-02-28	Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Cross Over Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fasting Condition [NCT06043297]	Phase 1	30 participants (Actual)	Interventional	2023-02-23	Completed
Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial [NCT00496769]	Phase 3	6,421 participants (Actual)	Interventional	2007-08-31	Completed
Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention [NCT01885585]		100 participants (Actual)	Observational	2014-07-31	Completed
Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation [NCT01885598]		3,335 participants (Actual)	Observational	2013-07-10	Completed
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation [NCT04642430]	Phase 4	3,018 participants (Anticipated)	Interventional	2021-07-06	Recruiting
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism [NCT03266783]	Phase 4	2,760 participants (Anticipated)	Interventional	2017-12-13	Recruiting
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation [NCT05679024]	Phase 3	1,400 participants (Anticipated)	Interventional	2023-02-17	Recruiting
A Phase 2 Pilot Randomized Controlled Trial Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients [NCT04243122]	Phase 2	44 participants (Actual)	Interventional	2021-02-17	Active, not recruiting
Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence [NCT00562289]	Phase 3	664 participants (Actual)	Interventional	2007-12-31	Completed
Pharmacokinetics, Pharmacodynamics and Safety of Apixaban on Hemodiafiltration [NCT04952792]	Phase 2	11 participants (Actual)	Interventional	2021-05-20	Completed
A Phase I Placebo-Controlled, Open-Label, Crossover Study to Assess the Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra in Healthy Volunteers [NCT02270918]	Phase 1	12 participants (Actual)	Interventional	2014-11-30	Completed
Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation [NCT02007655]		6,372 participants (Actual)	Observational	2013-09-01	Completed
Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France - Cross-sectional Study [NCT02714855]		2,081 participants (Actual)	Observational	2015-10-31	Completed
Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation: Prospective Randomized Trial [NCT02633774]		200 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Real-world Comparative Effectiveness of Apixaban Versus VKA [NCT02687854]		18,591 participants (Actual)	Observational	2016-02-12	Completed
A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 Mg And 5.0 Mg BID Apixaban In Combination With Standard Therapy In Patients With Recent (≤7 Days) Acute Coronary Syndrome (ACS) [NCT00852397]	Phase 2	151 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to See termination reason in detailed description.)
The Comparative Safety of Direct Oral Anticoagulants Versus Warfarin for the Treatment of Venous Thromboembolism [NCT02833987]		59,525 participants (Actual)	Observational	2015-03-31	Completed
Oral Anticoagulant Bleeding Rate and Discontinuation and Adherence Patterns in Non-Valvular Atrial Fibrillation (NVAF) Patients [NCT02792335]		28,000 participants (Actual)	Observational	2012-01-31	Completed
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome [NCT04850378]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2021-03-25	Recruiting
A Randomized, Open-Label, Single Dose, Four Way Cross-Over Bioavailability Study Comparing Three Modified Release Formulations Of Apixaban Tablets To Apixaban Immediate Release Tablets In Healthy Volunteers [NCT00914641]	Phase 1	16 participants (Actual)	Interventional	2009-06-30	Completed
Apixaban for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension [NCT05304455]		40 participants (Actual)	Interventional	2022-04-01	Completed
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation Using Healthcare Data for Pragmatic Research: A Randomised Controlled Trial [NCT04700826]	Phase 4	3,000 participants (Anticipated)	Interventional	2021-06-01	Recruiting
Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19 [NCT04736901]		90 participants (Actual)	Observational	2020-12-01	Completed
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants [NCT02912234]	Phase 1	20 participants (Actual)	Interventional	2016-09-30	Completed
A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects [NCT02074358]	Phase 1	43 participants (Actual)	Interventional	2014-02-28	Completed
"A Pilot Study of an Oral Anticoagulant Apixaban for theTreatment of Venous Thromboembolism in Children and Adolescents" [NCT04041843]	Phase 2	25 participants (Actual)	Interventional	2017-06-02	Completed
Randomized Controlled Trial of Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism [NCT04168203]	Phase 4	600 participants (Anticipated)	Interventional	2021-03-01	Active, not recruiting
Direct Oral Anticoagulant Therapy With the HeartMate 3 LVAD: A Pilot Study [NCT04974684]		45 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Pilot Randomized Study of the Sidlenafil Efficacy in Combination With Oral Anticoagulants in the Treatment of Patients With Intermediate-high Risk of Pulmonary Embolism [NCT02946944]	Phase 1	100 participants (Anticipated)	Interventional	2016-10-31	Recruiting
Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage [NCT03153150]	Phase 3	203 participants (Actual)	Interventional	2018-03-28	Completed
Pharmacokinetics and Pharmacodynamics Assessment of Apixaban and Edoxaban in Patients With Child B Liver Cirrhosis [NCT05869591]	Phase 2	32 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Apixaban Discontinuation Prior to Major Surgery [NCT02935751]		130 participants (Anticipated)	Observational	2016-10-31	Completed
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study [NCT03456648]	Phase 2	24 participants (Actual)	Interventional	2016-09-25	Completed
A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Tr [NCT03276143]	Phase 2	813 participants (Actual)	Interventional	2017-09-21	Completed
Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System [NCT03026556]		42,534 participants (Actual)	Observational	2016-12-29	Completed
A Phase II Study to Evaluate the Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT) [NCT03594045]	Phase 2	5 participants (Actual)	Interventional	2018-12-18	Terminated(stopped due to Withdrawal of funding by sponsor)
A Phase I, Randomized, Single-Dose, Open-Label, Four-Way Crossover Study to Evaluate the Comparative Bioavailability of Apixaban for TAH3311 Oral Dissolving Film Versus ELIQUIS® Oral Tablet in Healthy Male and Female Subjects [NCT05995119]	Early Phase 1	12 participants (Actual)	Interventional	2022-12-05	Completed
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF) [NCT03996772]	Phase 3	350 participants (Anticipated)	Interventional	2019-06-03	Recruiting
Study of Apixaban Oral Solution Bioavailability When Administered Through a Nasogastric Tube in Healthy Subjects [NCT02034578]	Phase 1	75 participants (Actual)	Interventional	2011-07-31	Completed
The Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Warfarin Comparative Effectiveness Research Study [NCT03271450]		416,000 participants (Anticipated)	Observational	2017-07-01	Enrolling by invitation
DEFIANCE - ClotTriever® Thrombectomy System vs. Anticoagulation Alone for Treatment of Deep Vein Thrombosis [NCT05701917]		300 participants (Anticipated)	Interventional	2023-01-06	Recruiting
Oral Anticoagulation After Cardiac Surgery in the Era of Direct Oral Anticoagulants: is Large Use of Vitamin K Antagonists Still Justified? [NCT04002011]	Phase 2	0 participants (Actual)	Interventional	2022-03-09	Withdrawn(stopped due to Submission process abandoned. No patient enrolled.)
Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects on Hemodialysis [NCT01340586]	Phase 1	18 participants (Actual)	Interventional	2011-06-30	Completed
An Open Label, Randomized, 2-period Crossover Study Evaluating Single Dose Food Effect On Apixaban Commercial Image Tablets In Healthy Subjects [NCT01437839]	Phase 1	22 participants (Actual)	Interventional	2011-09-30	Completed
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis [NCT04981327]	Phase 3	1,300 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
Anticoagulation Strategies for the Treatment of Acute Venous Thromboembolism in Medicare Fee For-Service Patients With End-Stage Renal Disease Using USRDS Data [NCT04818151]		14,914 participants (Actual)	Observational	2021-01-01	Completed
A Multicenter, International, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel-group, 2-arm, Phase 3 Study to Compare the Efficacy and Safety of the Oral FXIa Inhibitor Asundexian (BAY 2433334) With Apixaban for the Preventio [NCT05643573]	Phase 3	14,830 participants (Actual)	Interventional	2022-12-05	Active, not recruiting
Effectiveness and Safety of Rivaroxaban Compared With Apixaban in Cancer-Associated Venous Thromboembolism: A Head-to-Head (H2H) Analysis of the United States Cohort of the Observational Study in Cancer Associated Thrombosis for Rivaroxaban (H2H-OSCAR-US) [NCT05461807]		2,437 participants (Actual)	Observational	2022-07-14	Completed
OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke: a Randomised Controlled Trial [NCT03759938]		3,478 participants (Anticipated)	Interventional	2019-06-18	Recruiting
FREEDOM COVID Anticoagulation Strategy Randomized Trial [NCT04512079]	Phase 4	3,460 participants (Actual)	Interventional	2020-09-08	Completed
COVID-19 Post-hospital Thrombosis Prevention Trial: An Adaptive, Multicenter, Prospective, Randomized Platform Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients With COVID-19 Following Hospital Discharge [NCT04650087]	Phase 3	1,219 participants (Actual)	Interventional	2021-02-15	Completed
The Effectiveness and Safety of Apixaban Versus Warfarin in Non-valvular Atrial Fibrillation (NVAF) Patients With the History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study [NCT04198844]		0 participants (Actual)	Observational	2019-11-18	Withdrawn(stopped due to Interaction term analysis result was not significant and thus comparative effectiveness for primary and secondary outcomes could not be considered per protocol.)
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms [NCT04192916]		442 participants (Actual)	Observational	2019-09-01	Completed
A Randomized Controlled Trial to Investigate Whether a Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at the Time of Device Surgery, in Patients With Moderate to High Risk of Arterial Thrombo-embolic Events, Leads to a Reduction in the [NCT01675076]	Phase 3	663 participants (Actual)	Interventional	2013-01-31	Completed
APB Study: Apixaban Pharmacokinetics in Bariatric Patients [NCT02406885]	Phase 4	33 participants (Actual)	Interventional	2017-07-19	Completed
The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design [NCT02366871]	Phase 2	400 participants (Actual)	Interventional	2015-04-28	Completed
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS) [NCT02701062]	Phase 4	562 participants (Actual)	Interventional	2016-02-29	Completed
APIXABAN DRUG UTILIZATION STUDY IN STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF) [NCT03441633]		51,690 participants (Actual)	Observational	2016-02-18	Completed
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants [NCT02754154]		321,182 participants (Actual)	Observational	2014-12-31	Completed
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study [NCT04684212]		2,931 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interaction Between Tegoprazan and Novel Oral Anticoagulants (NOACs) After Multiple Oral Dosing in Healthy Volunteers [NCT05723510]	Phase 1	87 participants (Actual)	Interventional	2023-03-06	Completed
Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) [NCT01884350]	Phase 4	1,217 participants (Actual)	Interventional	2013-10-15	Completed
Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIa Inhibitor BAY2433334 to Apixaban in Patients With Atrial Fibrillation [NCT04218266]	Phase 2	755 participants (Actual)	Interventional	2020-01-30	Completed
Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition [NCT04344717]	Phase 4	84 participants (Anticipated)	Interventional	2020-12-20	Recruiting
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension [NCT04007289]	Phase 3	166 participants (Anticipated)	Interventional	2019-06-24	Recruiting
APIDULCIS: Extended Anticoagulation With Low-dose Apixaban After a Standard Course Anticoagulation in Patients With a First Venous Thromboembolism Who Have Positive D-dimer [NCT03678506]	Phase 4	800 participants (Actual)	Interventional	2018-08-16	Terminated(stopped due to The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval [CI], 4.5-11.2))
Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder [NCT01707394]	Phase 1	49 participants (Actual)	Interventional	2013-01-10	Completed
Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients [NCT01727427]		695 participants (Actual)	Observational	2012-11-30	Completed
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy [NCT03080883]	Phase 3	370 participants (Actual)	Interventional	2017-07-14	Active, not recruiting
Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis. [NCT04462003]	Phase 3	100 participants (Anticipated)	Interventional	2019-07-03	Recruiting
Protocol CV185017: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis [NCT00252005]	Phase 2	520 participants	Interventional	2005-11-30	Completed
A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered VMX-C001 in Healthy Subjects (Part 1) and in Combination With Selected Dire [NCT05152420]	Phase 1	105 participants (Actual)	Interventional	2021-10-29	Completed
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study [NCT02559856]	Phase 4	72 participants (Actual)	Interventional	2016-05-31	Completed
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy [NCT02958969]	Phase 4	50 participants (Actual)	Interventional	2018-02-28	Completed
A Study to Assess the Absorption of Apixaban (BMS-562247) Sprinkle Capsules Compared With Tablets in Healthy Volunteers [NCT03509883]	Phase 1	94 participants (Actual)	Interventional	2018-04-26	Completed
A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma [NCT02749617]	Phase 2	2 participants (Actual)	Interventional	2016-08-09	Terminated(stopped due to Study was stopped due to lack of enrollment.)
Efficacy and Safety of Vascular Boot Warming Program After Acute DVT±PE for Earlier Resolution of Venous Thromboembolism (VTE) and Prevention of Post Thrombotic Syndrome: A Pilot Study. [NCT03465735]		15 participants (Actual)	Interventional	2017-01-13	Terminated(stopped due to Due to lack of recruitment of eligible participants)
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data [NCT05264168]		41,875 participants (Actual)	Observational	2021-05-03	Completed
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data [NCT05256797]		529,536 participants (Actual)	Observational	2021-05-03	Completed
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data [NCT04593030]		220,518 participants (Actual)	Observational	2020-09-01	Completed
Study of Bioavailability of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects [NCT02034565]	Phase 1	48 participants (Actual)	Interventional	2010-02-28	Completed
Early Post-Marketing Study of Eliquis (Apixaban), in Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE in Adults [NCT02345343]		100 participants (Anticipated)	Observational	2015-05-04	Completed
Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects [NCT02262533]	Phase 1	15 participants (Actual)	Interventional	2007-06-30	Completed
A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE) [NCT04128254]	Phase 4	1,000 participants (Anticipated)	Interventional	2020-01-31	Not yet recruiting
A Randomized Controlled Trial Comparing Apixaban Versus Enoxaparin Following Microsurgical Breast Reconstruction [NCT04504318]	Phase 1/Phase 2	106 participants (Anticipated)	Interventional	2020-08-12	Recruiting
The efficAcy and Safety of aPixaban In REal-world Practice in Korean Frail Patients With Atrial Fibrillation: a Prospective Multicenter Non-interventional, Observational Study: ASPIRE Study [NCT05773222]		2,500 participants (Anticipated)	Observational [Patient Registry]	2019-08-12	Active, not recruiting
Avoiding Anticoagulation After IntraCerebral Haemorrhage [NCT03243175]	Phase 3	300 participants (Anticipated)	Interventional	2019-01-24	Recruiting
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial [NCT03148457]		2,013 participants (Actual)	Interventional	2017-11-06	Completed
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design [NCT01924325]	Phase 2/Phase 3	10,000 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque [NCT02090075]	Phase 4	66 participants (Actual)	Interventional	2014-09-30	Completed
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants [NCT02664155]	Phase 3	203 participants (Actual)	Interventional	2016-10-19	Terminated(stopped due to recruiting difficulties)
Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation [NCT02608099]	Phase 4	300 participants (Actual)	Interventional	2015-11-30	Completed
DIrect Oral Anticoagulant for Antithrombotic Management Of mechaNical Aortic Valve Implanted Patients for Valvular Heart Disease Study [NCT05687448]	Phase 4	1,044 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
The Direct Oral Anticoagulation Versus Warfarin After Cardiac Surgery Trial [NCT04284839]	Phase 3	6,215 participants (Anticipated)	Interventional	2021-07-18	Recruiting
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices [NCT04865978]	Phase 2	30 participants (Actual)	Interventional	2021-12-14	Completed
A Pilot Trial of Restarting Direct Oral Anticoagulants After Traumatic Intracranial Hemorrhage [NCT04891861]	Phase 3	100 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Hydroxychloroquine and Apixaban: Analysis of Physiological Parameters for the Prevention of Complications in Patients With Infection With the New Coronavirus (Covid-19). A Randomized Clinical Trial [NCT04788355]	Phase 3	176 participants (Actual)	Interventional	2020-07-01	Completed
A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism [NCT02585713]	Phase 3	300 participants (Actual)	Interventional	2015-11-20	Completed
Monotherapy Anticoagulation To Expedite Home Treatment of Venous [NCT03404635]		1,300 participants (Actual)	Observational	2017-08-04	Completed
A Pilot Study in Cancer Patients With Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in the Upper Extremity Treated With Low Molecular Weight Heparin (LMWH) and Apixaban (Catheter 3) [NCT03100071]		70 participants (Anticipated)	Observational	2017-05-15	Recruiting
VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe) [NCT04618913]		1 participants (Anticipated)	Observational	2020-12-14	Active, not recruiting
Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial [NCT04746339]	Phase 4	411 participants (Actual)	Interventional	2021-03-04	Terminated(stopped due to Due to the decrease in COVID cases and in the recruitment rate, and DSMB orientation.)
A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion [NCT02100228]	Phase 4	1,500 participants (Actual)	Interventional	2014-07-14	Completed
Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis [NCT01999179]		27 participants (Actual)	Interventional	2014-06-30	Completed
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring [NCT01706146]	Phase 4	59 participants (Actual)	Interventional	2012-10-31	Completed
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation [NCT02283294]	Phase 3	91 participants (Actual)	Interventional	2015-04-30	Completed
Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the St [NCT03254147]		53,969 participants (Actual)	Observational	2017-10-15	Completed
Prospective, Observational, Non-interventional Open-label Multicenter Registry Regarding the Incidence of Heavy Menstrual Bleeding in Women of Reproductive Age Treated With Direct Oral Anticoagulants Because of Venous Thromboembolism [NCT04477837]		150 participants (Anticipated)	Observational [Patient Registry]	2020-10-15	Recruiting
A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT [NCT02464969]	Phase 4	250 participants (Anticipated)	Interventional	2015-11-22	Recruiting
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data [NCT04736719]		19,002 participants (Actual)	Observational	2020-09-22	Completed
THE REAL WORLD EVIDENCE ON TREATMENT PATTERNS, EFFECTIVENESS, AND SAFETY OF DRUGS FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN KOREA [NCT03572972]		64,684 participants (Actual)	Observational	2018-01-31	Completed
Stroke/Systemic Embolism and Major Bleeding in Patients Newly Treated With Oral Anticoagulants: a Real World Study From Portuguese Administrative Claims Data [NCT04808934]		0 participants (Actual)	Observational	2020-06-01	Withdrawn(stopped due to Withdrawn due to COVID19 pandemic. Several delays affected this study, therefore company decided to not conduct the study. It was cancelled prior to any enrollment.)
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancrea [NCT03139487]	Phase 2	176 participants (Anticipated)	Interventional	2017-08-07	Recruiting
Safety and Effectiveness of Rivaroxaban and Apixaban Compared to Warfarin in Non-valvular Atrial Fibrillation Patients in the Routine Clinical Practice in the UK [NCT03847181]		45,164 participants (Actual)	Observational	2019-02-28	Completed
PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli [NCT02378623]	Phase 2	0 participants (Actual)	Interventional	2015-05-31	Withdrawn(stopped due to Sponsor withdrew funding - May 2016)
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation [NCT05035277]	Phase 3	360 participants (Anticipated)	Interventional	2021-12-04	Recruiting
Prostate Cancer VTE in Sweden: Epidemiology and Anticoagulation Treatment of VTE [NCT03965741]		97,765 participants (Actual)	Observational	2019-05-30	Completed
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis (SAFE-D) [NCT03987711]	Phase 2	151 participants (Actual)	Interventional	2019-12-10	Completed
Validation Study Protocol - Additional Study on Fresh Samples STA - Apixaban Calibrator & STA - Apixaban Control [NCT03073265]		109 participants (Actual)	Observational	2017-05-08	Completed
Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial) [NCT02427126]	Phase 3	352 participants (Actual)	Interventional	2015-12-31	Completed
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke [NCT03192215]	Phase 3	1,015 participants (Actual)	Interventional	2018-01-19	Terminated(stopped due to The DSMB halted the trial prematurely due to futility without any safety concerns.)
An Exploratory Study of the Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy [NCT04191928]	Phase 1	4 participants (Actual)	Interventional	2020-03-03	Completed
Pharmacokinetics of Apixaban and Tacrolimus or Cyclosporine in Kidney and Lung Transplant Recipients [NCT04023760]	Phase 4	14 participants (Actual)	Interventional	2019-06-26	Completed
A Phase I, Open-Label, Crossover, Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus in Healthy Volunteers [NCT03083782]	Phase 1	12 participants (Actual)	Interventional	2017-04-18	Completed
A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery [NCT01884337]	Phase 4	557 participants (Actual)	Interventional	2015-03-24	Completed
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation [NCT01938248]	Phase 4	4,012 participants (Actual)	Interventional	2015-05-31	Completed
[NCT05187286]		0 participants	Expanded Access		Available
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury [NCT05484557]		60 participants (Anticipated)	Interventional	2023-09-06	Recruiting
A Randomized Controlled Trial on the Use of Postoperative Extended Venous Thromboprophylaxis in Patients With Inflammatory Bowel Disease: A Pilot Study [NCT03935451]	Early Phase 1	60 participants (Anticipated)	Interventional	2021-09-01	Recruiting
Active-control, Multicenter, Randomized, Open-label, Safety And Efficacy Study Evaluating The Use Of Apixaban In The Treatment Of Symptomatic Deep Vein Thrombosis And Pulmonary Embolism In Japanese [NCT01780987]	Phase 3	80 participants (Actual)	Interventional	2013-01-31	Completed
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty [NCT04878497]		1,000,000 participants (Anticipated)	Observational	2021-03-30	Active, not recruiting
COVID-19 Outpatient Thrombosis Prevention Trial A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID Adults Not Requiring Hospitalization at Time of Diagnosis [NCT04498273]	Phase 3	657 participants (Actual)	Interventional	2020-09-07	Terminated(stopped due to an event rate lower than anticipated)
A Randomized Trial of the Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery: a Pilot Study [NCT05006287]	Phase 2	100 participants (Anticipated)	Interventional	2021-10-01	Not yet recruiting
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents (ADAPT AF-DES) [NCT04250116]	Phase 4	960 participants (Anticipated)	Interventional	2020-04-28	Recruiting
Real-world Evidence for Non-valvular Atrial Fibrillation Patients Treated With Oral Anticoagulation in the Nordics [NCT04249401]		134,897 participants (Actual)	Observational	2020-03-01	Completed
Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis [NCT03692065]	Phase 3	1,767 participants (Actual)	Interventional	2018-10-11	Active, not recruiting
A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment [NCT02933697]	Phase 3	108 participants (Actual)	Interventional	2017-06-20	Completed
International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism [NCT03778502]		300 participants (Anticipated)	Observational [Patient Registry]	2019-10-01	Recruiting
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With NVAF With a History of Stroke or Transient Ischemic Attack - a Nationwide Retrospective Observational Study Using Claims Data in Japan [NCT05321810]		10,000 participants (Actual)	Observational	2022-04-15	Completed
Relative Bioavailability of Crushed Apixaban Tablets Administered With Water or Apple Sauce Compared With Intact Tablet in Healthy Subjects [NCT02101112]	Phase 1	69 participants (Actual)	Interventional	2014-03-31	Completed
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access [NCT04489849]	Phase 4	150 participants (Anticipated)	Interventional	2020-03-14	Recruiting
Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus [NCT03232398]	Phase 3	40 participants (Actual)	Interventional	2018-01-01	Completed
Evaluate the Safety of Apixaban in Patients Who Undergo Cardiovascular Implantable Electronic Device (CIED) Procedure: A Randomized Pilot Study [NCT02450682]	Phase 2	0 participants (Actual)	Interventional	2016-02-29	Withdrawn
Bioavailability of Apixaban Oral Solution Administered Through a Nasogastric Tube in the Presence of Boost® Plus and Apixaban Administered as Crushed Tablet Through a Nasogastric Tube Relative to Apixaban Oral Solution in Healthy Subjects [NCT02034591]	Phase 1	37 participants (Actual)	Interventional	2011-10-31	Completed
Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease [NCT02179177]	Phase 3	16 participants (Actual)	Interventional	2015-01-31	Terminated(stopped due to funding has been exhausted)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00313300 (10) [back to overview]	Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses
NCT00313300 (10) [back to overview]	Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B
NCT00313300 (10) [back to overview]	Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses
NCT00313300 (10) [back to overview]	Number of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B
NCT00313300 (10) [back to overview]	Event Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B
NCT00313300 (10) [back to overview]	Event Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses
NCT00313300 (10) [back to overview]	Number of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants
NCT00313300 (10) [back to overview]	Number of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B
NCT00313300 (10) [back to overview]	Number of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants
NCT00313300 (10) [back to overview]	Event Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B
NCT00320255 (12) [back to overview]	Number of Participants With All-Cause Death
NCT00320255 (12) [back to overview]	Number of Participants With Composite of Confirmed Major Bleeding and Clinically Relevant Nonmajor (CRNM) Bleeding
NCT00320255 (12) [back to overview]	Number of Participants With Composite of Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and Venous Thromboembolism (VTE)-Related Death
NCT00320255 (12) [back to overview]	Number of Participants With Composite of Venous Thromboembolism (VTE) and All-cause Death
NCT00320255 (12) [back to overview]	Number of Participants With Composite of Venous Thromboembolism (VTE) and VTE-related Death
NCT00320255 (12) [back to overview]	Number of Participants With Deep Vein Thrombosis
NCT00320255 (12) [back to overview]	Number of Participants With Distal Deep Vein Thrombosis
NCT00320255 (12) [back to overview]	Number of Participants With Nonfatal Pulmonary Embolism
NCT00320255 (12) [back to overview]	Number of Participants With Proximal Deep Vein Thrombosis
NCT00320255 (12) [back to overview]	Number of Participants With Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and All-cause Death
NCT00320255 (12) [back to overview]	Number of Participants With Pulmonary Embolism (Fatal or Nonfatal)
NCT00320255 (12) [back to overview]	Number of Participants Who Died and With Adverse Events (AEs), Serious Adverse Events (SAEs), Bleeding AEs, and Discontinuations Due to AEs
NCT00371683 (24) [back to overview]	Event Rate for Total Participants With Adjudicated VTE/All-Cause Death With Onset During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate of Adjudicated MI, Stroke, and Thrombocytopenia Events During the Follow-Up Period
NCT00371683 (24) [back to overview]	Mean Change From Baseline in Heart Rate During the Treatment Period
NCT00371683 (24) [back to overview]	Mean Change From Baseline in Systolic and Diastolic Blood Pressure During the Treatment Period
NCT00371683 (24) [back to overview]	Number of Participants With Electrolyte Chemistry Laboratory Marked Abnormalities During the Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Total Participants With VTE/ VTE-Related Death With Onset During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Number of Participants With Hematology Laboratory Marked Abnormality During the Treatment Period
NCT00371683 (24) [back to overview]	Event Rate of Adjudicated VTE / VTE-related Death With Onset During the Treatment Period
NCT00371683 (24) [back to overview]	Event Rate of Composite of Adjudicated Proximal DVT, Non-Fatal PE and All-Cause Death With Onset During the Intended Treatment Period PE and All-cause Death During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With Adjudicated Myocardial Infarction (MI) Acute Ischemic Stroke and Thromboembolic Events With Onset During the Treatment Period
NCT00371683 (24) [back to overview]	Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects
NCT00371683 (24) [back to overview]	Number of Participants With Liver and Kidney Function Chemistry Laboratory Marked Abnormalities During the Treatment Period
NCT00371683 (24) [back to overview]	Number of Participants With Other Chemistry Laboratory Marked Abnormalities During the Treatment Period
NCT00371683 (24) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), AEs Leading to Discontinuation, and Deaths - Treated Population
NCT00371683 (24) [back to overview]	Event Rate for Participants With Major Bleeding, Clinically Relevant (CR) Non-Major (N-M) Bleeding , Major or Clinically Relevant (CR) Non-Major (N-M) Bleeding, Any Bleeding With Onset During the Follow-Up Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With Major Bleeding, Clinically Relevant Non-Major Bleeding, Major or Clinically Relevant Non-Major Bleeding, Any Bleeding With Onset During the Treatment Period - Treated Population
NCT00371683 (24) [back to overview]	Event Rate for Participants With PE (Fatal or Non-Fatal), DVT (All, Symptomatic Proximal, and Distal, Asymptomatic) With Onset During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With Proximal DVT, Distal DVT, Asymptomatic Proximal DVT, Asymptomatic Distal DVT With Onset During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With All-Cause Death During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With Proximal DVT/Non-Fatal PE/ VTE-Related Death With Onset During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With Symptomatic VTE/ All-Cause Death With Onset During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With Symptomatic VTE/ VTE-Related Death With Onset During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With VTE-Related Death With Onset During the Intended Treatment Period
NCT00371683 (24) [back to overview]	Event Rate for Participants With VTE/Major Bleeding/All-Cause Death With Onset During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period
NCT00412984 (19) [back to overview]	Number of Participants With Events of All-Cause Death During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period
NCT00412984 (19) [back to overview]	Number of Participants With Net-Clinical Benefit During Treatment Period
NCT00412984 (19) [back to overview]	Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Rate of Adjudicated All-Cause Death During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period
NCT00412984 (19) [back to overview]	Rate of All Bleeding Events During Treatment Period
NCT00412984 (19) [back to overview]	Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period
NCT00412984 (19) [back to overview]	Rate of Net-Clinical Benefit During Treatment Period
NCT00412984 (19) [back to overview]	Number of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period
NCT00412984 (19) [back to overview]	Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period
NCT00412984 (19) [back to overview]	Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period
NCT00412984 (19) [back to overview]	Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period
NCT00412984 (19) [back to overview]	Number of Participants With All Bleeding Events During Treatment Period
NCT00423319 (14) [back to overview]	Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period
NCT00423319 (14) [back to overview]	Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)
NCT00423319 (14) [back to overview]	Number of Participants With a Bleeding-related Adverse Event During the Treatment Period
NCT00423319 (14) [back to overview]	Number of Participants With a Bleeding-related Adverse Event During the Treatment Period (Continued)
NCT00423319 (14) [back to overview]	Number of Participants With a Bleeding-related Adverse Events During the Treatment Period (Continued)
NCT00423319 (14) [back to overview]	Number of Participants With Adverse Events Related to Elevations in Liver Function Test Results With Onset During the Treatment Period
NCT00423319 (14) [back to overview]	Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period
NCT00423319 (14) [back to overview]	Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)
NCT00423319 (14) [back to overview]	Number of Participants With Neurologic Adverse Events With Onset During the Treatment Period
NCT00423319 (14) [back to overview]	Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), Major or CRNM, and Any Bleeding During the Treatment Period
NCT00423319 (14) [back to overview]	Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period
NCT00423319 (14) [back to overview]	Rates of Adjudicated Myocardial Infarction (MI)/Stroke, MI, Stroke, and Thrombocytopenia During the Intended Treatment Period
NCT00423319 (14) [back to overview]	Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period
NCT00423319 (14) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), and Death as Outcome
NCT00452530 (7) [back to overview]	Summary of Laboratory Marked Abnormalities on Hematology and Liver and Kidney Function Test Results During the Treatment Period (Patients With Available Measurements)
NCT00452530 (7) [back to overview]	Summary of Laboratory Marked Abnormalities in Urinalysis Results During the Treatment Period-Treated Subjects With Available Measurements (Urinalysis)
NCT00452530 (7) [back to overview]	Summary of Laboratory Marked Abnormalities in Electrolyte and Other Clinical Test Results During the Treatment Period (Patients With Available Measurements)
NCT00452530 (7) [back to overview]	Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome
NCT00452530 (7) [back to overview]	Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period
NCT00452530 (7) [back to overview]	Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period
NCT00452530 (7) [back to overview]	Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM
NCT00457002 (32) [back to overview]	Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population
NCT00457002 (32) [back to overview]	Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Incidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of All Bleeding During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Incidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated PE With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Number of Participants With Marked Abnormalities in Glucose, Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants
NCT00457002 (32) [back to overview]	Symptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period
NCT00457002 (32) [back to overview]	Incidence of Major Bleeding During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Mean Change From Baseline in Heart Rate in Treated Participants
NCT00457002 (32) [back to overview]	Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Deaths, and Discontinuations Due to AEs During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Number of Participants With Events of Special Interest for Liver Function and Neurology During Treatment Period in Treated Participants With Available Measurements
NCT00457002 (32) [back to overview]	Number of Participants With Liver-Related Elevations During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Number of Participants With Marked Abnormalities in Electrolyte Laboratory Tests During Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Incidence of Events of Special Interest of Adjudicated Myocardial Infarction, Stroke, and Thrombocytopenia During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Mean Change From Baseline in Diastolic Blood Pressure in Treated Participants During Treatment Period
NCT00457002 (32) [back to overview]	Number of Participants With Marked Abnormalities in Hematology Laboratory Tests During Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Number of Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests During the Treatment Period in Treated Participants
NCT00457002 (32) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure in Treated Participants During Treatment Period
NCT00496769 (9) [back to overview]	Event Rates for Major Bleeding, Major or Clinically Relevant Nonmajor (CNRM) Bleeding, and All Bleeding in the Double-blind Period
NCT00496769 (9) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs), Bleeding AEs, Discontinuations Due to AEs, and Death as Outcome
NCT00496769 (9) [back to overview]	Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality (Continued)
NCT00496769 (9) [back to overview]	Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality (Continued)
NCT00496769 (9) [back to overview]	Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality
NCT00496769 (9) [back to overview]	Event Rate of All-cause Death; Net Clinical Benefit-Composite of Stroke, Systemic Embolism, Myocardial Infarction, Vascular Death, and Major Bleeding; and Vascular Death
NCT00496769 (9) [back to overview]	Rate of Unrefuted Bleeding From First Dose of Double-blind Study Drug to First Occurence of Unrefuted Bleeding During the Double-blind Treatment Period
NCT00496769 (9) [back to overview]	Event Rate of Stroke/Systemic Embolism During the Intended-treatment Period
NCT00496769 (9) [back to overview]	Event Rate for the Composite of Stroke of Any Type, Systemic Embolism, Myocardial Infarction, or Vascular Death During the Double-blind Treatment Period
NCT00633893 (22) [back to overview]	Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation
NCT00633893 (22) [back to overview]	Adjudicated Total Bleeding During the Treatment Period - Treated Participants
NCT00633893 (22) [back to overview]	Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation
NCT00633893 (22) [back to overview]	Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation
NCT00633893 (22) [back to overview]	Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
NCT00633893 (22) [back to overview]	Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
NCT00633893 (22) [back to overview]	Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation
NCT00633893 (22) [back to overview]	Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation
NCT00633893 (22) [back to overview]	Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants
NCT00633893 (22) [back to overview]	Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants
NCT00633893 (22) [back to overview]	Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants
NCT00633893 (22) [back to overview]	Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation
NCT00633893 (22) [back to overview]	Adjudicated Major Bleeding During the Treatment Period - Treated Population
NCT00633893 (22) [back to overview]	Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation
NCT00633893 (22) [back to overview]	Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation
NCT00633893 (22) [back to overview]	Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation
NCT00633893 (22) [back to overview]	Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
NCT00633893 (22) [back to overview]	Number of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation
NCT00633893 (22) [back to overview]	Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation
NCT00633893 (22) [back to overview]	Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation
NCT00633893 (22) [back to overview]	Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation
NCT00633893 (22) [back to overview]	Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period
NCT00643201 (21) [back to overview]	Incidence of All-Cause Death During the Intended Treatment Period
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants
NCT00643201 (21) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants
NCT00643201 (21) [back to overview]	Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding
NCT00643201 (21) [back to overview]	Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests
NCT00643201 (21) [back to overview]	Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests
NCT00643201 (21) [back to overview]	Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests
NCT00643201 (21) [back to overview]	Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests
NCT00643201 (21) [back to overview]	Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period
NCT00643201 (21) [back to overview]	Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period
NCT00787150 (14) [back to overview]	Mean Prothrombin Time-International Normalized Ratio (PT-INR) at Each Time Point in Participants Treated With Apixaban
NCT00787150 (14) [back to overview]	Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) Bleeding Events During the Treatment Period
NCT00787150 (14) [back to overview]	Number of Participants With Clinically Relevant Non-major Bleeding Events During the Treatment Period
NCT00787150 (14) [back to overview]	Mean Prothrombin Fragment 1+2 (F1+2) at Each Time Point in Participants Treated With Warfarin or Apixaban
NCT00787150 (14) [back to overview]	Number of Participants With Total Bleeding Events During the Treatment Period
NCT00787150 (14) [back to overview]	Mean Plasma Apixaban Concentration at Each Time Point in Participants Treated With Apixaban
NCT00787150 (14) [back to overview]	Number of Participants With Stroke, Systemic Embolism, or All-Cause Death During the Intended Treatment Period
NCT00787150 (14) [back to overview]	Mean D-Dimer at Each Time Point in Participants Treated With Warfarin or Apixaban
NCT00787150 (14) [back to overview]	Mean Anti-Xa Activity (Apixaban Units) at Each Time Point in Participants Treated With Apixaban
NCT00787150 (14) [back to overview]	Mean Activated Partial Thromboplastin Time (aPTT) at Each Time Point in Participants Treated With Apixaban
NCT00787150 (14) [back to overview]	Number of Participants With Stroke or Systemic Embolism During the Intended Treatment Period
NCT00787150 (14) [back to overview]	Number of Participants With Myocardial Infarction or All-Cause Death During the Intended Treatment Period
NCT00787150 (14) [back to overview]	Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) or Clinically Relevant Non-major Bleeding Adjudicated by Clinical Event Committee During the Treatment Period
NCT00787150 (14) [back to overview]	Mean Prothrombin Time (PT) at Each Time Point in Participants Treated With Apixaban
NCT00831441 (12) [back to overview]	Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants
NCT00831441 (12) [back to overview]	Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants
NCT00831441 (12) [back to overview]	Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants
NCT00831441 (12) [back to overview]	Event Rate of Stroke During the Intended Treatment Period - Randomized Participants
NCT00831441 (12) [back to overview]	Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants
NCT00831441 (12) [back to overview]	Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants
NCT00831441 (12) [back to overview]	Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants
NCT00831441 (12) [back to overview]	Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants
NCT00831441 (12) [back to overview]	Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants
NCT00831441 (12) [back to overview]	Event Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants
NCT00831441 (12) [back to overview]	Event Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants
NCT00831441 (12) [back to overview]	Event Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants
NCT00852397 (8) [back to overview]	Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI)-Defined Major Bleeding Occurring During the Treatment Period.
NCT00852397 (8) [back to overview]	Percentage of Participants Who Had International Society on Thrombosis and Haemostasis (ISTH)-Defined Individual Bleeding Endpoints (Clinically-relevant Non-major [CRNM] or Minor Bleeding) During the Treatment Period.
NCT00852397 (8) [back to overview]	Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction, Unstable Angina and Stroke During 30 Days After Discontinuation of Therapy.
NCT00852397 (8) [back to overview]	Percentage of Participants Who Had Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major and Clinically-relevant Non-major (CRNM) Bleeding Events Occurring During the Treatment Period.
NCT00852397 (8) [back to overview]	Percentage of Participants Who Had Major Bleeding Occurring During the Treatment Period Per International Society on Thrombosis and Haemostasis (ISTH) Definitions.
NCT00852397 (8) [back to overview]	Percentage of Participants Who Had One or More All Bleeding Occurring During the Treatment Period.
NCT00852397 (8) [back to overview]	Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI) Defined-individual Bleeding Endpoints (Minor or Minimal Bleeding) During the Treatment Period.
NCT00852397 (8) [back to overview]	Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction (MI), Unstable Angina, and Non-hemorrhagic Stroke Occurring During the Intended Treatment Period.
NCT01340586 (26) [back to overview]	Mean Renal Clearance (CLR) of BMS-730823
NCT01340586 (26) [back to overview]	Mean Plasma Terminal Half-life (T-Half) of BMS-730823
NCT01340586 (26) [back to overview]	Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823
NCT01340586 (26) [back to overview]	Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban
NCT01340586 (26) [back to overview]	Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823
NCT01340586 (26) [back to overview]	Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban
NCT01340586 (26) [back to overview]	Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban
NCT01340586 (26) [back to overview]	Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823
NCT01340586 (26) [back to overview]	Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823
NCT01340586 (26) [back to overview]	Percentage of Apixaban Extracted During Hemodialysis
NCT01340586 (26) [back to overview]	Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban
NCT01340586 (26) [back to overview]	Percentage of BMS-730823 Extracted During Hemodialysis
NCT01340586 (26) [back to overview]	Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for Apixaban
NCT01340586 (26) [back to overview]	Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for BMS-730823
NCT01340586 (26) [back to overview]	Mean Hemodialysis Clearance (CLD) of Apixaban
NCT01340586 (26) [back to overview]	Number of Participants Who Died or Experienced Serious Adverse Events (SAEs) or Adverse Events Leading to Discontinuation
NCT01340586 (26) [back to overview]	Number of Participants With Laboratory Marked Abnormalities
NCT01340586 (26) [back to overview]	Mean Hemodialysis Clearance (CLD) of BMS-730823
NCT01340586 (26) [back to overview]	Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban
NCT01340586 (26) [back to overview]	Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban
NCT01340586 (26) [back to overview]	Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban
NCT01340586 (26) [back to overview]	Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban
NCT01340586 (26) [back to overview]	Mean Percent Dose of Apixaban Recovered in Dialysate (%DR)
NCT01340586 (26) [back to overview]	Mean Percent Dose of Apixaban Recovered in Urine (%UR)
NCT01340586 (26) [back to overview]	Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban
NCT01340586 (26) [back to overview]	Mean Renal Clearance (CLR) of Apixaban
NCT01706146 (2) [back to overview]	Bleeding Incidence
NCT01706146 (2) [back to overview]	Number of Days on Anticoagulation
NCT01758432 (9) [back to overview]	Efficacy: Percent Change From Baseline in Unbound Apixaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration
NCT01758432 (9) [back to overview]	Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )
NCT01758432 (9) [back to overview]	Andexanet Apparent Terminal Elimination Half-life (t1/2)
NCT01758432 (9) [back to overview]	Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration
NCT01758432 (9) [back to overview]	Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration
NCT01758432 (9) [back to overview]	Andexanet Time of Maximum Observed Plasma Concentration (Tmax)
NCT01758432 (9) [back to overview]	Andexanet Maximum Observed Plasma Concentration (Cmax)
NCT01758432 (9) [back to overview]	Andexanet Total Systemic Clearance (CL)
NCT01758432 (9) [back to overview]	Andexanet Total Volume of Distribution (Vss)
NCT01780987 (6) [back to overview]	Number of Participants With Adjudicated All Bleeding Events During the Treatment Periods
NCT01780987 (6) [back to overview]	Number of Participants With Adjudicated Recurrent Symptomatic Venous Thromboembolism (VTE) ［Nonfatal Deep Venous Thrombosis (DVT) or Nonfatal Pulmonary Embolism (PE)］ or VTE-Related Death During the Intended Treatment Period
NCT01780987 (6) [back to overview]	Number of Participants With Adjudicated Major Bleeding Events ［Per International Society on Thrombosis and Homeostasis (ISTH) Definition］During the Treatment Period
NCT01780987 (6) [back to overview]	Number of Participants With Major Bleeding Events ［Per International Society on Thrombosis and Homeostasis (ISTH) Definition］ or Clinically Relevant Non-major (CRNM) Bleeding Events Adjudicated by Clinical Event Committee During the Treatment Period
NCT01780987 (6) [back to overview]	Number of Participants With Adjudicated Thrombotic Burden Worsened in Acute Symptomatic Proximal Deep Venous Thrombosis (DVT)
NCT01780987 (6) [back to overview]	Number of Participants With Adjudicated Thrombotic Burden Worsened in Acute Symptomatic Pulmonary Embolism (PE)
NCT01884337 (2) [back to overview]	Number of Participants With Composite of Venous Thromboembolism (VTE)/All Cause Death at the End of Treatment + 2 Days
NCT01884337 (2) [back to overview]	Number of Participants With Composite of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding/Clinically Relevant Non-major Bleeding (CRNM) While Undergoing Elective TKR or THR at the End of Treatment + 2 Days
NCT01884350 (6) [back to overview]	Non-adherence Predictors of 20% or More (vs. at Least 80% Adherence) at 24 Weeks
NCT01884350 (6) [back to overview]	Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen
NCT01884350 (6) [back to overview]	Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period
NCT01884350 (6) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death
NCT01884350 (6) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death
NCT01884350 (6) [back to overview]	Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 12 to 24 Weeks Period Compared With During the First 12 Weeks
NCT01999179 (5) [back to overview]	PTS Assessment Completion
NCT01999179 (5) [back to overview]	Number of Participants With Post-thrombotic Syndrome
NCT01999179 (5) [back to overview]	Number of Participants With Recurrent Thrombosis
NCT01999179 (5) [back to overview]	Biomarker Sample Collection
NCT01999179 (5) [back to overview]	Number of Participants With Major Bleeding
NCT02034565 (5) [back to overview]	Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
NCT02034565 (5) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Treatment-Related Adverse Events (AEs), Deaths or Discontinuation of Study Drug Due to AEs
NCT02034565 (5) [back to overview]	Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban
NCT02034565 (5) [back to overview]	Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban
NCT02034565 (5) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT02034578 (8) [back to overview]	Number of Participants With Clinically Significant Electrocardiogram, Vital Sign, or Physical Examination Findings
NCT02034578 (8) [back to overview]	Number of Participants With Marked Abnormality in Hematology, Chemistry and Urinalysis Laboratory Tests
NCT02034578 (8) [back to overview]	Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration, AUC(0-T), of Apixaban
NCT02034578 (8) [back to overview]	Adjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban
NCT02034578 (8) [back to overview]	Mean Plasma Elimination Half-Life (T-HALF) of Apixaban
NCT02034578 (8) [back to overview]	Median Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban
NCT02034578 (8) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Death
NCT02034578 (8) [back to overview]	Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time, AUC(INF), of Apixaban
NCT02034591 (6) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths or Discontinuation of Study Drug Due to AEs
NCT02034591 (6) [back to overview]	Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban
NCT02034591 (6) [back to overview]	Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban
NCT02034591 (6) [back to overview]	Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
NCT02034591 (6) [back to overview]	Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban
NCT02034591 (6) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT02074358 (28) [back to overview]	Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuation Due to AEs - Treatment Population
NCT02074358 (28) [back to overview]	Number of Participants With Marked Abnormalities (MA) in Laboratory Tests - Treated Population
NCT02074358 (28) [back to overview]	Number of Participants With Out of Range Electrocardiogram (ECG) Intervals and Number of Participants With a Change From Baseline of Greater Than 30 Milliseconds in QT and QTcF
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in Coagulation Parameter INR From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in Coagulation Parameter International Normalized Ratio (INR) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in Coagulation Parameters Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in Coagulation Parameters PT and aPTT From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in TGA Lag Time and TGA Time to Peak From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	Mean Change From Baseline Temperature on Day 4 and Day 7
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in Endogenous Thrombin Potential (ETP) From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	Adjusted Geometric Mean AUC (0-12) of Apixaban on Day 4
NCT02074358 (28) [back to overview]	Adjusted Geometric Mean AUC (0-24) for Apixaban on Day 4
NCT02074358 (28) [back to overview]	Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours After Dose Administration [AUC(0-24)] of Apixaban on Day 4
NCT02074358 (28) [back to overview]	Geometric Mean Area Under the Plasma Concentration-Time Curve in One Dosing Interval [AUC(0-12)] of Apixaban on Day 4
NCT02074358 (28) [back to overview]	Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban on Day 4
NCT02074358 (28) [back to overview]	Geometric Mean Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban on Day 4
NCT02074358 (28) [back to overview]	Geometric Mean Trough Observed Plasma Concentration at the End of One Dosing Interval (12h) [Cmin] of Apixaban on Day 4
NCT02074358 (28) [back to overview]	Mean Terminal Elimination Half-Life (T-HALF) of Apixaban on Day 4
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in Plasma Anti-Xa Activity From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in TGA Peak Height From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in TGA Peak Height From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in TGA Velocity Index From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameters: Adjusted Mean Change in TGA Lag Time and Adjusted Mean Change in TGA Time to Peak From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	PD Parameter: Adjusted Mean Change in TGA Velocity Index From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	Pharmacodynamic (PD) Parameter: Adjusted Mean Change in Endogenous Thrombin Potential (ETP) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo
NCT02074358 (28) [back to overview]	Mean Change From Baseline in Diastolic and Systolic Blood Pressure on Day 4 and Day 7
NCT02074358 (28) [back to overview]	Mean Change From Baseline in Heart Rate on Day 4 and Day 7
NCT02074358 (28) [back to overview]	Mean Change From Baseline in Respiration Rate on Day 4 and Day 7
NCT02090075 (2) [back to overview]	Coronary Plaque on CT Angiography
NCT02090075 (2) [back to overview]	Coronary Artery Calcium (CAC) Score
NCT02100228 (11) [back to overview]	Duration of Hospital Stay of Participants
NCT02100228 (11) [back to overview]	Number of Participants Who Used Image Guidance Approach
NCT02100228 (11) [back to overview]	Number of Participants With Acute Stroke Event
NCT02100228 (11) [back to overview]	Number of Participants With All Cause Death
NCT02100228 (11) [back to overview]	Number of Participants With Clinically Relevant Non-Major Bleeding Events
NCT02100228 (11) [back to overview]	Number of Participants With Major Bleeding Event
NCT02100228 (11) [back to overview]	Number of Participants With Systemic Embolism Event
NCT02100228 (11) [back to overview]	Time to First Attempt of Cardioversion
NCT02100228 (11) [back to overview]	Number of Cardioversion Attempt of Participants
NCT02100228 (11) [back to overview]	Number of Participants With Their Rhythm Status
NCT02100228 (11) [back to overview]	Number of Participants With Different Type of Cardioversion Events
NCT02101112 (7) [back to overview]	Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban
NCT02101112 (7) [back to overview]	Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
NCT02101112 (7) [back to overview]	Relative Bioavailability (Frel) of Apixaban
NCT02101112 (7) [back to overview]	Terminal Plasma Half-life (T-HALF) of Apixaban
NCT02101112 (7) [back to overview]	Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban
NCT02101112 (7) [back to overview]	Number of Participants With Serious Adverse Events, Death, or Discontinuation Due to Adverse Events by Study Completion
NCT02101112 (7) [back to overview]	Adjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban
NCT02179177 (3) [back to overview]	Number of Hospitalizations During Treatment
NCT02179177 (3) [back to overview]	Change in Pain as Measured by Visual Analog Scale (VAS)
NCT02179177 (3) [back to overview]	Daily Pain Scores While Hospitalized as Measured by VAS
NCT02283294 (2) [back to overview]	Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA
NCT02283294 (2) [back to overview]	Number of Participants With an Intracranial Hemorrhage Assessed by MRI/CT
NCT02366871 (6) [back to overview]	Number of Participants With Incidence of Clinically Relevant Non Major Bleeding Events
NCT02366871 (6) [back to overview]	Number of Participants With Incidence of Major Bleeding
NCT02366871 (6) [back to overview]	Change in Quality of Life From Baseline to 28 Days Post-op
NCT02366871 (6) [back to overview]	Number of Participants With a Patient Satisfaction Assessment
NCT02366871 (6) [back to overview]	Number of Participants With Incidence of Venous Thromboembolism (VTEs): Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
NCT02366871 (6) [back to overview]	Number of Participants Who Met Medication Adherence Rates
NCT02369653 (22) [back to overview]	The Number of Participants With Non-fatal Pulmonary Embolism (PE)
NCT02369653 (22) [back to overview]	The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death
NCT02369653 (22) [back to overview]	The Number of Participants With Non-fatal Asymptomatic Deep Vein Thromboses (DVT)
NCT02369653 (22) [back to overview]	The Number of Participants With Minor Bleeding Events
NCT02369653 (22) [back to overview]	The Number of Participants With Major and Clinically Relevant Non-Major Bleeding (CRNMB)
NCT02369653 (22) [back to overview]	The Number of Participants With CVAD Patency Restoration Events After Thrombolytic Therapy Use
NCT02369653 (22) [back to overview]	The Number of Participants With Clinically Relevant Non-Major Bleeding Events (CRNMB)
NCT02369653 (22) [back to overview]	The Number of Participants With Cerebral Venous Sinus Thrombosis (CVST)
NCT02369653 (22) [back to overview]	The Number of Participants With an Arterial Thromboembolic Event
NCT02369653 (22) [back to overview]	The Number of Participants With a CVAD-Related Infection
NCT02369653 (22) [back to overview]	The Number of Participants Needing Catheter Replacements During the Study
NCT02369653 (22) [back to overview]	The Number of Participant Deaths
NCT02369653 (22) [back to overview]	Maximum Observed Concentration (Cmax)
NCT02369653 (22) [back to overview]	The Number of Participants With Adjudicated Major Bleeding
NCT02369653 (22) [back to overview]	Area Under the Concentration-Time Curve [AUC(TAU)]
NCT02369653 (22) [back to overview]	Anti-FXa Activity
NCT02369653 (22) [back to overview]	Anti-FXa Activity
NCT02369653 (22) [back to overview]	Trough Observed Concentration (Cmin)
NCT02369653 (22) [back to overview]	The Number Participants Experiencing Superficial Vein Thrombosis Events
NCT02369653 (22) [back to overview]	The Number of Platelet Transfusions Needed During the Study
NCT02369653 (22) [back to overview]	The Number of Participants With Venous Thromboembolism (VTE)-Related-death
NCT02369653 (22) [back to overview]	The Number of Participants With Non-fatal Symptomatic Deep Vein Thromboses (DVT)
NCT02406885 (3) [back to overview]	Change in Pharmacokinetics as Assessed by Cmax (Max Concentration)
NCT02406885 (3) [back to overview]	Change in Pharmacokinetics as Assessed by Area Under the Curve (AUC)
NCT02406885 (3) [back to overview]	Change in Pharmacodynamics as Assessed by Factor Xa Levels (Percent Activity)
NCT02415400 (7) [back to overview]	The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA
NCT02415400 (7) [back to overview]	Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA
NCT02415400 (7) [back to overview]	The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period
NCT02415400 (7) [back to overview]	The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin
NCT02415400 (7) [back to overview]	The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA
NCT02415400 (7) [back to overview]	The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin
NCT02415400 (7) [back to overview]	The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period
NCT02585713 (3) [back to overview]	6 Month Bleeding Rate
NCT02585713 (3) [back to overview]	Time to the First Event of the Composite Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE)
NCT02585713 (3) [back to overview]	Composite Bleeding Rate: Major Bleed or a Clinically Relevant Non-major Bleed
NCT02608099 (16) [back to overview]	Number of Patients With Cardiovascular Death
NCT02608099 (16) [back to overview]	Number of Patients With Thrombotic Events
NCT02608099 (16) [back to overview]	Number of Patients With Composite of Clinically Significant Bleeding and Thrombotic Events
NCT02608099 (16) [back to overview]	Number of Patients With Cardiovascular Death
NCT02608099 (16) [back to overview]	Number of Patients With TIAs or Non-Hemorrhagic Strokes
NCT02608099 (16) [back to overview]	Number of Patients With TIAs or Non-Hemorrhagic Strokes
NCT02608099 (16) [back to overview]	Number of Patients With Thrombotic Events
NCT02608099 (16) [back to overview]	Number of Patients With Major Bleeding
NCT02608099 (16) [back to overview]	Number of Patients With Major Bleeding
NCT02608099 (16) [back to overview]	Number of Patients With Death
NCT02608099 (16) [back to overview]	Number of Patients With Death
NCT02608099 (16) [back to overview]	Number of Patients With Composite of Major Bleeding and Thrombotic Events
NCT02608099 (16) [back to overview]	Number of Patients With Composite of Major Bleeding and Thrombotic Events
NCT02608099 (16) [back to overview]	Number of Patients With Composite of Clinically Significant Bleeding and Thrombotic Events
NCT02608099 (16) [back to overview]	Number of Patients With Clinically-Significant Bleeding
NCT02608099 (16) [back to overview]	Number of Patients With Clinically-Significant Bleeding
NCT02701062 (8) [back to overview]	Composite Event Rates for ALL Subjects Regardless of POAF Through 365 Days
NCT02701062 (8) [back to overview]	Number of Perioperative Complications Associated With AtriClip Placement
NCT02701062 (8) [back to overview]	Composite Event Rates Between Subjects Diagnosed With Post-operative Atrial Fibrillation (POAF) (Through 365 Days)
NCT02701062 (8) [back to overview]	Composite Event Rates Between Subjects Not Diagnosed With POAF (Through 30 Days)
NCT02701062 (8) [back to overview]	Number of Subjects With Intraoperative Successful Exclusion of LAA.
NCT02701062 (8) [back to overview]	Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Median Values)
NCT02701062 (8) [back to overview]	Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Mean Values)
NCT02701062 (8) [back to overview]	Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Event Rates)
NCT02744092 (11) [back to overview]	Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire
NCT02744092 (11) [back to overview]	Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire
NCT02744092 (11) [back to overview]	Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 6-months
NCT02744092 (11) [back to overview]	Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 3-months
NCT02744092 (11) [back to overview]	Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]	Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]	Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]	Cumulative Non-Fatal VTE Recurrence at 6 Months (%)
NCT02744092 (11) [back to overview]	Cumulative Rates of Major Bleeding
NCT02744092 (11) [back to overview]	Mortality Reported by Participants' Surrogates (Via Study-specific Questionnaire) or Clinicians (Via Study-specific Case Report Form)
NCT02744092 (11) [back to overview]	Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02829957 (9) [back to overview]	Number of Participants With Major Hemorrhage
NCT02829957 (9) [back to overview]	Number of Participants With Venous Thromboembolism (VTE)
NCT02829957 (9) [back to overview]	Number of Patients That Held Drug for Menorrhagia
NCT02829957 (9) [back to overview]	PBAC Scores
NCT02829957 (9) [back to overview]	Number of Participants Who Crossed Over to Another Anticoagulant
NCT02829957 (9) [back to overview]	Number of Participants Who Discontinued Planned Drug Administration
NCT02829957 (9) [back to overview]	Hemoglobin Concentration
NCT02829957 (9) [back to overview]	Number of Participants With Clinically Relevant Non-major Bleeding
NCT02829957 (9) [back to overview]	Physical Component Summary of Standard From 36
NCT02889562 (5) [back to overview]	Total Post-operative Length of Stay
NCT02889562 (5) [back to overview]	Units of Blood Given After Initiation of Anticoagulation Medication
NCT02889562 (5) [back to overview]	Time in Therapeutic Range of INR, if on Warfarin
NCT02889562 (5) [back to overview]	Number of Participants With Thromboembolytic Events
NCT02889562 (5) [back to overview]	Number of Participants With Strokes
NCT02942407 (10) [back to overview]	Number of Participants Experiencing Systemic Embolism
NCT02942407 (10) [back to overview]	Number of Participants Experiencing Stroke, Systemic Embolism, Major Bleeding or All-cause Mortality
NCT02942407 (10) [back to overview]	Number of Participants Experiencing Stroke or Systemic Embolism
NCT02942407 (10) [back to overview]	Number of Participants Experiencing Stroke
NCT02942407 (10) [back to overview]	Number of Participants Experiencing Mortality
NCT02942407 (10) [back to overview]	Number of Participants Experiencing ISTH (International Society on Thrombosis and Haemostasis) Major or Clinically Relevant Non-major Bleeding
NCT02942407 (10) [back to overview]	Area Under the Plasma Apixaban Concentration Curve From 0 to 12 Hours After Dose (AUCO-12)
NCT02942407 (10) [back to overview]	Apixaban Plasma Concentration, Cmin
NCT02942407 (10) [back to overview]	Apixaban Plasma Concentration, Cmax
NCT02942407 (10) [back to overview]	Persistence of Therapy
NCT02958969 (4) [back to overview]	Frequency of Major and Clinically Relevant Non-major Bleeding
NCT02958969 (4) [back to overview]	Frequency of Symptomatic Venous Thromboembolism
NCT02958969 (4) [back to overview]	Frequency of All-cause Mortality
NCT02958969 (4) [back to overview]	Frequency of Atherothrombotic Events
NCT02981472 (15) [back to overview]	The Number of Participants With Adjudicated Major Bleeding
NCT02981472 (15) [back to overview]	The Number of Participants With Adjudicated CRNM Bleeding
NCT02981472 (15) [back to overview]	The Number of Participant Deaths in the Study
NCT02981472 (15) [back to overview]	Maximum Observed Concentration (Cmax)
NCT02981472 (15) [back to overview]	Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events
NCT02981472 (15) [back to overview]	Area Under the Concentration-Time Curve in One Dosing Interval (AUC (TAU))
NCT02981472 (15) [back to overview]	Kids Informed Decrease Complications Learning on Thrombosis (KIDCLOT) IMPACT Score
NCT02981472 (15) [back to overview]	The Number of Participants With Thrombotic Events and Thromboembolic Event-Related Death
NCT02981472 (15) [back to overview]	The Child and Parent Reports of Pediatric Quality of Life Inventory (PedsQL)
NCT02981472 (15) [back to overview]	Chromogenic FX Assay (Apparent FX Level)
NCT02981472 (15) [back to overview]	Anti-FXa Activity
NCT02981472 (15) [back to overview]	Trough Observed Concentration (Cmin)
NCT02981472 (15) [back to overview]	Time of Maximum Observed Concentration (Tmax)
NCT02981472 (15) [back to overview]	The Number of Participants With Drug Discontinuation Due to Adverse Effects, Intolerability, or Bleeding
NCT02981472 (15) [back to overview]	The Number of Participants With All Adjudicated Bleeding
NCT02982590 (4) [back to overview]	Change of Left Ventricular Thrombosis (LVT) by More Than 50%
NCT02982590 (4) [back to overview]	Clinically Definite Cardiac Embolic Ischemic Stroke
NCT02982590 (4) [back to overview]	Life Threatening Bleeding
NCT02982590 (4) [back to overview]	Percent Change in Left Ventricular Thrombus (LVT) Size
NCT03026556 (13) [back to overview]	Overall Major Bleeding
NCT03026556 (13) [back to overview]	Stroke Overall (Hemorrhagic, Ischemic, Uncertain)
NCT03026556 (13) [back to overview]	TIA
NCT03026556 (13) [back to overview]	Upper GI Bleeding
NCT03026556 (13) [back to overview]	Major Intracranial Bleeding
NCT03026556 (13) [back to overview]	Major GI Bleeding
NCT03026556 (13) [back to overview]	Major Extracranial Bleeding
NCT03026556 (13) [back to overview]	Lower GI Bleeding
NCT03026556 (13) [back to overview]	Ischemic Stroke
NCT03026556 (13) [back to overview]	Hemorrhagic Stroke
NCT03026556 (13) [back to overview]	All-cause Mortality
NCT03026556 (13) [back to overview]	Major Urogenital Bleeding
NCT03026556 (13) [back to overview]	Major Other Bleeding
NCT03080883 (3) [back to overview]	Cumulative Incidence Function of DVT/PE Treating Death or AE Resulting in End of Treatment as Competing Risk by Study Arm
NCT03080883 (3) [back to overview]	CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk
NCT03080883 (3) [back to overview]	Proportion of Patients Who Experienced at Least One Bleeding Event
NCT03196349 (7) [back to overview]	Number of Subjects With Recurrent Venous Thromboembolism (VTE)
NCT03196349 (7) [back to overview]	Number of Subjects With Clinically Relevant Bleeding Events
NCT03196349 (7) [back to overview]	Number of Subjects Experiencing Vascular Events (Myocardial Infarction, Ischemic Stroke)
NCT03196349 (7) [back to overview]	Number of Subjects Experiencing Major Bleeding
NCT03196349 (7) [back to overview]	Number of Subjects Experiencing Clinically Relevant Non-major Bleeding
NCT03196349 (7) [back to overview]	Number of Subjects With Premature Termination of Study Medication
NCT03196349 (7) [back to overview]	Number of Subjects Experiencing All-cause Mortality
NCT03251482 (13) [back to overview]	Number of Participants With Clinically Relevant Non-major (CRNM) Bleeding Events (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Composite of Major and CRNM Bleeding Events (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Death (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Major Bleeding Event (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Major Bleeding or CRNM Bleeding Events (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Minimal Bleeding Events (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Treatment-emergent Bleeding Events (Clinical Events Committee [CEC]- Adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Distal DVT (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Proximal and Distal DVT (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated)
NCT03251482 (13) [back to overview]	Number of Participants With Major VTE (CEC-adjudicated)
NCT03254147 (2) [back to overview]	The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma.
NCT03254147 (2) [back to overview]	The Number of Patients With Cardiac Tamponade and Pericardiocentesis.
NCT03310021 (6) [back to overview]	Change in Thrombin Generation From Baseline to the End of Bolus (EOB) Nadir.
NCT03310021 (6) [back to overview]	Percent Change in Anti-Fxa Activity From Baseline to the End of Bolus (EOB) Nadir.
NCT03310021 (6) [back to overview]	Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir.
NCT03310021 (6) [back to overview]	Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Bolus (EOB) Nadir.
NCT03310021 (6) [back to overview]	Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Infusion (EOI) Nadir.
NCT03310021 (6) [back to overview]	Change in Thrombin Generation From Baseline to the End of Infusion (EOI) Nadir.
NCT03441633 (10) [back to overview]	Number of Participants by Their Sociodemographic Characteristics: Body Mass Index (BMI)
NCT03441633 (10) [back to overview]	Apixaban Adherence With VKA, Dabigatran and Rivaroxaban by Number of Defined Daily Dose (NDDD)
NCT03441633 (10) [back to overview]	International Normalized Ratio (INR) Values During the Last 12 Months Values in Participants Previously Treated With VKA
NCT03441633 (10) [back to overview]	Number of Participants by Comedications
NCT03441633 (10) [back to overview]	Number of Participants by Comorbidity
NCT03441633 (10) [back to overview]	Number of Participants With Apixaban Adherence With VKA, Dabigatran and Rivaroxaban as Assessed by Discontinuation Throughout the Year
NCT03441633 (10) [back to overview]	Risk of Bleeding Events: HAS-BLED Score
NCT03441633 (10) [back to overview]	Risk of Thromboembolic Events: CHA2DS2Vasc Score
NCT03441633 (10) [back to overview]	Risk of Thromboembolic Events: CHADS2 Score
NCT03441633 (10) [back to overview]	Time in Therapeutic Range (TTR) Values During the Last 12 Months Values in Participants Previously Treated With VKA
NCT03509883 (16) [back to overview]	AUC (INF) - Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time
NCT03509883 (16) [back to overview]	T-Half - Terminal Plasma Half Life.
NCT03509883 (16) [back to overview]	AUC (0-T) - Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration
NCT03509883 (16) [back to overview]	Number of Participants With Out-of Range Vital Signs: Blood Pressure
NCT03509883 (16) [back to overview]	Tmax - Time of Maximum Observed Plasma Concentration
NCT03509883 (16) [back to overview]	Number of Participants With Out-of Range ECG Evaluations
NCT03509883 (16) [back to overview]	Number of Participants With Adverse Events Regardless of Causality, Serious Adverse Events and Adverse Events Leading to Discontinuation
NCT03509883 (16) [back to overview]	Concentration as Measured by Maximum Observed Plasma Concentration (Cmax)
NCT03509883 (16) [back to overview]	Number of Participants With a Given Clinical Laboratory Abnormality
NCT03509883 (16) [back to overview]	Physical Measurement - Height
NCT03509883 (16) [back to overview]	Frel - Relative Bioavailability
NCT03509883 (16) [back to overview]	Physical Measurement - Weight
NCT03509883 (16) [back to overview]	Physical Measurement - Body Mass Index (BMI)
NCT03509883 (16) [back to overview]	Number of Participants With Out-of Range Vital Signs: Temperature
NCT03509883 (16) [back to overview]	Number of Participants With Out-of Range Vital Signs: Respiration Rate
NCT03509883 (16) [back to overview]	Number of Participants With Out-of Range Vital Signs: Heart Rate (Bpm)
NCT03572972 (16) [back to overview]	Event Rate of Major Bleeding Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Major Bleeding Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Other Bleeding Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Other Bleeding Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Stroke/Systemic Embolism Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Stroke/Systemic Embolism Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Systemic Embolism Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Hemorrhagic Stroke Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Gastrointestinal (GI) Bleeding Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Gastrointestinal (GI) Bleeding Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Intracranial Hemorrhage Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Hemorrhagic Stroke Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Intracranial Hemorrhage Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Ischemic Stroke Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Systemic Embolism Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Ischemic Stroke Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03594045 (8) [back to overview]	Time to Platelet Recovery
NCT03594045 (8) [back to overview]	Cumulative Incidence of New Symptomatic Thromboembolic Complications (TEC) Within 30 Days of the Initiation of Apixaban
NCT03594045 (8) [back to overview]	Cumulative Incidence of Major Bleeding
NCT03594045 (8) [back to overview]	Cumulative Incidence of Limb Amputation
NCT03594045 (8) [back to overview]	Cumulative Incidence of All Cause Mortality
NCT03594045 (8) [back to overview]	Composite Cumulative Incidence of New TEC and Major Bleeding
NCT03594045 (8) [back to overview]	Composite Cumulative Incidence of All-cause Mortality, Limb Amputation and New TEC
NCT03594045 (8) [back to overview]	Cumulative Incidence of New Thromboembolic Complications (TEC)
NCT04218266 (5) [back to overview]	Number of Participants With ISTH Major Bleeding
NCT04218266 (5) [back to overview]	Number of Participants With ISTH Minor Bleeding
NCT04218266 (5) [back to overview]	Number of Participants of ISTH Clinically Relevant Non-major (CRNM) Bleeding
NCT04218266 (5) [back to overview]	Number of Participants With All Bleeding
NCT04218266 (5) [back to overview]	Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding
NCT04498273 (1) [back to overview]	Hospitalization for Cardiovascular/Pulmonary Events
NCT04681482 (8) [back to overview]	Event Rate Per 100 Participant-Years For First Occurrence of Net Clinical Benefit After Index Date in Obese Participants
NCT04681482 (8) [back to overview]	Event Rate Per 100 Participant-Years For First Occurrence of Net Clinical Benefit After Index Date in Morbidly Obese Participants
NCT04681482 (8) [back to overview]	Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Morbidly Obese Participants
NCT04681482 (8) [back to overview]	Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Obese Participants
NCT04681482 (8) [back to overview]	Time in Therapeutic Range (TTR) During Follow-up Period
NCT04681482 (8) [back to overview]	Charlson Comorbidity Index (CCI)
NCT04681482 (8) [back to overview]	Event Rate Per 100 Participant-Years For First Occurrence of Stroke or Systemic Embolism (SE) Events After Index Date in Obese Participants
NCT04681482 (8) [back to overview]	Event Rate Per 100 Participant-Years For First Occurrence of Stroke or Systemic Embolism (SE) Events After Index Date in Morbidly Obese Participants
NCT05022563 (60) [back to overview]	Number of Participants Who Switched to Another Anticoagulant Therapy
NCT05022563 (60) [back to overview]	Number of Participants Who Completely Discontinued Index Anticoagulant Treatment
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Interruption in Index Anticoagulant Treatment
NCT05022563 (60) [back to overview]	Overall Index Anticoagulant Treatment Duration
NCT05022563 (60) [back to overview]	Time to Treatment Discontinuation
NCT05022563 (60) [back to overview]	Time to Treatment Interruption
NCT05022563 (60) [back to overview]	Time to Treatment Switch
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation
NCT05022563 (60) [back to overview]	Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months

Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses

Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study

Intervention	percentage of participants (Number)
Placebo	10.5
Apixaban 2.5mg BID	20.6
Apixaban 10mg QD	22.5

Intervention	percentage of participants (Number)
Placebo	6.1
Apixaban 2.5mg BID	15.1
Apixaban 10mg QD	17.6
Apixaban 10mg BID	24.2
Apixaban 20 mg QD	23.9

Intervention	Participants (Number)
Cohort 1: Placebo	0
Cohort 1: Apixaban, 5 mg	0
Cohort 1: Apixaban, 10 mg	0
Cohort 1: Apixaban, 20 mg	0
Cohort 2: Placebo	0
Cohort 2: Apixaban, 5 mg	0

Intervention	Participants (Number)
	Deaths	SAEs	Bleeding AEs	Discontinuations due to AEs
Cohort 1: Apixaban, 10 mg	0	3	11	4
Cohort 1: Apixaban, 20 mg	0	5	12	4
Cohort 1: Apixaban, 5 mg	1	6	15	4
Cohort 1: Placebo	2	9	6	7
Cohort 2: Apixaban, 5 mg	0	0	2	0
Cohort 2: Placebo	0	1	1	1

Intervention	percentage of participants (Number)
Apixaban 2.5mg BID	2.13
Enoxaparin 30 mg SC Injection q 12 Hours	1.97

Intervention	percentage of participants (Number)
	MI/Stroke	MI	Stroke	Thrombocytopenia
Apixaban 2.5mg BID	0.06	0.06	0.00	0.00
Enoxaparin 30 mg SC Injection q 12 Hours	0.06	0.06	0.00	0.00

Intervention	bpm (Mean)
	Heart Rate Day 1 (n=240,237)	Heart Rate Day 2 (n=1575,1574)	Heart Rate Day 3 (n=1490,1498)	Heart Rate Day 4 (n=127,134)	Heart Rate Day 12 (n=1495, 1462)
Apixaban 2.5mg BID	2.3	4.6	4.5	7.6	-0.3
Enoxaparin 30 mg SC Injection q 12 Hours	2.7	4.5	5.0	9.4	-0.1

Intervention	mmHg (Mean)
	Diastolic BP Day 1 (n=240, 237)	Diastolic BP Day 2 (n=1577, 1574)	Diastolic BP Day 3 (n=1489,1498)	Diastolic BP Day 4 (n=127,134)	Diastolic BP Day 12 (n=1495,1463)	Systolic BP Day 1 (n=240,237)	Systolic BP Day 2 (n=1577,1574)	Systolic BP Day 3 (n=1489,1498)	Systolic BP Day 4 (n=127,134)	Systolic BP Day 12 (n=1495,1463)
Apixaban 2.5mg BID	-0.4	1.7	2.3	0.6	7.3	1.5	5.4	4.7	2.8	9.1
Enoxaparin 30 mg SC Injection q 12 Hours	-0.9	1.5	2.1	0.3	7.5	-0.7	4.2	4.3	1.4	8.9

Intervention	participants (Number)
	Calcium low (n=1569,1562)	Calcium high (n=1569,1562)	Chloride low (n=1568,1562)	Chloride high (n=1568,1562)	Bicarbonate low (n=1568,1561)	Potassium low(n=1568,1559)	Potassium high(n=1568,1559)	Sodium low (n=1568,1562)	Sodium high (n=1568,1562)
Apixaban 2.5mg BID	1	0	11	0	11	54	26	23	2
Enoxaparin 30 mg SC Injection q 12 Hours	5	1	17	1	13	56	20	39	0

Intervention	participants (Number)
	Hemoglobin low (n=1561,1549)	Hematocrit low (n=1558,1547)	Platelet count low (n=1556,1543)	Erythrocytes low (n=1557,1547)	Leukocytes low(n=1583,1572)	Leukocytes high(n=1583,1572)	Basophils high (n=1577, 1564)	Eosinophils high (n=1577, 1564)	Lymphocytes low (n=1577,1564)	Lymphocytes high (n=1577,1564)	Monocytes high (n=1577,1564)	Neutrophils low (n=1577,1564)
Apixaban 2.5mg BID	386	135	6	130	8	214	0	32	125	2	4	4
Enoxaparin 30 mg SC Injection q 12 Hours	392	157	9	149	11	210	2	13	117	4	4	5

Intervention	percentage of participants (Number)
Apixaban 2.5mg BID	8.91
Enoxaparin 30 mg SC Injection q 12 Hours	8.61

Intervention	percentage of participants (Number)
Apixaban 2.5mg BID	8.99
Enoxaparin 30 mg SC Injection q 12 Hours	8.85

Intervention	participants (Number)
	ALP high (n=1573,1563)	ALT high (n=1573,1562)	AST high (n=1573,1562)	Bilirubin direct high (n=1563,1553)	Bilirubin total high(n=1572,1562)	Creatinine high (n=1569,1562)
Apixaban 2.5mg BID	42	33	29	63	2	17
Enoxaparin 30 mg SC Injection q 12 Hours	55	45	40	54	8	28

Intervention	participants (Number)
	Fasting Glucose low (n=611, 579)	Fasting Glucose high (n=611, 579)	Total Protein low (n=1568,1562)	CK high (n=1573,1563)	Uric Acid high (n=1567,1562)
Apixaban 2.5mg BID	8	54	527	52	22
Enoxaparin 30 mg SC Injection q 12 Hours	5	28	513	45	12

Intervention	participants (Number)
	SAE	Bleeding AE	AEs leading to discontinuation	Deaths
Apixaban 2.5mg BID	123	110	60	3
Enoxaparin 30 mg SC Injection q 12 Hours	123	144	58	5

Intervention	percentage of participants (Number)
	Major Bleeding (n=1563, 1553)	CR N-M Bleeding (n=1563, 1553)	Major or CR N-M Bleeding (n=1563, 1553)	Any Bleeding (n=1563, 1553)
Apixaban 2.5mg BID	0.13	0.26	0.38	0.90
Enoxaparin 30 mg SC Injection q 12 Hours	0.13	0.45	0.58	1.29

Intervention	percentage of participants (Number)
	Major Bleeding (n=1596, 1588)	CR N-M Bleeding (n=1596, 1588)	Major or CR N-M Bleeding(n=1596, 1588)	Any Bleeding (n=1596, 1588)
Apixaban 2.5mg BID	0.69	2.19	2.88	5.33
Enoxaparin 30 mg SC Injection q 12 Hours	1.39	2.96	4.28	6.80

Intervention	percentage of participants (Number)
	PE (Fatal or Non-Fatal) (n=1599, 1596)	Non-Fatal PE (n=1599, 1596)	All DVT n=1142, 1122	Symptomatic DVT (n=1599, 1596)	Asymptomatic DVT (n=1139,1115)	Symptomatic Proximal DVT (n=1599,1596)	Symptomatic Distal DVT (n=1599,1596)
Apixaban 2.5mg BID	1.00	0.88	7.79	0.19	7.55	0.13	0.06
Enoxaparin 30 mg SC Injection q 12 Hours	0.44	0.44	8.20	0.44	7.62	0.19	0.38

Intervention	percentage of participants (Number)
	Proximal DVT (n=1254, 1207)	Distal DVT (n=1146, 1133)	Asymptomatic Proximal DVT (n=1252, 1204)	Asymptomatic Distal DVT (n=1145, 1127)
Apixaban 2.5mg BID	0.72	7.24	0.56	7.16
Enoxaparin 30 mg SC Injection q 12 Hours	0.91	8.03	0.66	7.54

Intervention	percentage of participants (Number)
Apixaban 2.5mg BID	1.25
Enoxaparin 30 mg SC Injection q 12 Hours	1.00

Intervention	percentage of participants (Number)
Apixaban 2.5mg BID	9.90
Enoxaparin 30 mg SC Injection q 12 Hours	10.60

apixaban

Cross-References

Synonyms (96)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Pathways (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (42)

Molecular Functions (12)

Ceullar Components (13)

Bioassays (189)

Research

Studies (2,319)

Market Indicators

Research Demand Index: 119.97

Study Types

Clinical Trials (265)

Trial Overview

Trial Outcomes

Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses

Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B

Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses

Number of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B

Event Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B

Event Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses

Number of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants

Number of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B

Number of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants

Event Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B

Number of Participants With All-Cause Death

Number of Participants With Composite of Confirmed Major Bleeding and Clinically Relevant Nonmajor (CRNM) Bleeding

Number of Participants With Composite of Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and Venous Thromboembolism (VTE)-Related Death

Number of Participants With Composite of Venous Thromboembolism (VTE) and All-cause Death

Number of Participants With Composite of Venous Thromboembolism (VTE) and VTE-related Death

Number of Participants With Deep Vein Thrombosis

Number of Participants With Distal Deep Vein Thrombosis

Number of Participants With Nonfatal Pulmonary Embolism

Number of Participants With Proximal Deep Vein Thrombosis

Number of Participants With Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and All-cause Death

Number of Participants With Pulmonary Embolism (Fatal or Nonfatal)

Number of Participants Who Died and With Adverse Events (AEs), Serious Adverse Events (SAEs), Bleeding AEs, and Discontinuations Due to AEs

Event Rate for Total Participants With Adjudicated VTE/All-Cause Death With Onset During the Intended Treatment Period

Event Rate of Adjudicated MI, Stroke, and Thrombocytopenia Events During the Follow-Up Period

Mean Change From Baseline in Heart Rate During the Treatment Period

Mean Change From Baseline in Systolic and Diastolic Blood Pressure During the Treatment Period

Number of Participants With Electrolyte Chemistry Laboratory Marked Abnormalities During the Treatment Period

Event Rate for Total Participants With VTE/ VTE-Related Death With Onset During the Intended Treatment Period

Number of Participants With Hematology Laboratory Marked Abnormality During the Treatment Period

Event Rate of Adjudicated VTE / VTE-related Death With Onset During the Treatment Period

Event Rate of Composite of Adjudicated Proximal DVT, Non-Fatal PE and All-Cause Death With Onset During the Intended Treatment Period PE and All-cause Death During the Intended Treatment Period

Event Rate for Participants With Adjudicated Myocardial Infarction (MI) Acute Ischemic Stroke and Thromboembolic Events With Onset During the Treatment Period

Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects

Number of Participants With Liver and Kidney Function Chemistry Laboratory Marked Abnormalities During the Treatment Period

Number of Participants With Other Chemistry Laboratory Marked Abnormalities During the Treatment Period

Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), AEs Leading to Discontinuation, and Deaths - Treated Population

Event Rate for Participants With Major Bleeding, Clinically Relevant (CR) Non-Major (N-M) Bleeding , Major or Clinically Relevant (CR) Non-Major (N-M) Bleeding, Any Bleeding With Onset During the Follow-Up Period

Event Rate for Participants With Major Bleeding, Clinically Relevant Non-Major Bleeding, Major or Clinically Relevant Non-Major Bleeding, Any Bleeding With Onset During the Treatment Period - Treated Population

Event Rate for Participants With PE (Fatal or Non-Fatal), DVT (All, Symptomatic Proximal, and Distal, Asymptomatic) With Onset During the Intended Treatment Period

Event Rate for Participants With Proximal DVT, Distal DVT, Asymptomatic Proximal DVT, Asymptomatic Distal DVT With Onset During the Intended Treatment Period

Event Rate for Participants With All-Cause Death During the Intended Treatment Period

Event Rate for Participants With Proximal DVT/Non-Fatal PE/ VTE-Related Death With Onset During the Intended Treatment Period

Event Rate for Participants With Symptomatic VTE/ All-Cause Death With Onset During the Intended Treatment Period

Event Rate for Participants With Symptomatic VTE/ VTE-Related Death With Onset During the Intended Treatment Period

Event Rate for Participants With VTE-Related Death With Onset During the Intended Treatment Period

Event Rate for Participants With VTE/Major Bleeding/All-Cause Death With Onset During the Intended Treatment Period

Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period

Number of Participants With Events of All-Cause Death During the Intended Treatment Period

Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period

Intervention	Number of events per 100 patient years (Number)
	Ischemic or Unspecified Stroke (n=162, 175)	Hemorrhagic Stroke (n=40, 78)	Systemic Embolism (n=15, 17)	Myocardial Infarction (n=90, 102)
Apixaban	0.97	0.24	0.09	0.53
Warfarin	1.05	0.47	0.10	0.61

Intervention	participants (Number)
	AE	SAE	Bleeding AE	Discontinuations due to AE	Deaths
Apixaban	7406	3182	2288	688	429
Warfarin	7521	3302	2961	758	468

Intervention	participants (Number)
	Ischemic or Unspecified Stroke	Hemorrhagic Stroke	Systemic Embolism
Apixaban	159	38	15
Warfarin	173	76	16

Intervention	Number of events per 100 patient years (Number)
	Severe (n=80, 172))	Severe or Moderate (n=199, 328)
Apixaban	0.52	1.29
Warfarin	1.13	2.18

Intervention	Number of events per 100 patient years (Number)
	Major (n=148, 256)	Major or Minor (n=239, 370)
Apixaban	0.96	1.55
Warfarin	1.69	2.46

Intervention	Number of events per 100 patient years (Number)
	Stroke / SE / Major Bleeding (n=521, 666)	Stroke / SE / All-Cause Death (ACD) (n=752, 837)	Stroke / SE / Major Bleeding / ACD (n=1009, 1168)	Stroke / SE / MI / ACD (n=810, 906)	Ischemic or Unspecified Stroke / ACD (n=725, 796)	Hemorrhagic Stroke / ACD (n=622, 703)	SE / ACD (n=613, 679)	MI / ACD (n=663, 740)
Apixaban	3.17	4.49	6.13	4.85	4.32	3.68	3.63	3.93
Warfarin	4.11	5.04	7.20	5.49	4.78	4.20	4.05	4.43

Intervention	Percentage of events/patients evaluated (Number)
Apixaban, 2.5 mg BID Plus Placebo	1.39
Enoxaparin, 40 mg QD Plus Placebo	3.86

Intervention	Participants (Number)
	Alkaline phosphatase, high (n=2631, 2618)	Alanine aminotransferase, high (n=2629, 2616)	Aspartate aminotransferase, high (n=2629, 2616)	Bilirubin, direct, high (n=2622, 2604)	Bilirubin, total, high (n=2630, 2617)	Blood urea nitrogen (BUN), high (n=2618, 2598)	Creatinine, high (n=2618, 2598)	Calcium, total, low (n=2618, 2598)	Calcium, total, high (n=2618, 2598)	Chloride, serum, low (n=2615, 2594)	Bicarbonate, low (n=2615, 2595)	Potassium, serum, low (n=2614, 2594)	Potassium, serum, high (n=2614, 2594)	Sodium, serum, low (n=2615, 2594)	Sodium, serum, high (n=2615, 2594)
Apixaban, 2.5 mg BID Plus Placebo	55	50	73	145	24	19	21	7	0	6	8	73	61	29	5
Enoxaparin, 40 mg QD Plus Placebo	57	83	73	139	12	17	25	18	1	6	8	73	47	23	4

Intervention	Participants (Number)
	Postprocedural hematoma	Operative hemorrhage	Incision site hematoma	Incision site hemorrhage	Postprocedural hemorrhagic	Hematuria traumatic	Periorbital hematoma	Subcutaneous hematoma	Traumatic hematoma	Hematoma	Wound hemorrhage	Hemorrhage	Hematuria	Hemorrhage urinary tract	Urethral hemorrhage	Epistaxis	Hemoptysis
Apixaban, 2.5 mg BID Plus Placebo	20	19	14	13	4	1	1	1	0	34	18	13	41	1	0	33	3
Enoxaparin, 40 mg QD Plus Placebo	23	14	10	19	7	1	0	0	1	38	15	13	39	1	2	25	1

Intervention	Participants (Number)
	Hemorrhagic anemia	Ecchymosis	Petechiae	Hemorrhage subcutaneous	Increased tendency to bruise	Vaginal hemorrhage	Menorrhagia	Uterine hemorrhage	Conjunctival hemorrhage	Hematoma infection	Spinal hematoma
Apixiban, 2.5 mg BID Plus Placebo	20	5	2	1	0	2	1	0	1	1	0
Enoxaparin, 40 mg QD Plus Placebo	15	9	2	0	5	0	0	1	0	0	1